Development of an In-Vitro Tissue Engineered Blood Vessel Mimic Using Human Large Vessel Cell Sources by Delagrammaticas, Dimitri E
 
 
 
DEVELOPMENT OF AN IN-VITRO TISSUE ENGINEERED BLOOD VESSEL 
MIMIC USING HUMAN LARGE VESSEL CELL SOURCES 
 
 
 
 
 
 
 
A Thesis 
 Presented to the Faculty of   
California Polytechnic State University  
San Luis Obispo 
 
 
 
 
 
In Partial Fulfillment of the Requirements for the Degree 
Master of Science in Biomedical Engineering 
 
 
By 
Dimitri Emmanuel Delagrammaticas 
May 2009 
 
 
 ii 
 
 
 
 
 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2009 Dimitri E. Delagrammaticas 
ALL RIGHTS RESERVED 
 
 
 iii 
THESIS COMMITTEE MEMBERSHIP 
 
 
TITLE: DEVELOPMENT OF AN IN-VITRO TISSUE 
ENGINEERED BLOOD VESSEL MIMIC USING 
HUMAN LARGE VESSEL CELL SOURCES 
 
 
AUTHOR: Dimitri E. Delagrammaticas 
 
DATE SUBMITTED: May 2009 
 
 
 
COMMITTEE CHAIR:  Dr. Kristen O’Halloran Cardinal, PhD 
  
COMMITTEE MEMBER: Dr. Trevor Cardinal, PhD 
  
COMMITTEE MEMBER: Dr. Lily Laiho, PhD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
ABSTRACT 
 
DEVELOPMENT OF AN IN-VITRO TISSUE ENGINEERED BLOOD VESSEL 
MIMIC USING HUMAN LARGE VESSEL CELL SOURCES  
 
Dimitri E. Delagrammaticas 
 
Tissue engineering is an emerging field that offers novel and unmatched potential 
medical therapies and treatments.  While the vast aim of tissue engineering endeavors is 
to provide clinically implantable constructs, secondary applications have been developed 
to utilize tissue-engineered constructs for in-vitro evaluation of devices and therapies.  
Specifically, in-vitro blood vessel mimics (BVM) have been developed to create a bench-
top blood vessel model using human cells that can be used to test and evaluate vascular 
disease treatments and intravascular devices.  Previous BVM work has used fat derived 
human microvascular endothelial cells (EC) sodded on an ePTFE scaffold.  To create a 
more physiologically accurate model, a dual layer of large vessel endothelial and smooth 
muscle cells (SMC) on an ePTFE tube is investigated throughout this thesis.  Human 
umbilical vein endothelial cells (HUVEC) and human umbilical vein smooth muscle cells 
(HUVSMC) were chosen as the large vessel cell types and cultivated according to 
standard procedures.  Before dual sodding, sodding density experiments with HUVSMC 
were performed to determine the number of cells required to create a confluent cell layer.  
HUVSMC sodded by trans-luminal pressure at densities ranging from 3.5x105 cells/cm2 
to 1.0x106 cells/cm2 were run for one day to observe luminal coverage.  After 
determining the desirable range for HUVSMC sodding, HUVSMC experiments with 
5.0x105 cells/cm2 and 7.5x105 cells/cm2 were run over seven days to evaluate progression 
of the graft over time.  Histology and SEM methods were used for analysis.  A HUVEC 
study was next conducted over 7 days to confirm that the large vessel endothelial cell 
 
 
 v 
could be sodded and sustained on ePTFE in-vitro.  Next, dual sodding was performed by 
pressure sodding HUVSMC at 7.5x105 cells/cm2 followed by trans-luminal flow for 30 
minutes.  HUVECs were subsequently trans-luminally pressure sodded at 5.0x105 
cells/cm2 followed by an additional 30 minutes of trans-luminal flow; perfusion flow 
began following the final 30 minutes of trans-luminal flow.   Experiments for the dual 
layered grafts were run for both one and seven days to evaluate and develop the dual 
sodding protocol as well as observe the co-culture over time.  Analysis of the dual 
layered grafts was performed by SEM, histology, and fluorescence microscopy.  
HUVECs were incubated with Cell Tracker™ prior to dual sodding and both cell types 
with bisbenzimide after graft harvest to attempt to distinguish between cell types.  Results 
from the thesis illustrate that large vessel smooth muscle and endothelial cells can be 
sodded onto ePTFE scaffolds and sustained within the in-vitro BVM system for up to 7 
days.  Furthermore, cost analysis demonstrates that the addition of a smooth muscle cell 
layer adds minimal costs to the BVM system.  In conclusion, the studies contained within 
this thesis culminate in a protocol for the dual sodding of smooth muscle and endothelial 
cells with the aim of creating a physiologically representative co-culture blood vessel 
mimic. 
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 2 
Overview 
Tissue engineering is an emerging field offering the potential for novel and 
unmatched medical therapies and treatments.  While the prevalent aim of tissue 
engineering is to provide clinically relevant therapies, secondary applications of the 
technology have developed that may offer additional value.  One such application, 
referred to as an in-vitro blood vessel mimic (BVM), aims to use tissue-engineered 
constructs for in-vitro evaluation of devices and therapies [1].  The purpose of such a 
blood vessel mimic is to create a living bench top model, which can be used to test and 
evaluate intravascular devices and disease treatments, thereby supplementing or 
potentially replacing early animal test models.  The Cardinal et al. BVM [1], consisting 
of an expanded poly[tetrafloroethlyene] (ePFTE) polymer tube lined with an intimal layer 
of liposuction fat-derived human microvascular endothelial cells (HMVEC), served as 
the foundation to the BVM described within this thesis.  
The specific focus of this thesis and the tissue engineering laboratory group at Cal 
Poly, San Luis Obispo, was to expand upon the previous BVM model and explore new 
approaches for creating a more physiologic in-vitro tissue engineered blood vessel mimic.  
Included in this research was the investigation and sourcing of large vessel cells, with the 
intent of creating a dual sodded layer of smooth muscle and endothelial cells.  Ultimately, 
a BVM with human umbilical vein smooth muscle cells (HUVSMC) and human 
umbilical vein endothelial cells (HUVEC) on expanded ePTFE was attempted as the final 
dual layer BVM model.  In order to understand the relevance and need for a bench top 
blood vessel model, foundational information regarding vascular disease prevalence, 
vascular disease pathology, and blood vessel anatomy is presented.  A discussion related 
to current vascular disease treatments, intravascular device test methods, and the current 
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state of tissue-engineered blood vessels will also be presented to further establish the role 
and potential application of an in-vitro tissue engineered blood vessel mimic.  
Clinical Pathology 
Cardiovascular disease contributes to more than 1 in every 5 American deaths and 
the need for approximately half a million coronary artery bypass surgeries each year.  It is 
the leading cause of death for both men and women in the United States, and claims more 
lives than the next five leading causes of death combined [2, 3].  Atherosclerosis, the 
clogging or hardening of arterial vessels as illustrated in figure 1.1, is the general term 
used to describe most of the common cardiovascular abnormalities, typically developing 
to some extent in all people beginning at birth [4-6].  
 
 
Figure 1.1 - Artery with atherosclerotic plaque and accompanying cells (right) 
compared to normal artery (left) [7]. (Image used with permission, see Appendix M) 
 
The condition usually progresses as stresses and injury within the vessel initiate a 
cascade that leads to the formation and build up of plaque lesions.  These plaque lesions, 
generally consisting of scattered smooth muscle cells, macrophages, foam cells, 
lymphocytes, cholesterol crystals, and cell debris develop into thick fibrous layers of 
connective tissue that causes physical blockage of the vessel and results in poor or 
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restricted blood flow [4, 8].  Poor flow, especially in the coronary vessels, ultimately 
leads to necrosis downstream of the blockage, potentially causing ischemic heart disease, 
myocardial infarction, stroke, or gangrene of the limbs.  Common risk factors, including 
high cholesterol, high blood pressure, smoking, diabetes, obesity, limited physical 
activity, age, and genetic propensity can all contribute to the accelerated onset and 
premature effects of atherosclerosis [9]. 
Current Medical Treatments 
Current treatments for atherosclerosis include pharmaceutical and lifestyle options 
as well as physical interventions, involving invasive vessel replacement surgery or 
minimally invasive catheter based procedures.  Angioplasty and stenting constitute two of 
the most common minimally invasive catheter based procedures.  Angioplasty procedures 
make use of balloon dilatation catheters to open occluded vessels by mechanically 
compressing plaque against the vessel.  Often a small metal scaffold known as a stent is 
deployed following dilatation to help maintain proper flow and mechanical characteristics 
of the diseased vessel. 
 
Figure 1.2 - Angioplasty and stent deployment [10].  (Image used with permission, 
see Appendix M) 
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While lower risk and generally an outpatient procedure, minimally invasive 
catheter treatments have shown mixed results, as past experiences treating simple to 
complex lesions resulted in restenosis for as many as fifteen to sixty percent of 
percutaneous coronary interventions [11].  This restenosis, or the reduction in diameter of 
the vessel lumen following an intravascular procedure, is often the result of the cellular 
response to the injury imparted by balloon dilatation and the stresses of the stent pressing 
against the vessel walls.  Pharmaceutical compounds and drug-eluting stents (DES) have 
been developed to reduce the effects of restenosis, however, continued study is required 
to conclusively determine the long-term effectiveness of these therapies [11].   
Conversely, invasive vessel replacement procedures employ surgical methods to 
replace or circumvent the diseased vessel.  Replacement vessels may be comprised of 
autologous tissue or synthetic biomaterials [12].  Autologous tissue refers to tissue 
harvested from and implanted into the same patient.  The saphenous vein in the leg and 
the internal mammary artery in the chest are most often used as autologous vessel sources 
for transplantation [12].  Typical synthetic graft materials may include expanded 
poly[tetrafloroethlyene] (ePTFE) or poly[ethyleneterephthalate] (PET, commercial name: 
Dacron).  These synthetic materials have been successfully implemented for large vessel 
replacements in peripheral disease cases.  For small diameter grafts (<6 mm), such as for 
the coronary arteries, clinical practice has shown autologous sources to have superior 
long-term patency and biocompatibility when compared to synthetic grafts, explained by 
the presence of a viable endothelial lining [13, 14].  Yet, despite the improved results 
using autologous sources for small diameter bypass conduits, many times a suitable 
autologous graft may not be available due to disease or previous harvesting, and as many 
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as thirty percent of patients in need of a coronary vascular bypass graft lack a suitable 
autologous vessel [15].  Therefore, a need for additional treatment options has driven the 
development of novel techniques such as tissue engineering.  
Tissue Engineered Vascular Constructs 
While still in its infancy as a medical treatment method, the aim of tissue-
engineered approaches is to combine cellular and biological science with engineering 
means to develop treatments that promote the growth and differentiation of cells and 
tissues that are anatomically and physiologically typical.  The classic tissue engineering 
paradigm involves incorporating the isolation and culture of cells with a supporting 
scaffold and cultivation environment.  Furthermore, the scaffold material and cultivation 
environments are often developed and maintained to closely mimic the physiologic 
environment that the tissue of interest would experience.  The Cardinal et al. tissue-
engineered blood vessel mimic, as an example, made use of a tubular polymer scaffold in 
conjunction with human endothelial cells.  To support cellular development, the tubular 
graft was surrounded by a media containing typical nutrients, and connected to a 
perfusion flow bioreactor system maintained at 37°C and 5% CO2 [1].   
Key advantages to tissue engineering approaches are that various cell sources 
ranging from allogeneic, autologous, or even xenogenic can be used to take advantage of 
intrinsic biocompatibility and tissue function.  Intrinsic biocompatibility is achieved 
when the tissue-engineered constructs contain cells that are specific, and in the case of 
autologous, identical, to the species and host biochemistry, cellular function, and 
immunological identity.      
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With regard to the cardiovascular system, advances in tissue engineering are 
providing hope for the fabrication of substitute blood vessels for implantation.  In the 
case of coronary artery bypass, where patients may not have a suitable autologous bypass 
graft for harvesting, tissue engineered blood vessels (TEBV) may potentially provide a 
way of creating a substitute biologic vessel for implantation.   
Moreover, tissue-engineering approaches stand to offer not only a potential 
method for supplementary clinical therapies, but may also aid in the development of life 
saving devices and treatments.  The application of tissue engineered blood vessel mimics 
(BVM) centers on creating in-vitro, bench-top bioreactor units to create and sustain blood 
vessels that possess human tissue and structure that is anatomically similar to native 
vessels.  Once vessels are created, devices such as bare metal stents, dilatation catheters, 
pharmaceutical agents, or drug eluting stents can be deployed within the vessel, and the 
physiologic and biological response studied.  This particular application of tissue 
engineered vascular grafts serves as the impetus for the BVM work described within this 
thesis.  Specific examples and techniques for a range of tissue-engineered blood vessels 
will be reviewed in subsequent sections. 
Preclinical Testing  
Fundamental to the discussion of potentially using a tissue engineered BVM as a 
preclinical in-vitro device development tool is understanding the regulatory and oversight 
authority of the United States Food and Drug Administration (FDA).  Although currently 
a BVM system would not be recognized by the FDA as a acceptable pre-clinical test 
method, as it has not been validated or widely implemented, it may certainly be 
recognized in the future and thus it is important to understand the responsibility and 
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jurisdiction that the government agency possesses, especially as it relates to the 
development of medical devices.   
Established in 1906 following the passage of the Federal Food and Drugs Act, the 
FDA serves as a public safety and regulatory agency overseeing the U.S. manufacture 
and sale of human and animal drugs, therapeutic agents of biological origin, medical 
devices, radiation-emitting products for consumer, medical, and occupational use, 
cosmetics, and animal feed [16].  As technology and health safety knowledge grew 
throughout the twentieth century, amendments to the food and drug acts, in particular the 
Medical Device Amendments of 1976, have further defined the scope and regulatory 
jurisdiction of the agency.  Major changes instituted following 1975 have included 
classification of devices based on the associated risk, pre-market approval and clearance, 
and mandates of the manufacturer to prove product safety and efficacy and to report any 
adverse events [16].   
Proving the safety and efficacy of a product prior to market approval is 
accomplished through analysis and investigation by means of preclinical and clinical 
testing.  Preclinical analysis can assume unlimited pathways and most commonly 
includes some level of bench-top, in-vitro, and animal studies.  Using stents as an 
example device, bench-top analysis will often take the form of stress or fatigue tests to 
make certain that the stent will be able to withstand physiologic forces imposed on it and 
to ensure the mechanical integrity of the stent and delivery system.  Once simple 
mechanical or bench-top tests have been completed, a device may also be subject to in-
vitro biological tests, where a culture of relevant cells or other biologic agents can be 
used to test factors such as cytotoxicity and cytocompatibility.   
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After completing all bench-top and in-vitro testing, devices are next subject to 
numerous animal studies, often beginning with small rodents or rabbits, and progressing 
into larger animal models depending on the device and study objectives.  For 
intravascular devices, porcine studies often serve as the final preclinical model due to 
anatomical similarities [17].  Only after preclinical evaluation can a device be considered 
for human clinical studies.  
Although preclinical studies provide valuable information and a degree of safety 
assuredness prior to human use, therapies that prove beneficial in animal studies may not 
always provide remarkable results in human trials.   It is known that animal models may 
often show a faster or more complete healing response than humans.  This observation 
may be due to factors including species-specific tissue responses, or that devices, 
including stents, are often implanted into non-diseased animals given the burden and 
complexity of creating consistent diseased animal models [18].  Thus, although animal 
studies are an invaluable analysis method, animal studies alone cannot always predict the 
success of a device or therapy, highlighting the value of other preclinical analysis 
methods such as cytotoxicity tests, or one day, a tissue-engineered BVM.      
In-vitro tests, including the potential use of tissue-engineered constructs, may also 
provide pre-clinical value by being a more cost effective testing method.  Independent of 
the scientific value of conducting preclinical animal studies is the cost and ethical 
contentions surrounding the use of living animals as test subjects.  Apart from any ethical 
points of view, costs alone can prohibit, or at least dramatically limit, a company or 
researcher’s ability to test and develop new products and technologies.  Using stents 
again as an example, many preclinical studies begin with rabbits due the similarities in 
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size between the rabbit iliac and human coronary artery.  According to Charles River 
Laboratories, a leading provider of research models and laboratory animal support, rabbit 
models can range from eighty-five to one hundred and eighty-five dollars per animal, 
depending on the particular species and requirements of the research lab.  After 
conducting preliminary small-scale studies in rabbits, many companies may move to 
canine or porcine models; according to a leading cardiovascular device company, a 
USDA purpose bred canine model may cost above one thousand dollars [19].  Important 
to note is that this cost is for the direct cost of the animal alone, and does not account for 
the surgery and analysis, or the costs of housing animals and maintaining an animal 
facility according the guidelines set forth by the Institutional Animal Care and Use 
Committee (IACUC).  Appropriately equipping a facility to maintain and observe canine 
models, including associated veterinary staffing and facility expenses, is estimated to cost 
over one million dollars per year [19].   
Given the high costs associated with conducting and maintaining animal testing 
facilities, an opportunity exists for a tissue engineered blood vessel system, including the 
system developed in this thesis, to serve as a more cost effective preclinical analysis 
system.  Consisting of a peristaltic pump, bioreactor chamber, media reservoir, and 
connecting tubing, the BVM system used throughout this thesis and illustrated in figure 
1.3 costs approximately fifteen dollars per system to build.  Initial infrastructure costs 
that are required to support BVM studies, including the purchase of incubators and cell 
culture equipment, are estimated at fifty thousand dollars.  Final costs, including the 
consumable and cellular cost per graft, are about one hundred dollars per graft; a sharp 
contrast to the cost required to maintain an animal facility.  However, while a BVM may 
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be a simple and inexpensive preclinical analysis tool, a tissue-engineered BVM will not 
serve to eliminate animal models, especially considering the complexity and widely 
undiscovered biochemical interactions and cellular mechanisms that occur in a complete 
organism that could not be feasibly replicated in-vitro.  Rather a BVM is intended to 
minimize the need for extensive animal use, or to refine product designs prior to animal 
trials.  
 
Fig 1.3a 
Fig 1.3b 
 
Figure 1.3 - The top image shows a solid model of the blood vessel mimic system, 
including bioreactor chamber, pump and media reservoir.  The direction of fluid flow 
is indicated by the arrows (1.3a).  Below two BVM systems are set up inside the 
incubator (1.3b). 
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Native Blood Vessel Anatomy and Physiology 
After considering the pre-clinical relevance of an in-vitro vessel system, it is 
necessary to understand the structure and function of native blood vessels, which the 
BVM aims to mimic.  Within the cardiovascular system, three sub classifications of 
blood carrying conduits are identified as arteries, veins, and capillaries.  While each of 
the vessel types is generally responsible for carrying blood throughout the body, each 
vessel classification possesses structural and functional differences.   
The most apparent and fundamental difference between arteries, veins, and 
capillaries is that arteries are responsible for carrying blood away from the heart, whereas 
veins carry blood toward the heart.  Moreover, capillaries serve to link arteries to veins as 
well as provide a location for the exchange of gasses and nutrients between the vascular 
system and tissue beds.  Arteries generally have thicker walls than veins to accommodate 
higher luminal pressure and pulsatile flow.  Given the lower pressure within veins, many 
of the great veins have valves to prevent backflow.  Larger veins may also have a greater 
capacity to mediate an inflammatory response than arteries.  A result of the larger 
mechanical forces imparted upon arteries, distinct regions of the arterial tree, including 
branch points and large curvatures where disturbed flow may result, have an increased 
susceptibility for cellular activation, inflammation, coagulation, and atherosclerosis [20].  
Therefore, due to this arterial propensity for disease and that the arterial vessels are the 
focus of many of the cardiovascular treatments and therapies, tissue-engineered blood 
vessel strategies typically focus on mimicking the structure, function, and physiological 
environment of native arteries.  The remainder of this blood vessel anatomy review will 
focus primarily on arterial structure and function, although comparisons between veins 
and arteries are incorporated.   
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Normal artery structure is comprised of three layers: intima, media, and adventitia 
[21].  The innermost layer, known as the intima, consists of a monolayer of endothelial 
cells that form an anti-thrombogenic surface minimizing friction and preventing platelet 
aggregation [8].  Typically flat and elongated in shape, the endothelial cells (EC) of the 
intima are orientated with their long axis aligned parallel with the flow of blood [8].  The 
endothelial cell layer is generally responsible for regulating vessel permeability and 
smooth muscle cell activity [8].  Larger vessels may also contain a sub-endothelial layer 
known as the basement membrane to structurally support the endothelium [8].  Present 
within the cytoplasm of the endothelial cells are rodlike inclusions called Weibel-Palade 
bodies.  These cytoplasmic inclusions contain von Willebrand factor, also known as 
coagulation factor VIII [8].  Primarily secreted by the arterial endothelial cells, von 
Willebrand factor is often used as an antibody target for immunohistochemical 
identification [8].  
Although the intimal lining of all three of the vessel classifications contains an 
endothelial layer that creates a semi-permeable barrier between the blood and tissue, it is 
important to note that endothelial cells from each vessel type are distinct in comparison to 
each other.  Of the three vessel types, the endothelial lining of capillaries differs most 
starkly from the endothelium of veins and arteries.  Endothelial cells of capillaries are 
highly adapted to the underlying tissue, and depending on the location of the capillary 
bed, are observed to have non-fenestrated, fenestrated, or discontinuous morphologies 
[8]. Conversely, veins and arteries are only observed with non-fenestrated endothelium 
where the tight junctions of arteries are noted tighter than veins [8, 22].  
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The observed morphology and alignment of native endothelial cells from each 
vessel also differs.  Often creating only a 10-micron diameter tube wide enough to allow 
the passage of red blood cells one at a time, an endothelial cell from a capillary exhibits a 
“c” shape encompassing the entire diameter of the vessel [8].  In contrast, EC 
morphology in an artery is long and narrow with the cells aligned in the direction of 
undisturbed flow; endothelial cells from veins exhibit a shorter, wider cell morphology 
[20].  While the cell phenotype of the endothelium is distinct to each vessel category, it is 
speculated that there also exists an element of morphologic plasticity.  Drawing from 
observations gathered from coronary bypass grafting, venous grafts, when used in arterial 
locations, show morphological changes including a thickening of the vessel wall, an 
attribute that generally characterizes arterial vessels.  Furthermore, human saphenous 
veins perfused ex-vivo under physiologic aterial flow conditions showed increased 
production of arterial specific markers and matrix metalloproteinases (MMPs), a family 
of zinc-dependent proteolytic enzymes responsible for extra cellular matrix (ECM) 
degradation during the migration of smooth muscle cells [20, 23].   Altogether, evidence 
demonstrating the phenotypic plasticity of veins appears to suggest that venous and 
arterial identity is, to a certain degree, mediated by the microenvironment of the vessel 
[20].  This is important to understand in the context of this thesis because depending on 
the microenvironment created by a tissue engineering system, cell morphology may 
appear atypical or the cells may respond by producing or not producing various cellular 
factors, potentially compromising the success of the tissue-engineered construct.    
Comprised primarily of elastin sheets and smooth muscle cells (SMC), the middle 
layer known as the media, is responsible for the majority of the vessel strength and the 
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regulation of circulatory dynamics.  The smooth muscle cells, circumferentially arranged 
in a gradual spiral relative to the luminal axis of the vessel, express a spindle shape with 
an elongated nucleus and synthesize collagen, elastin, and other extracellular matrix 
components [9].  Additionally, the smooth muscle cells in the media layer respond to 
specific growth factors produced and excreted by endothelial cells located in the intima 
layer [9].  These growth factors, including PDGF and FGF, may stimulate smooth muscle 
cells to proliferate and migrate toward the adjacent inner intima layer, key characteristics 
in both normal vessel repair and also in the pathological pathways of atherosclerosis and 
restenosis [8].           
The final outermost layer making up the arterial vessel, the adventitia is 
comprised primarily of collagen and elastic fibers produced by fibroblasts that protect 
and reinforce the vessel, as well as prevent the expansion of the vessel beyond 
physiologic limits during the systolic period of the cardiovascular cycle.  In the larger 
vessels, a tiny vessel network, known as the vaso vasorum, is also contained within the 
adventitia to nourish the external tissue of the blood vessel wall [8].   
 
Figure 1.4 – Graphical representation of native artery anatomy [24].  (Image used 
with permission, see Appendix M) 
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Alternate Blood Vessel Replacement Conduits – An Overview of Synthetic Grafts 
and Tissue Engineered Blood Vessel Methods  
Tissue engineering groups have taken various approaches to replicate the three 
layers of a blood vessel.  The literature describes work where the adventitia is recreated 
from either biological or synthetic materials, and often smooth muscle and endothelial 
cells extracted from human sources are used to replicate the medial and intimal layers.  
Although this thesis focuses on developing the cellular component of the engineered in-
vitro blood vessel mimic, it is important to first understand the fundamental role the 
scaffold plays when creating a tissue engineered construct.   
Synthetic Grafts 
For blood vessel specific applications, some of the most common synthetic 
materials include ePTFE and Dacron [15].  While these materials provide excellent 
biocompatibility and customizable porosity properties, albeit not by the end-user, major 
limitations include low compliance and poor bioactive characteristics.  In particular, 
ePFTE is a popular scaffold due to bioactive inertness, better patency rates than similar 
synthetic materials, and material properties that are highly consistent and customizable.  
However, in-vivo use of small diameter ePTFE grafts has led to limited success, likely a 
result of the absence of an endothelial lining and the failure of cells to adhere in-vivo 
under normal blood flow conditions [14, 25-27].  Furthermore, studies have shown that 
smooth muscle and endothelial cells respond to pulsatility and radial stresses rather 
dramatically, thus, the restricted compliance of a scaffold, especially ePTFE which 
possesses poor radial compliance characteristics, presents a major limitation for graft 
materials [28].   
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New elastic compliant synthetic scaffold materials, including polyurethanes and 
poly(carbonate-urea)urethane, have shown to improve cellular response and compliance 
characteristics of the vessel [29].  Work undertaken by the Cal Poly tissue engineering 
group has strived to address the shortcomings of ePTFE by investigating electro-spun 
scaffolds both of a copolymer blend of 90% poly(L-lactic acid) and 10% poly(ε-
caprolactone) as well as poly(L-lactic-glycolic acid).  Material characterization and 
usefulness of these new scaffolds for the BVM remains undetermined.   
To address the biocompatibility and bioactive limitations of synthetic scaffolds, 
other groups have attempted to use biological scaffolds, including extracted collagen and 
decellularized porcine carotids [12, 30, 31].  While these scaffolds do offer improved 
compatibility and biological compliance, they tend to be weak, difficult to handle, and 
inconsistent.   
Based on the drawbacks and limitations of both synthetic and biologic options 
described, no one scaffold, has gained unanimous acceptance.  Yet, it is important to 
recognize the foundational role a scaffold plays in establishing a tissue-engineered 
construct, and having identified a variety of scaffold options commonly used for blood 
vessel engineering, one can better understand the why a particular scaffold and cell 
combination is employed for a particular tissue-engineered blood vessel applications.   
Early TEBV Examples 
Examples of isolating and sodding cells onto polymeric substrates, as the first 
“tissue engineered vascular constructs” can be traced back to the 1970s [14, 32], yet work 
to develop a completely biologic vessel surfaced in 1986 when Weinberg and Bell 
presented the vision of creating a living blood vessel produced in-vitro.  Their published 
work describes a method for seeding collagen gel tubes with bovine aortic endothelial 
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cells, smooth muscle cells, and fibroblasts.  Their methods included first casting collagen, 
culture medium, and smooth muscle cells into a tube shape using a cylindrical mold and 
polished glass mandrel.  After approximately one week, the collagen and SMC construct 
was wrapped in a Dacron sleeve for additional mechanical support and the glass mandrel 
was removed.  The two ends of the collagen tube were cannulated and a suspension of 
endothelial cells was injected into the lumen; the vessel was subsequently rotated at 1 
revolution/min for one week.  Weinberg and Bell reported that the in-vitro construct 
grossly represented a muscular artery, possessing many characteristics of a mammalian 
muscular artery, including an endothelial lining which functioned like a normal 
endothelium [33].  Although analysis showed the model to have limited mechanical 
integrity, especially burst pressure, the publication served as the first example of a 
completely tissue-engineered graft created in-vitro [13].   
During the same year, Foxhall et al. experimented with sodding endothelial cells 
inside ePTFE and Dacron grafts [26].  Attempting to create a more clinically applicable 
construct by addressing the thrombosis observed of synthetic grafts, Foxhall proposed a 
method of sodding endothelial cells extracted from human saphenous veins onto polymer 
scaffolds.  Four-millimeter diameter Dacron and ePTFE grafts were obtained and 
pretreated to enhance cell attachment and growth with a collagen, culture media, and 
fibronectin solution.  Human saphenous vein endothelial cells were then harvested from 
culture and a cell suspension was injected into the pretreated grafts.  After sodding, the 
ends of the graft were clamped and the construct was placed into a culture flask 
containing media.  To promote an even distribution of cell attachment the graft was 
rotated after two hours.  While pre-treating the scaffolds allowed Foxhall to produce 
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endothelialized grafts, attempts to sod cells onto untreated ePTFE or Dacron according to 
the same sodding methods proved unsuccessful, and few cells were observed to adhere or 
grow well on either untreated material.  Also noted was that Dacron proved to be a less 
suitable substrate for cell sodding, potentially a result of the more irregular and 
mechanically less consistent structure of Dacron in comparison to ePTFE.  Foundational 
in the evolution of blood vessel tissue engineering, Foxhall’s efforts demonstrated that 
adult human endothelial cells could be used to endothelialize the lumen of synthetic 
vessel prostheses.  
While both Weinberg and Bell and Foxhall et al. can be considered pioneers in 
the field of blood vessel tissue engineering, the ensuing twenty-three years have seen the 
development of a wide range of methods and techniques that aim to further improve both 
in-vivo and in-vitro application.  Studies conducted by groups including Zilla et al. and 
Swedenborg et al. have established that the patency rate of small diameter synthetic grafts 
can be improved by endothelialization.  Therefore, focusing on cell source selection and 
sodding techniques has been the aim of many tissue engineering blood vessel approaches 
[14, 34-36].  Over the evolutionary process of tissue engineered blood vessels, several 
methodologies for cell sodding have been developed, primarily distinguished by the 
physical force utilized in each process; two of the more common techniques include 
gravitational sodding and hydrostatic sodding [32].  
Sodding Methods  
Sodding efficiency is of particular importance for tissue engineered constructs, 
especially in clinical applications given the substantial costs and time required to harvest 
and culture cells, as well as the effort and infrastructure necessary to maintain a sterile 
environment to prevent infection [14].  Lengthy cultivation or sodding times can limit the 
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practicality of a tissue-engineered construct, especially in emergency situations, where 
the time to wait for cells to be cultured and a graft to be developed may not exist.  
Efficient sodding protocols may therefore lead to more rapid construct development by 
minimizing the time required to achieve a total number of cells necessary for a given 
sodding density [14, 32].  
The most basic of the sodding methods is gravitational cell sodding, which 
utilizes gravitational forces to deliver cells onto the luminal surface of a vascular graft 
[32].  This method, used by Foxhall, is generally performed by filling the graft with a 
suspension of harvested endothelial cells in culture media and maintaining the graft 
horizontally for a determined period of time, rotating periodically to ensure even 
distribution of cells.  In particular, endothelialization by gravitational sodding requires 
that cells undergo morphological conformation into a flattened shape [32].  Early 
gravitational sodding attempts of less than 2 hours often resulted in endothelial cell losses 
up to 95 percent once luminal flow was initiated, prompting the practice of sodding 
followed by 7 to 14 days of post-sodding cultivation [26, 32, 37].  Although simple in 
practice, the lengthy cultivation time of gravitational sodding may limit the practicality of 
the method for some applications.   
Hydrostatic endothelial cell sodding, also referred to as pressure sodding, makes 
use of a pressure differential across a microporous material, either by inter-luminal 
pressure or extra-luminal vacuum pressure, to physically force suspended cells into the 
luminal surface of the vascular graft [32].  A major advantage of pressure sodding is that 
the technique permits relatively fast and efficient cell distribution.  
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In addition to physical sodding techniques, investigators may also use a 
“biological glue” in conjunction with either gravitational or hydrostatic sodding as a 
chemical method to further promote cellular adhesion [32].  Biological glues may include 
substances such as collagen, extracellular matrix, or fibronectin, and serve to “stick” the 
cells to the graft material [32].  A concern with using these substances, especially in 
clinical application, is that any area not covered by cells is prone to exaggerated platelet 
aggregation, clotting, and acute graft failure [32].  In a strictly in-vitro system, which is 
void of common blood clotting constituents such as platelets, the worry of exposed 
biological glue is not a concern for clotting or graft failure.        
Cell Sources and Single Cell Source TEBV Models 
Equally numerous to the number of sodding techniques presented in the literature 
are the various cell sources used for sodding.  Common sources of autologous tissue for 
blood vessel engineering can be divided into either large vessel, (extracted from veins or 
arteries including the umbilical vein/artery or saphenous vein), or microvascular 
(MVEC), which are typically extracted from omental or subcutaneous adipose tissue 
[15].  Human umbilical vein endothelial cells (HUVECs) are highly utilized for in-vitro 
use, cited in both publications related to vascular tissue engineering [31, 38-41] as well as 
in core vascular biology study [42-45] primarily due to their accessibility and 
noninvasive extraction from the typically discarded umbilical vein.   As a result, 
HUVECs have become a well-characterized, cost effective and readily available large 
vessel cell source.   Hedeman et al. presented work comparing HMVECs to HUVECs in 
terms of anticoagulation factor thrombomodulin expression, stating that HUVECs were 
selected to compare against HMVECs due to their prevalence in the in-vitro literature 
[31, 38, 40, 41, 46].  
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In addition to large vessel sources like the umbilical vein, microvacular 
enthothelial cells are also often chosen for sodding of vascular constructs because of their 
abundance in the adipose tissue [47].  Adipose tissue can be extracted from the omentum 
and pericardium through minimally invasive surgical methods, or from subcutaneous fat 
by means of liposuction [47].  Given that the microvascular ECs are exceedingly 
abundant in the adipose tissue, sufficiently high numbers of cells can be obtained for 
sodding grafts without an intermediate cell culture [15, 47].  Despite this, controversy 
exists whether cells extracted from adipose tissue are truly endothelial cells.  Some 
investigators claim that cells extracted from adipose tissue are not endothelial cells, but 
rather mesothelial cells [15, 48-53], while others maintain that the extracted cells are 
indeed endothelial cells [15, 54-56] and point out that each express similar anticoagulant 
substances and that the differences between endothelial and mesothelial cells are 
realistically only in name.   
Furthermore, aside from the physiologic and anatomical differences previously 
discussed between large vessel and microvascular endothelial cells in the anatomy 
section of this introduction, experimental and clinical experience suggests that harvesting 
cells from large vessel veins, as opposed to artery or microvascular, represent the best 
source for physiologically and anatomically representative endothelial cells [46].  This is 
explained by the phenotypic plasticity of these cells and studies showing the accelerated 
formation of an endothelial layer when large vessel vein endothelial cells are sodded onto 
polymeric scaffolds [15, 47].  However, tissue engineering applications using large vessel 
vein endothelial cells are many times limited by the need for expanding and culturing 
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prior to sodding, not often a concern when using microvacular cells given the abundance 
of endothelial cells that can be extracted from adipose tissue [15].   
Co-culture systems 
Given the physiologic relationship between the smooth muscle of the media and 
endothelium of the intima, many groups have pursued the development of dual cell 
source tissue-engineered grafts by incorporating both smooth muscle and endothelial 
cells as a way to take advantage of the interactions between SMCs and ECs.  Co-culture 
systems may take several forms including the culture of SMCs and ECs on opposite sides 
of membranes, sodding of EC on collagen gels infused with SMC, or the direct co-culture 
of EC on SMC [57-61].  Wu et al. describes a method by which a collagen membrane 
was sodded with EC and SMC for the dual sodding construction of a vascular graft.  In 
this model, type I collagen was extracted from porcine skin and molded into membrane 
form under vacuum, and neonatal Wistar rat cardiac SMCs and ECs were harvested for 
sodding [12].  Smooth muscle cells were first sodded onto the outside surface of the 
collagen membrane followed by sodding of the endothelial cells on the inside of the 
membrane.  This method serves as one example of a co-culture system in which smooth 
muscle cells and endothelial cells are sodded on separate sides of a membrane. 
The model presented by Weinberg and Bell represents an example of a co-culture 
system where the smooth muscle cells were infused into a collagen gel and endothelial 
cells sodded onto the collagen construct.  Johnson et al. presented a similar collagen gel 
co-culture model, however, specifically for the in-vitro study of vascular biology [62].  
Unlike Weinberg and Bell who attempted to create an anatomically analogous tubular 
vascular construct, the Johnson model was set up in a parallel plate flow chamber with 
linear cultures of smooth muscle and endothelial cells.  In this model, type I rat tail 
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collagen tubes were cast with human aortic smooth muscle cells and cultured.  Human 
aortic endothelial cells were subsequently sodded onto the surface of the collagen and 
smooth muscle construct.  The results from the Johnson study demonstrated that the type 
of ECM and presence of smooth muscle cells, as well as the application of shear stresses, 
extensively influences endothelial cell activity [62].   
While the collagen gel and membrane co-culture systems provide a method to 
produce a blood vessel construct using biological scaffold materials, these systems can 
generally only bring the ECs and SMCs to within only 10-50 µm of each other, 
increasing the diffusion distance for short lived metabolites that play a role in cell 
interactions [32].  Therefore, a system of direct co-culture of endothelial cells onto 
smooth muscle cells represents a model for cells to be in close contact with one another, 
facilitating the interactions and communication between each.   
Having identified the shortcomings of other co-culture methods, Lavender et al. 
[61] reported the development of a system for the direct co-culture of endothelial cells 
onto smooth muscle cells, specifically with the aim of examining substrate material, 
culture media, cell seeding density, and SMC phenotype.  This co-culture model 
consisted of a layer of porcine carotid artery SMC sodded onto a culture surface coated 
with a basal adhesion protein [61].  After several days of culture, a medial adhesion 
protein was added onto the SMC layer followed by the direct sodding of porcine carotid 
endothelial cells.  Similar to the Johnson model, studies reported by Lavender were 
performed in a parallel plate flow chamber.  Experimentation with various combinations 
of culture media and growth environments led to the conclusion that successful co-culture 
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could be obtained using a polystyrene substrate with a combination of a subconfluent, 
non-proliferative population of SMC and a confluent density of EC [61].   
Additional direct culture construction methods demonstrated by L’Heureux et al. 
[40, 63] and McFetridge et al. [31] describe vascular grafts made with a co-culture of 
SMC and EC through the layering of SMC sheets and subsequent luminal EC sodding.  
In both methods, human umbilical vein smooth muscle cells were cultured for 3 to 4 
weeks to form tissue sheets.  These tissue sheets, which included addition of adventitial 
fibroblasts, were wrapped around a mandrel and cultured for 8 weeks.  Ultimately, the 
mandrel was removed and human umbilical vein endothelial cells sodded onto the lumen 
of the grafts; the complete co-culture system was then cultured for an additional week.  
This work demonstrates that a dual layer TEBV can be created through the co-culture of 
human umbilical vein cells and further illustrates methods by which a the protocols of 
this thesis will be derived. 
Another co-culture system developed by Sun et al. [64] made use of bovine aortic 
cell sources and ePFTE tubes as scaffold substrates.  According to their methods, smooth 
muscle cells were sodded by pressure sodding onto the luminal surface of the ePFTE, 
pretreated with 70% ethanol and coated with a layer of fibronectin.  Following a culture 
time of 7 days after smooth muscle sodding, endothelial cells were pressure sodded 
directly on the SMC layer.  Using ePTFE and a co-culture of SMC and EC, the Sun blood 
vessel serves as a foundation for the ePTFE co-culture BVM described in this thesis. 
Together, the work completed by Sun, L’heureux, and McFetridge demonstrates a 
variety of co-culture approaches.  By understanding the focus of these methods and 
modifying elements of each to suit an in-vitro application, protocols for creating a more 
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physiologic dual layer blood vessel mimic can be developed and are pursued throughout 
this thesis.  
TEBV Summary 
Presented as an overview of general blood vessel tissue engineering methods, the 
preceding review of the literature demonstrates the wide variety and complex scope of 
blood vessel tissue engineering approaches.  Clinical experience suggests that a blood 
vessel substitute that most closely resembles a native vessel will be most successful.  
However, a blood vessel construct that best resembles native structure, the L’Heureux 
model for example, may fail to meet the clinical requirement of being producible in a fast 
and efficient manner.  Allowing three months for a graft to develop, as is required by the 
L’Heureux model, may be unfeasible for some clinical or commercial applications.  
Therefore, given the multitude of applications and objectives, no one method for creating 
a tissue engineered construct has emerged as standard practice, and the evolution and 
development of new techniques, methods, and approaches will continue to drive the field 
of tissue-engineered blood vessels.  For the purposes of our laboratory and this thesis 
work, the range of existing techniques provides a foundation for improving the current in-
vitro BVM system. 
Restenosis and the Relevance of Incorporating of a Smooth Muscle Layer into a 
BVM System 
The mechanism of restenosis is of particular interest to the study and development 
of intravascular devices and atherosclerotic therapies given the correlation between 
physiological responses and the overall success of the procedures.  Several molecular and 
cellular events are sequentially responsible for the collective effects of restenosis 
following an intravascular procedure.  The initial reaction observed following 
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intravascular device implantation is elastic recoil by the elastic fibers, which is 
responsible for the decrease in lumen diameter characterizing the early phases of 
restenosis.  The balloon catheter stretching, as well as subsequent device implantation if a 
stent or other intravascular device is used, causes injury and stripping of the endothelial 
lining resulting in endothelial activation, subintimal exposure, and a cascade of platelet 
adherence and aggregation, fibrinogen binding, and thrombus formation.  The newly 
formed thrombus acts as a scaffold for neointimal growth and activated platelets release 
chemotactic factors that stimulate smooth muscle cell proliferation and migration to the 
injury site.  Following migration, the smooth muscle cells may reorganize the thrombus 
and synthesize ECM and collagen, furthering the restenosis.  Continued inflammatory 
and cellular responses contribute to an array of events, which direct matrix and cellular 
proliferation.  Gradual remodeling eventually leads to the overall loss in lumen size, and 
although vessel stenting serves to minimize the mechanical effect of elastic recoil, device 
implantation and deeper penetration of stent struts exacerbate the cellular mechanisms 
leading to in-stent restenosis. [11]  
Given that the primary cellular mechanisms of restenosis are driven by the 
migration of smooth muscle cells, the need to address the occurrence of in-stent 
restenosis due to cellular mechanisms has driven the advent of stents coated with anti-
proliferative agents, better known as drug eluting stents (DES).  Paclitaxel, 
dexamethason, and sirolimus are of the more common anti-proliferary agents used as 
DES drugs, and serve to minimize the neointimal hyperplasia associated with in-stent 
restenosis [65].  During a study to observe the effects of dexamethasone on rat aortic 
smooth muscle cells, it was found that MMP production and SMC migration was 
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inhibited in a dose-dependent fashion without an increase in early or late apoptosis [23].  
Similar studies using paclitaxel in rabbit iliac also show dose-dependent decrease in 
neointimal growth [18].  More specifically, paclitaxel acts to inhibit mitosis by 
stimulating microtubule formation, binding to the β-tubulin subunit, and provoking the 
disassembly of the microtubules, simultaneously resulting in irregular accumulations of 
microtubules that arrest cells in G2/M phase of mitosis.  Additionally, paclitaxel shows 
effects that are independent of cell cycle, including increased integrin mobility and 
adhesion molecule activation.  Interestingly, the effect of paclitaxel is distinct inhibition 
of SMC migration, both in-vivo and in-vitro [65]. 
Similar to paclitaxel and dexamethasone, sirolimus analogues rapamycin and 
everolimus have also been used to control the smooth muscle cell effects of restenosis.  
Sirolimus is unique in that the primary mechanism is inhibition of DNA synthesis by 
binding an immunophilin protein that is upregulated in neointimal SMC.  Once bound, 
the sirolimus-immunophilin complex undergoes various modifications, ultimately acting 
on the checkpoints that control DNA damage and repair.  While the exact downstream 
pathways are not yet completely understood, the sirolimus complex is involved in the 
transition between G1 and S phases, thereby arresting the cell in late G1 before DNA 
replication can occur.  Studies using sirolimus eluting stents in porcine models have 
shown reduced inflammation, paralleled with the inhibition of neointimal hyperplasia.  
Furthermore, rapamycin has been shown to inhibit migration by promoting the 
contractile, as opposed to the proliferative, SMC phenotype [65].   
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The direct effect that many pharmacologic agents used with intravascular devices 
have on SMCs contributes to the proposed value of incorporating a smooth muscle cell 
layer into the BVM model. 
Goals of this Thesis 
Although much work has been done to create physiologically representative tissue 
engineered blood vessels, little work has focused specifically on creating an in vitro 
model to be used for evaluation of intravascular devices, especially using human cell 
sources.  Moreover, the setup complexity and labor required by some TEBV methods do 
not make them commercially feasible to meet the demand that exists for a time and cost 
efficient evaluation tool.  Such a tool could aid in the more rapid development of new 
devices, materials, and therapies, without the dependency and limitations associated with 
early animal studies and preclinical assessment.  Ultimately, faster and less expensive 
device development means safer and more accessible care for patients.  The Cardinal et 
al. BVM therefore aims to be a 3-dimensional, pre-assessment tool for the evaluation of 
tissue response to intravascular devices.  This BVM model is constructed using human 
microvessel endothelial cells (HMVEC) isolated from liposuction fat that are pressure 
sodded onto 3mm or 4 mm inner diameter ePFTE.  The in-vitro bioreactor system, which 
could be housed inside an average incubator, was configured with a BVM chamber 
housing the graft in series with a media reservoir and connected to a peristaltic pump for 
driving fluid flow through the BVM graft.   
Using the Cardinal et al. BVM as the foundational model, the goal of this thesis is 
to further develop a more physiologically representative blood vessel by addressing the 
cellular components of the in-vitro BVM system.  Given that the native structure of a 
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blood vessel contains three layers, including the distinctive cellular components of intima 
and media, adding a media layer into the blood vessel mimic system is of special interest 
for this study.  Integration of this smooth muscle layer may provide valuable utility to the 
BVM in the study of pharmacologic agents, especially those included in some drug 
eluting stents.  Furthermore, having established the differences between large vessel and 
microvascular endothelial cell sources, commercially available human large vessel cell 
sources will be investigated as a substitute to the human microvascular cells used in the 
previous model.   
Paramount in the continued development of the tissue engineered blood vessel 
mimic, is maintaining the theme of developing a cost effective and commercially feasible 
system.  Protocols and methods should be developed such that unnecessary costs and 
labor are not added.  Set-up time for the BVM should ideally be within one to two weeks, 
therefore, it is a goal of this thesis to determine the sodding densities of both SMC and 
EC to achieve confluent layers within one week.   
Objectives 
Taking into consideration the established goals of this thesis, it is the aim of the 
studies contained herein to investigate the following objectives.  First, commercially 
available large vessel smooth muscle cell and endothelial cell sources will be investigated 
and identified.  Once identified, experiments will be conducted to develop sodding 
protocols for smooth muscle cells alone on ePFTE.  Studies with variable sodding 
densities will be conducted to determine a minimum sodding density necessary to 
establish confluent cell coverage.  After the study with smooth muscle cells, studies will 
be conducted with the selected large vessel endothelial cells alone on ePTFE to support 
Chapter 1 – Introduction 
 
 31 
the hypothesis that a large vessel endothelial cell BVM can be created in a similar fashion 
to the previous HMVEC BVM.  Following the studies with SMC and EC individually, 
further experimentation will aim to develop a dual-sodding approach using the identified 
large vessel cell sources.  Development and implementation of protocols for blood vessel 
mimics using large vessel cell sources, with a final effort towards preliminary 
development of the dual-sodding approach will serve as the end goal of this thesis.  
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Introduction 
Treatments and clinical therapies for managing cardiovascular diseases, especially 
the effects of atherosclerosis, have undergone substantial growth, development, and 
practice, including the expanded use of angioplasty and stenting therapies.  However, the 
most significant challenge surrounding these interventional therapies continues to be 
controlling the effects of restenosis without altering the normal healing process [65].  The 
excessive proliferation of cells that characterizes restenosis is in part linked to a 
multiplication and migration of smooth muscle cells, often in response to the induced 
stress and damage to the vessel wall caused by the deployment of angioplasty balloons 
and stents [65].  Therefore, improving the physiological accuracy and analytical 
usefulness of the in-vitro blood vessel model should include investigating the addition a 
smooth muscle cell layer to the BVM.  Limited prior work exists using a combination of 
human smooth muscle cells and ePTFE scaffolds for tissue engineering applications, 
none of which address an in-vitro BVM application.  The Sun paper [64] presents a 
parallel SMC and EC co-culture on ePTFE, however, uses bovine aortic cells rather than 
human sources.   
The initial steps of introducing a SMC layer into the in-vitro BVM for this thesis 
included selecting the appropriate human SMC cell source, and experimenting to 
determine whether the cells adhere to the polymer scaffold.  Once established that the 
smooth muscle cells would adhere to the ePTFE scaffold, experiments to determine the 
minimum sodding densities were conducted.  The purpose of the experiments using 
smooth muscle cell alone was to understand at what sodding density a confluent cell layer 
could be achieved, as well as how the cell layer developed and changed, both 
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immediately after sodding and over an extended period of time.  Although the long-term 
goal of improving the cellular aspect of the BVM is to create a physiologic dual layer 
system, it is essential to first understand the feasibility of using each specific cell type 
individually.  Therefore, it was necessary to conduct a set of experiments with smooth 
muscle cells alone.  These experiments are described in this chapter. 
Materials and Methods 
The experimental approach for the smooth muscle cell studies was to first 
understand the cell density range required to create a confluent layer immediately after 
sodding, prior to any rearrangement or proliferation of the cells within the lumen of the 
graft.  Therefore, studies were conducted at densities from 2.5x105 cells/cm2 to 1.0x106 
cells/cm2.  These experiments were all conducted over the period of one day.  After 
evaluating the results of varying sodding densities, time studies were conducted to 
understand the dynamics of the cells over a 7 day time period.  Two additional studies at 
specific sodding densities of 5.0x105 and 7.5x105 cells/cm2 were run over 7 days.   
Cell Selection and Culture 
Human umbilical vein smooth muscle cells (HUVSMC) were selected as the cell 
type for the BVM smooth muscle component.  Umbilical vein cells were selected due to 
their prevalence observed throughout tissue engineering and blood vessel literature for 
reasons discussed in Chapter 1.  Briefly, the umbilical vein provides an accessible and 
therefore cost effective location for cell extraction.  The HUVSMC for this thesis were 
purchased from Sciencell Research Laboratories, Carlsbad, California.  Sciencell shipped 
the cells at a concentration of at least 5.0x105 cell/ml in 1 ml cryopreserved vials on dry 
ice.  The vials were quickly placed into a liquid nitrogen dewar upon arrival at Cal Poly, 
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San Luis Obispo.  When ready for culture, the vials of cells were thawed and cultured 
according standard practices.  During culturing, the cells were maintained at 37°C and 
5% CO2 in an 80-100% humidified incubator.  Temperature and carbon dioxide levels 
were monitored by thermometer and fyrite gas anaylser respectively; humidity was based 
on the incubator gage readings.  Untreated T75 and T225 BD cell culture flasks and 
Sciencell smooth muscle cell media were used for smooth muscle cell culture and 
population expansion.  Cell cultures were monitored using an inverted light microscope.  
Components of the smooth muscle cell culture media can be found in Appendix F.  
Passaging of the cells was conducted at approximately 80% to 95% confluency using 
0.25% trypsin (Sigma).  HUVSMC were received at P1 and passed and frozen at each 
passage level up to P14.  Cells designated for BVM studies were used between P8 to P14 
based on Sciencell data for cell phenotype in culture.    
Preparation of Bioreactor and ePTFE Grafts Prior to Set-up 
Set-up and preparation for each study began approximately one week prior to cell 
sodding.  For each study, the required number of grafts of four millimeter (4mm) 
diameter ePTFE tubing was cut to four-centimeter (4 cm) lengths.  A female luer to barb 
fitting was placed into each end of the graft and the ePTFE tube was sutured to the barb 
using 2-0 silk suture (see Appendix A).  Each of the sutured ePTFE grafts were placed 
into individual autoclave bags and autoclaved for 30 minutes at 250°C, with a 30 minute 
drying cycle.  The required number of forceps, flasks, and supplementary tools requiring 
sterilization were packaged and sterilized during this time preceding set-up of the study.  
Additionally, the bioreactor chambers, lids, two-port reservoir lids, and bioreactor tubing 
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were sent to the Cal Poly Veterinary Clinic to be Ethylene Oxide (EtO) gas sterilized, a 
process requiring a minimum of 24 hours to complete.   
The day before the study was used to finish preparing the sterilized grafts and to 
make the necessary culture medias (see Appendix A).  First, bioreactor media (also 
referred to as human complete without endothelial cell growth supplement (ECGS), with 
antibiotics) was made by combining 500 ml M199, 56 ml Fetal Bovine Serum (FBS), 0.6 
ml Fungizone, 5 ml Penicillin/Streptomycin, 5 ml L-Glutamine, and 2.8 ml HEPES 
buffer.  All constituents of the media were vacuum filtered through a 0.2 µm filter into a 
sterile bottle and labeled appropriately.  Next, conditioning media was made using 500 
ml M199, 83 ml Fetal Bovine Serum (FBS), and antibiotics (0.6 ml Fungizone and 5 ml 
Penicillin/Streptomycin).  The conditioning media constituents were also filtered into a 
sterile bottle and labeled.   
A volume of approximately 10-12 ml of conditioning media per graft was 
removed from the conditioning media bottle and placed under vacuum in a vacuum flask.  
This step, completed before the denucleation of the ePTFE grafts, is meant to remove air 
in the media, thereby minimizing renucleation of the grafts throughout the overnight 
conditioning.  The ensuing graft denucleation process required the grafts to be submerged 
in a tube of sterile 70% EtOH for 15 minutes followed by 15 minutes in sterile 100% 
EtOH.  The 70% and 100% concentrations of EtOH were placed into 50 ml conical tubes 
to accommodate the number of grafts used for the study, taking care that each graft was 
completely submerged.  The objective of the denucleation step was to remove air from 
within the pores of the ePTFE scaffold.  Typically, a 50 ml conical with 40-45 ml of 
alcohol would hold 4-5 grafts.  It was unnecessary to place each graft into individual 
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tubes as long as each graft was completely submerged in the EtOH and denucleation of 
the grafts was observed.  Periodic agitation by shaking or hitting the conical tube 
throughout the denucleation helped aid the process.  A visual inspection of the graft 
changing from white to transparent in color was used to determine if the grafts were 
sufficiently denucleated.  Following the final submersion in 100% EtOH, and after 
ensuring that all grafts were suitably denucleated, each graft was individually placed into 
a 15 ml conical tube containing 10-12 ml degassed conditioning media.  Each of these 
vials were labeled and placed into the incubator at 37°C overnight.  Any remaining 
degassed media was discarded and the previously mixed conditioning and bioreactor 
medias were placed into the refrigerator (4°C) for later use.   
All HUVSMC studies described within this chapter were conducted following 
these preparatory steps prior to each experiment.  Deviations from the described steps 
included using previously mixed media and skipping the EtO gas sterilization of the 
bioreactor chambers for acute studies.  Skipping the gas sterilization was excluded only 
during the first HUVSMC study (Study 1) due to the one day duration of Study 1. 
Set-up day 
Preparation on the day of a BVM study began by warming the previously mixed 
bioreactor and conditioning media in a 37°C water bath.  The appropriate number of 
bioreactor chambers, lids, two-port lids, and forceps were gathered and organized for 
easy access throughout the set-up.  The next step was the insertion of the sterile grafts 
into the sterile bioreactor chambers, requiring the use of sterile gloves and the assistance 
of a non-sterile partner.  Having both a sterile person and an aseptic partner served to 
ensure that sterility of the grafts was maintained during the set-up, thereby minimizing 
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the risk of infection during the study.  In short, the non-sterile partner gathered and 
provided the bioreactor chambers, two-port lids, and forceps as needed.  The sterile 
partner, careful to avoid touching any non-sterile surface, would take a bioreactor 
chamber from the non-sterile partner within the hood.  To avoid renucleation of the grafts 
during insertion, the non-sterile partner filled the chamber with approximately 250-300 
mL of bioreactor media prior to the insertion of the grafts.  Next, following aseptic 
handling techniques, the non-sterile partner collected the conditioned grafts from the 
incubator and provided them to the sterile partner.  The sterile partner, using sterile 
forceps, grasped the denucleated, conditioned grafts and inserted them into the bioreactor 
chamber, ensuring the blue lines on the ePTFE were facing up.  After the graft was 
secured into the chamber, the non-sterile partner closed the chamber with a lid.  This 
process was repeated for each graft set up during a given study (see Appendix A).  Once 
all lids were secured, the sterile partner could discontinue maintaining sterility and again 
handle non-sterile materials, continuing to follow proper aseptic techniques.   
The grafts were next actively primed using conditioning media (as opposed to the 
more passive method of priming by soaking grafts in conditioning media overnight).  A 
syringe containing conditioning media was connected to the inlet of the bioreactor and 
media was flushed through the graft until air contained within the lumen was removed.  
After flushing the lumen, the luminal outlet of the bioreactor chamber was clamped and 
approximately 20-30 mL of conditioning media was transmurally forced through the 
pores of the ePTFE.  This conditioning step was repeated for each graft.  Deviations from 
the described steps occurred only during the first HUVSMC run (Study 1), where the 
bioreactor media was substituted with the Sciencell SMC media.  Since it was unknown 
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whether the SMCs needed the supplementary grow factors in the Sceincell SMC media, 
and a test had not yet been completed culturing SMC in bioreactor media, the first study 
was conducted using Sciencell media.  After Study 1, a flask of HUVSMCs was cultured 
using bioreactor media without consequence to the cells.  Therefore, all subsequent runs 
were completed with bioreactor media as described in the methods and protocols. 
After syringe-priming each graft, two-port lids were placed onto 50mL conical 
tubes containing approximately 40-45mL of conditioning media.  The two-port tubing 
was primed with media and attached to the bioreactor chamber, ensuring that the inlet 
and outlet tubes of the bioreactor chamber were mated with the correct inlet and outlet of 
the two-port reservoir.  The assembled bioreactor and two-port reservoir (see Figure 1.3) 
were attached to a peristaltic pump inside a large Shellab incubator, maintained at 37°C 
and 5% CO2; humidity was not controlled inside the large incubator.  Initially, the outlet 
of the bioreactor chamber was opened to allow any air trapped within the tubing to pass; 
the objective is to avoid allowing air to pass through the pores of the graft.  Once any air 
was removed from the system, the luminal outlet of the bioreactor chamber was again 
clamped and the conditioning media was forced transmurally through the graft for a 
minimum of ten (10) minutes at 100 rpm (9 mL/min).  After this active conditioning 
period, the media flow was stopped and the conditioned chambers with grafts were left in 
the large incubator until sodding. At this time, the media reservoirs containing 
conditioning media were exchanged with reservoirs containing 40-40mL of bioreactor 
media.  All clamps on the bioreactor system were closed to prevent the backflow of 
media. 
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Cell Harvesting and Counting 
Depending on the number of BVMs and the designated cell sodding densities that 
were scheduled for a given study, cell culture of HUVSMC began 3 to 7 days prior to the 
set-up day.  Typically, a confluent T225 of HUVSMC, which contained on average 
approximately 15 million cells, provided a sufficient number of cells for each of the SMC 
studies described in this thesis.  Cell culture was closely monitored in the days 
immediately preceding set-up of a bioreactor run, and scheduling of the set-up was 
adjusted accordingly to ensure that the required number of cells for a given study were 
available. 
Following set-up and conditioning of the BVM grafts, cell flasks were removed 
from the small Shellab incubator and inspected.  Cells were harvested with approximately 
3 mL of trypsin for T75 flasks and 9 mL for T225 flasks.  Release of the cells from the 
culture flask was confirmed by observation under an inverted light microscope.  After 
cell release, the trypsin was deactivated with a volume of Sciencell SMC media 
equivalent to the volume of trypsin used.  A small volume (<1mL) of the suspension was 
transferred to a 15mL tube or microfuge/PCR tube.  The remaining suspension of cells 
was transferred to a 50 mL conical tube and placed into a centrifuge at setting 4 (1587.5 
rpm, 437.5 g’s) for 5 minutes in order to isolate the cells from suspension.   
During centrifugation of the cell culture, the small volume taken from the 
suspension was prepared for cell counting by mixing equal parts of the cell solution with 
trypan blue dye.  Typically, 100 µL of each would provide sufficient staining contrast 
and volume for use with a Neubauer Improved grid type hemocytometer (VWR catalog 
#82030-470).  The stained cell solution was vigorously mixed with a pipette and added to 
both the “A” and “B” side of the hemocytometer slide, and an average of the two counts 
Chapter 2 – Smooth Muscle Cell Layer 
 
 41 
was obtained for a given cell suspension.  Once the total number of cells was determined 
for the cell suspension, a re-suspension volume was next calculated.  For simplification, 
the re-suspension volume was typically based on the total cell count of the solution such 
that after re-suspension of the cells following centrifugation, a dilution of 1.0x106 
cells/mL was achieved.  For example, if the total count of cells was 12x106 cells, 12 mL 
of media would be added to re-suspend the centrifuged pellet.   
After establishing a re-suspension volume and allowing the 5 minute 
centrifugation cycle to finish, the 50 mL conical tube containing the centrifuged cell 
pellet was taken back into the hood and the supernatant aspirated off, taking care not to 
aspirate cells from the pellet at the bottom of the tube.  The cell pellet was next re-
suspended using the established volume of Sciencell SMC media.  This cell suspension, 
now ready for sodding was temporarily set-aside while the bioreactor chambers were 
removed from the incubator and prepared for sodding.  Removal of the bioreactors was 
typically completed during the centrifugation cycle thereby minimizing time for cells to 
settle before sodding.     
Sodding of Cells  
In preparation for cell sodding, the conditioned bioreactors with grafts and 
attached media reservoirs were removed from the large incubator and moved into the 
hood.  The bioreactors and reservoirs were arranged such that the bioreactor outlet could 
be disconnected into a petri dish to relieve the buildup of pressure during sodding.  The 
luminal outlet valve of the bioreactor chamber was maintained closed while the outlet to 
the extraluminal space was maintained open during the pressure sodding.  Once the 
bioreactors were arranged appropriately, the suspended mixture of cells was gently 
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agitated using a pipette to ensure a uniform cell suspension throughout the solution.  
Depending on the desired sodding density, an appropriate volume of cell suspension was 
collected into a syringe, injected through the three-way valve of the bioreactor inlet 
(proximal to the graft), and transmurally deposited onto the lumen of the ePTFE graft.  A 
steady yet gentle flow (approximately 2 mL/min) was manually maintained with the 
syringe during sodding.  
The sodding volume was determined according the surface area of each graft 
used, following the given formula: SA = 2πr(L) where r is the radius and L is the 
functional length of the graft.  For all SMC studies, 4 mm diameter, 4 cm long ePTFE 
grafts were used.  While the grafts were cut to 4 cm long, the functional length of the 
graft was assumed to be ½ cm less than the overall length due to the surface area lost to 
the barb connections the grafts were sutured to.  Therefore, for a 4 cm long graft, the 
functional surface area was calculated to be:  
SA = 2π(0.2)(3.5) cm2 
SA = 4.4 cm2 
 
After calculating the functional surface area, the appropriate volume of the re-suspended 
cell suspension required was calculated based on the desired sodding density. 
Volume cell re-suspension (mL) = 
(1/Re-suspended cell density (cell/mL)) * Desired sodding density (cells/cm2) * Functional Surface Area (cm2) 
 
Immediately following the deposit of cells by pressure sodding, each graft was “chased” 
with 7 – 10 mL of bioreactor media maintaining a gentle, steady pressure with the 
syringe.  This second injection was performed to ensure cells were forced into the graft 
lumen.  After chasing with bioreactor media, all valves on the system including the inlet 
and outlet were closed, preventing backflow from dislodging the cells, and the outlet of 
the bioreactor was reconnected to the reservoir.  The system was reattached to the 
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peristaltic pump in the large incubator and transmural flow (luminal outlet valve from 
graft still closed, all other valves open) immediately resumed at 10 rpm (0.8 mL/min).    
Pump Settings and Ramp-up Schedule 
Transmural flow established immediately after cell sodding was continued at 10 
rpm for one hour, after which time the luminal outlet valve of the bioreactor was opened, 
and luminal flow was maintained at 10 rpm for an additional hour.  After an hour of 
luminal flow at 10 rpm, the pump speed was increased to 20 rpm and maintained 
overnight.  Depending on the duration of the study, two actions proceeded the following 
morning.  For studies lasting one day (Study 1 & 3), luminal flow was maintained at 20 
rpm until the grafts were harvested for analysis.  For studies lasting longer than one day, 
luminal flow was increased in 15-rpm increments every hour until approximately 12 
mL/min (150 rpm) was achieved.  Flow was maintained at this rate until the graft was 
harvested.  For the seven-day studies, time points of 1, 3, 5, and 7 days were collected; 
day 1 grafts were harvested before pump RPM ramp up.  Additionally, for the longer 
duration grafts, the bioreactor media was changed every 3 days.   
Harvesting and Prepping of Grafts for Analysis 
Graft harvesting was performed at the conclusion of each study (see Appendix C).   
All of the clamps on the bioreactor system were quickly closed, the pump stopped 
immediately after closing the valves, and the system disconnected from the pump.  The 
chamber and reservoir were removed from the incubator onto a non-sterile working 
environment.  Depending on the number of grafts being harvested, 15 mL conical tubes 
containing approximately 10-12 mL of Histochoice were prepared and labeled for each 
graft.   The lid of the bioreactor was next detached from the chamber and the graft was 
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removed from the barbs of the fittings using a surgical scalpel, taking care not to twist or 
distort the graft.  Additionally, using a permanent laboratory pen, a black dot was marked 
at the distal end of the graft to indicate the direction of media flow.  The freed graft was 
finally transferred to the appropriate conical tube containing Histochoice.  Grafts 
remained in Histochoice at room temperature for at least 1 hour for fixation to occur.  
The remaining media and residual graft material were disposed of appropriately and the 
bioreactor systems cleaned with hot water in preparation for subsequent uses.      
SEM Imaging and Histological Analysis 
Depending on the analysis modality chosen, fixed grafts were prepared according 
to varying methods.  Analysis modalities for HUVSMC studies included scanning 
electron microscopy (SEM) and histological analysis.  Preparation for SEM analysis 
included removing the grafts from Hisotochoice and cutting circumferentially a 3 – 8 mm 
section using a surgical scalpel.  The remaining unused graft was returned to the 15 mL 
tube of Histochoice and stored.  The cut section was next cut in half luminal to yield two 
pieces that exposed the interior of the graft.  These prepared samples were left to air-dry 
overnight in a desiccator, fixed to an SEM stage, and gold sputtered for 30 - 60 seconds. 
The samples were ready for SEM imaging after gold sputtering.   
Samples for histological analysis were circumferentially cut from each graft and 
submerged into additional conical tubes filled with Histochoice.  Histology samples were 
embedded at either Cal Poly or taken to Central Coast Pathology (San Luis Obispo, CA) 
and oriented for luminal cross-sections, also taking note of the top/bottom (blue lines on 
ePTFE) and proximal/distal position in the block.  Samples were embedded with the 
distal side down.  After embedding, the samples were sectioned at 6-8µm and stained 
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with Hemotoxylin and Eosin (H&E) according to the protocol outlined in Appendix H.  
Images were collected using light microscopy and the cell layer thickness was analyzed 
using ImageJ software.  
Cost Analysis 
Cost analysis was conducted to compare the cost of setting up one HUVSMC 
BVM to other BVM systems, including the previous HMVEC model.  The analysis 
assumed a passage number of P8 and was used to determine the costs associated with 
thawing, passing once, and running one bioreactor, including media and disposable costs.             
Results 
Smooth Muscle Cells Under Light Microscopy 
After receipt of the cryopreserved HUVSMC vials from Sciencell, cells were 
cultured and expanded, as described in the Methods.  Throughout this process, 
morphological characterization and growth dynamics were examined using an inverted 
light microscope.  When grown on untreated culture flasks, human umbilical vein smooth 
muscle cells showed relatively homogeneous size and form, generally appearing 
elongated and spindle shaped.  At lower confluency, some cells showed a less elongated 
morphology, exhibiting a spread and flattened shape.  However, as confluency within the 
flask increased and cells began to make contact with one another, HUVSMC morphology 
generally represented the elongated spindle shape, where cells lined up to create a “dried 
riverbed” appearance.  Approximate population doublings occurred over 8 to 12 hours.  
As an example of the growth characteristics of the HUVSMC, a culture approximately 
40-50% confluent was passed at P2 at 9:30 am (see figure 2.1 a-c).  The cells were 
checked on the same day at 1:00 pm and 5:00 pm and showed 60-65% and 80-85% 
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confluency respectively.  The following morning the cells exhibited 100% confluency. 
The cells did not show a confluency-induced plateau phase and growth continued after 
100% confluency was achieved.      
 
Fig. 2.1a 
     
 
Fig. 2.1b 
     
 
Fig. 2.1c 
 
Figure 2.1 - HUVSMC in culture. 40-50% confluent at 9:30 am (a), 60-65% confluent 
at 1:00 pm (b), 80-85% confluent at 5:00 pm (c). 
 
ePTFE Reference 
An un-sodded sample of ePTFE, shown below in figure 2.2, was imaged to 
compare as a control to grafts sodded with cells.  Notice the porous nature of ePTFE and 
the microstructure of nodes and internodes that permits pressure sodding of cells.  The 
luminal axis of the graft, designated by arrows in figure 2.2a, is oriented in the vertical 
direction, and the nodes of the ePFTE are oriented circumferentially in relation to the 
lumen.   
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Figure 2.2 - Control sample of ePTFE at 148x (a) magnification and 1230x (b) 
magnification highlighting the porosity created by the node and inter-nodal 
structure.  The arrows in 2.2a signify the direction of the lumen axis.  The nodes and 
inter-nodes are labeled in 2.2b.    
 
Study Results  
General Observations and Deviations: Study 1 
Study 1 focused on experimenting with various sodding densities to determine a 
density range that resulted in a confluent cellular layer of SMCs.  In addition to analyzing 
different densities, Study 1 served to test the feasibility of pressure sodding and growing 
HUVSMC on ePTFE scaffolds with the particular bioreactor systems used in this thesis.  
Taking into account that Study 1 was scheduled to last one day and the media being used 
contained penicillin and streptomycin antibiotics, gas sterilization of the two-port lids 
was omitted for two of the four bioreactors setup due to scheduling constraints.  No 
indication of contamination or infection was seen upon examination of the grafts or 
media at the conclusion of the study for any of the bioreactors.   
HUVSMC cells were thawed at P8 in a T75 and passed and cultured in a T225 to 
achieve a confluent P9 cell population for sodding.  The 100% confluent T225 yielded an 
average cell count of 15x106 cells; the “A” and “B” cell count results from the 
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hemocytometer were 14x106 cells and 16x106 cells respectively.  The centrifuged pellet 
was resuspended in 15 mL of media to yield a solution with a cell density of 1.0x106 
cells/mL.   
During the insertion of the grafts into the biochambers, grafts 1 and 4 showed 
renucleation along portions of the graft.  The renucleation observed during graft insertion 
prompted a change in the procedure such that the chamber of the bioreactor was filled 
with media prior to transferring the graft from the conditioning media to the biochamber.  
Future bioreactor setups did not show renucleation after adjusting the procedure.   
Another deviation noted during the setup of Study 1 included not chasing 
bioreactors 3 and 4 with bioreactor media after sodding cells.  No observations could be 
made upon analysis of the grafts that suggested that omitting the chasing step 
significantly affected cell sodding.  Furthermore, during the transmural sodding stage of 
the setup, an observation was made that the clamp on bioreactor 3 was loose on the pump 
resulting in no or slow flow.  While this observation was made and resolved quickly, the 
possibility of backflow, and therefore potential cell loss, could not be dismissed. 
At the conclusion of the study during harvesting of the grafts, the observation was 
made that small air bubbles were trapped within the lumen of graft 1.  Later analysis of 
the graft showed voids within the cell layer, likely a result of the air bubbles observed in 
the lumen during the bioreactor run.   
Histology images were not analyzed for Study 1 since the grafts were cultivated 
for only one day and the aim of the Study 1 experiments was to observe cell coverage at 
different sodding densities rather than the development of a cell lining over time.  
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SEM Images: Study 1 
SEM images from Study 1 were taken to observe the presence of cells after 
sodding and show results of both under confluent and confluent cell linings.  Images 
taken from graft 1 at 2.5x105 cells/cm2 and graft 2 at 5.0x105 cells/cm2 sodding densities 
signify examples of an under confluent and confluent respectively.  With the exception of 
graft 3, which did not show the presence of any cells, grafts above 5.0x105 cells/cm2 
represented confluent linings.  Given that Study 1 was the first experimental run and the 
sodding protocol was not yet well practiced, especially when setting up multiple grafts at 
one time, the absence of cells from graft 3 was assumed to be operator error or mistakes 
made during sodding of that particular graft.  The loss of cells could have potentially also 
been a result of the pump loosening problem described of graft 3 in the previous section.  
Therefore, after Study 1, 5.0x105 cells/cm2 was identified as a minimum initial sodding 
density to achieve luminal coverage.  In general, cells did not show any particular 
alignment, only vaguely appearing aligned with the nodes of the ePTFE.  Furthermore, 
inexperience operating the SEM resulted in images at somewhat arbitrary magnifications 
during Study 1.  As experience with adjusting the SEM developed, images were taken at 
low (~25-35x) and high (~140-150x) magnification for a given sample.  All subsequent 
studies after Study1 were imaged at magnifications of approximately 25-35x and 140-
150x.  The cracked appearance of the cell layer in some SEM images may be a result of 
the drying process, SEM preparation, and or sample handling. 
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Fig. 2.3a 
     
 
Fig. 2.3b 
 
Figure 2.3 – Study 1, Graft 1: sodding density of 2.5x105 cells/cm2 at 191x (a) and 
378x (b) magnification.  Cells present but under confluent as the nodes of the ePTFE can 
be seen throughout the lumen.  Higher magnification image (2.2b) confirms the presence 
of cells as well as the under confluent state of the graft.   
 
 
 
 
 
Fig. 2.4 
 
Figure 2.4 – Study 1, Graft 2: sodding density of 5.0x105 cells/cm2 at 100x 
magnification.  Image at 100x confirms the presence of cells and a confluent lining of 
cells.  No cell orientation can be distinguished.  The cracked appearance of the image is 
attributed to the drying and SEM preparation steps, causing the cell layer to fragment as 
shown.   
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Fig. 2.5 
 
Figure 2.5 – Study 1, Graft 3: sodding density of 7.5x105 cells/cm2 at 180x 
magnification.  No cells can be observed on graft 3 of Study 1.  The lack of a cell lining 
can only be explained by inexperience or mistakes made during the bioreactor set-up. 
 
 
 
 
 
Fig. 2.6a 
      
Figure 2.6 – Study 1, Graft 4: sodding density of 1.0x106 cells/cm2 at 78x (a) and 
188x (b) magnification.  The image of graft 4 at 78x confirms the presence of cells and a 
uniform, confluent lining.  The area of bare ePTFE at the bottom of the images are 
attributed to sample handling, as cellular material was observed on the end of the forceps 
used to manipulate the graft.  Orientation of the cells was difficult to ascertain, potentially 
aligning with the nodes of the ePTFE and therefore circumferential to the fluid flow.  The 
arrows in figure 2.5b show the direction of fluid flow.  Higher magnification (2.6b) at the 
interface of the cell layer and void area of ePFTE shows the distinction between the 
presence of a cell lining and bare ePTFE.  
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General Observations and Deviations: Study 2 
After experimenting with varying sodding densities during Study 1, Study 2 
aimed at examining a specific density over a time period of 7 days.  Observations and 
analysis of the SEM images collected during Study 1 led to the decision to choose 
5.0x105 cells/cm2 as the sodding density for Study 2, given that 5.0x105 cells/cm2 was the 
lowest sodding density to achieve a relatively covered luminal surface.  Scheduling of the 
study allowed time for the sterilization of the bioreactors and two port lids, especially 
important considering the 7 day duration of the study.   
To observe the development of the cellular lining over the course of 7 days, 
histology images were collected and are presented later in this chapter.   
Passage 9 HUVSMCs were thawed, cultured, and used at P11 for Study 2.  After 
passing into a T225 at P11, small black debris was observed in the media prompting a 
media change.  Although the debris could not be identified and some remained after the 
change, the media appeared clear, and the cells continued to grow and multiply, generally 
appearing healthy.  Therefore it was concluded that the black debris was not a bacteria 
infection and the cells were used for Study 2.   
A 100% confluent T225 of P11 HUVSMC was obtained and yielded an average 
cell count of 14x106 cells; the “A” and “B” cell count results from the hemocytometer 
were 14.4x106 cells and 13.6x106 cells respectively.  The centrifuged pellet was 
resuspended in 14 mL of media to yield a solution with a cell density of 1.0x106 
cells/mL.   
Renucleation during insertion of the grafts was not observed and sodding 
protocols were followed correctly.  Furthermore, no observations of luminal bubbles 
were noted during extraction of the grafts at the respective time periods. 
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SEM Images: Study 2 
As with Study 1, SEM images collected for Study 2 were used to examine luminal 
coverage and surface morphology.  SEM images collected after Study 2 show cell 
coverage after 1 day and development of the cell lining over the course of 7 days.  The 
development of the lining is difficult to determine by en face SEM images, however the 
cell layer appears denser over the course of 7 days and elongation of cells is apparent at 
day 7, illustrated best in figure 2.11.   
 
 
Fig. 2.7a 
     
 
Fig. 2.7b 
 
Figure 2.7 – Study 2, 5.0x105 cells/cm2 sodding density: Day 1 at 26x (a) and 139x (b) 
magnification. Images demonstrate cell coverage across the luminal surface at day 1 
using 5.0x105 cells/cm2 as observed in Study 1. 
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Fig. 2.8a 
     
 
Fig. 2.8b 
 
Figure 2.8 – Study 2, 5.0x105 cells/cm2 sodding density: Day 3 at 21x (a) and 141x (b) 
magnification. Images confirm cells present and potentially increased coverage across 
the luminal surface.  
 
 
 
 
 
Fig. 2.9a 
     
 
Fig. 2.9b 
 
Figure 2.9 – Study 2, 5.0x105 cells/cm2 sodding density: Day 5 at 27x (a) and 141x (b) 
magnification.  Confluent cell coverage across the luminal surface of the graft.  The 
density of the cell layer appears thicker, and aside from the fracturing presumably an 
artifact of SEM processing, no exposed ePTFE is visible.  
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Fig. 2.10a 
     
 
Fig. 2.10b 
 
Figure 2.10 – Study 2, 5.0x105 cells/cm2 sodding density: Day 7 at 28x (a) and 142x 
(b) magnification.  Dense, uniform, and confluent luminal layer appearing well 
developed after 7 days.  No exposed ePFTE.  Cells appear elongated and aligned in 
relation to each other, better illustrated in figure 2.11. 
 
 
Figure 2.11 – Study 2, 5.0x105 cells/cm2 sodding density: Day 7 at 631x 
magnification.  At high magnification, cells appear elongated and aligned with one 
another.  The cracked surface is attributed to the SEM preparatory steps. 
 
Histology Images: Study 2 
Histological evaluation following Study 2 served to evaluate the formation and 
development of a luminal lining by observing a cross-sectional view.  Given the highly 
hydrophobic nature of ePFTE, the absence of cells in the day 1 graft is potentially 
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attributed to the histology work up, especially since SEM images confirmed the presence 
of cells within the same graft.  The cell layers observed of the day 3, 5, and 7 grafts may 
have better withstood the histology work up given the additional time the cells had to 
develop within the lumen, potentially establishing a stronger hold on the ePFTE.  Aside 
from the missing cell layer for day 1, the development of the lining is marked by a 
thickening of the cell layer from approximately 10 to 50 µm on day 3 to 180 to 210 µm 
on day 7.      
 
Figure 2.12 – Study 2, 5.0x105 cells/cm2 sodding density: Day 1.  Cell lining absent 
from Day 1 graft, potentially a result of the histology work up.  
 
 
 
 
 
Fig. 2.13  
Figure 2.13 – Study 2, 5.0x105 cells/cm2 sodding density: Day 3.  Notice the thin cell 
layer that lines the lumen.  Cell layer thickness of approximately 10-50 µm. 
 
Fig 2.12 
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Fig. 2.14  
Figure 2.14 – Study 2, 5.0x105 cells/cm2 sodding density: Day 5.  Continued 
development of the cell layer over time. Cell layer thickness of approximately 70-90 µm. 
 
Fig. 2.15  
Figure 2.15 – Study 2, 5.0x105 cells/cm2 sodding density: Day 7.  Thick and developed 
cell layer after 7 days.  Cell layer thickness of approximately 180-210 µm. 
 
General Study Observations and Deviations: Study 3 
Study 3 served to re-evaluate variable sodding densities through the selection of a 
tighter range of densities from 3.5x105 cells/cm2 to 9.5x105 cells/cm2 in 1.5x105 cells/cm2 
increments.  Cells used for Study 3 were thawed at P12 and passed and expanded to 
achieve a confluent T225 of P13 cells for sodding.  The >100% confluent T225 yielded 
an average cell count of 19.64x106 cells; the “A” and “B” cell count results from the 
hemocytometer were 20.16x106 cells and 19.12x106 cells respectively.  The centrifuged 
pellet was resuspended in 19.6 mL of media to yield a solution with a cell density of 
1.0x106 cells/mL.   
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Renucleation during insertion of the grafts was not observed and sodding 
protocols were followed correctly.  Furthermore, no observations of luminal bubbles 
were noted during extraction of the grafts.  As with Study 1, histology images were not 
collected for Study 3 since the grafts were cultivated for only one day and the aim was to 
observe cell coverage at different sodding densities rather than the development of a cell 
lining over time.  
SEM Images: Study 3 
To confirm previous results and ensure that the absence of cells on graft 3 of 
Study 1 was operator error, SEM images were collected for the grafts created during 
Study 3.  Images show uniform and sufficiently confluent cell coverage for grafts 4 and 
5.  Grafts 1 and 2 showed slightly under confluent linings, despite 5.0x105 cells/cm2 
(Graft 2 of Study 3) being confluent in previous studies.  Furthermore, graft 3 showed an 
irregular disposition of cells that cannot be accounted for, maybe only explained by 
mistakes made during in the sodding or setup.  The inconsistency of the cell linings 
observed of grafts in this study sodded below 8.0x105 cells/cm2 led to the decision based 
on the combined data from Study 1 and 3 to conduct a time study (Study 4) using 7.5x105 
cells/cm2 as the initial sodding density.  
 
Chapter 2 – Smooth Muscle Cell Layer 
 
 59 
 
Fig. 2.16a 
     
 
Fig. 2.16b 
 
Figure 2.16 – Study 3, Graft 1: sodding density of 3.5x105 cells/cm2 at 27x (a) and 
140x (b) magnification. Cells present but under confluent after 1 day – exposed ePTFE. 
 
 
 
 
 
Fig. 2.17a 
    
 
Fig. 2.17b 
  
Figure 2.17 – Study 3, Graft 2: sodding density of 5.0x105 cells/cm2 at 33x (a) and 
150x (b) magnification.  Slightly under confluent after 1 day – some exposed ePTFE. 
Chapter 2 – Smooth Muscle Cell Layer 
 
 60 
 
Fig. 2.18a 
     
 
Fig. 2.18b 
          
Figure 2.18 – Study 3, Graft 3: sodding density of 6.5x105 cells/cm2 at 30x (a) and 
145x (b) magnifications. Irregular cell coverage. Irregular and incomplete cell coverage 
likely a result of deviations during setup and sodding. 
 
 
 
 
 
Fig. 2.19a 
     
 
Fig. 2.19b 
 
Figure 2.19 – Study 3, Graft 4: sodding density of 8.0x105 cells/cm2 at 35x (a) and 
74x (b) magnification. Dense and uniform cell layer with sufficient luminal coverage 
after 1 day. No exposed ePTFE. 
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Fig. 2.20a 
     
 
Fig. 2.20b 
 
Figure 2.20 – Study 3, Graft 5: sodding density of 9.5x105 cells/cm2 at 31x (a) and 
141x (b) magnification.  Dense and uniform cell layer with sufficient luminal coverage 
after 1 day. No exposed ePTFE. 
 
General Study Observations and Deviations: Study 4 
Study 4 aimed at examining a second density over a time period of 7 days.  
Observations and results collected throughout Study 1, 2, and 3 led to the decision to 
choose 7.5x105 cells/cm2 as the sodding density for Study 4 to serve as a comparison to 
Study 2.  Three vials of P14 HUVSMC cells were thawed into one T225 and cultured to 
achieve a confluent cell population for sodding.  The 100% confluent T225 yielded an 
average cell count of 17.56x106 cells; the “A” and “B” cell count results from the 
hemocytometer were 17.84x106 cells and 17.28x106 cells respectively.  The centrifuged 
pellet was resuspended in 17.6 mL of media to yield a solution with a cell density of 
1.0x106 cells/mL.   
Renucleation during insertion of the grafts was not observed and sodding 
protocols were followed correctly.  Luminal bubbles were noted during extraction of the 
day 5 graft at the time harvesting, but not in any other graft.  SEM and histology images 
are presented in the next sections. 
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SEM Images: Study 4 
SEM images collected from Study 4 grafts show uniform and confluent cell 
coverage after 1 day, and the further development of the cell lining over the course of 7 
days.  The development of the lining is difficult to determine by en face SEM images, 
however the cell layer does appear to become denser over the course of 7 days.  Given 
the confluent layer achieved after day one using 7.5x105 cells/cm2, shown in figure 2.17, 
and the potential inconsistency of sodding at 5.0x105 cells/cm2, moving forward, 7.5x105 
cells/cm2 was the sodding density chosen to most confidently realize a confluent cell 
lining immediately after sodding. 
      
 
Fig. 2.21a 
     
 
Fig. 2.21b 
 
Figure 2.21 – Study 4, 7.5x105 cells/cm2 sodding density: Day 1 at 38x (a) and 154x 
(b) magnification.  Dense and luminal lining that is sufficiently confluent after 1 day.  
No exposed ePFTE. 
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Fig. 2.22 
 
 
Figure 2.22 – Study 4, 7.5x105 cells/cm2 sodding density: Day 3 at 158x 
magnification.  Dense, uniform, and confluent luminal layer.  Cells elongated and appear 
aligned to each other. 
 
 
 
 
 
Fig. 2.23a 
     
 
Fig. 2.23b 
    
Figure 2.23 – Study 4, 7.5x105 cells/cm2 sodding density: Day 5 at 36x (a) and 146x 
(b) magnification.  Dense and uniform luminal layer.  Void observed on right side of 
graft (a) was linked to air bubble (sample was from the top of graft).  Developed luminal 
lining - no exposed ePFTE where cell layer exists. 
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Fig. 2.24a 
     
 
Fig. 2.24b 
 
 
Figure 2.24 – Study 4, 7.5x105 cells/cm2 sodding density: Day 7 31x (a) and 132x (b) 
magnification. Dense, uniform, and confluent cell layer.  Developed luminal lining - no 
exposed ePFTE. 
 
Histology Images: Study 4 
Histological evaluation following Study 4 served to evaluate the formation and 
development of a luminal lining, and compare to the results of Study 2.  Unlike, the 
results of Study 2, the day 1 graft of Study 4 showed a thin layer of cells, approximately 
10 µm thick.  Although cells were present, they were pulled off of the ePTFE graft, likely 
a result of the histology staining and processing.  As with the previous SMC time study, 
Study 4 grafts showed the development of the lining that grew in thickness from 
approximately 10 µm on day 1 to approximately 260 µm on day 7.  In comparison to 
Study 2, the Study 4 grafts showed an overall thicker layer over the course of the 7 day 
study.  
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Fig. 2.25       
Figure 2.25 – Study 4, 7.5x105 cells/cm2 sodding density: Day 1.  In this image the cell 
layer has pulled away from the ePTFE during the histology processing.  Cell layer 
thickness of approximately 10 µm (measuring perceived cell layer only – not distance of 
cell layer from surface of ePTFE). 
 
 
Fig. 2.26 
Thinner layer going 
up sides of graft 
Thicker layer at bottom of 
graft  
Figure 2.26 – Study 4, 7.5x105 cells/cm2 sodding density: Day 3. Cell layer thickness 
ranges from 40 - 100 µm.  This image is taken from the bottom of the graft, therefore 
note how the layer tapers thinner at the sides of the image in comparison to the center.  
This is likely a result of gravity causing cells to fall to the bottom of the graft during 
sodding.    
 
Fig. 2.27       
Figure 2.27 – Study 4, 7.5x105 cells/cm2 sodding density: Day 5.  Established cell layer 
after 5 days. Cell layer thickness of approximately 200 - 220 µm. 
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Fig. 2.28  
Figure 2.28 – Study 4, 7.5x105 cells/cm2 sodding density: Day 7. Cell layer thickness 
of approximately 160 - 260 µm.  Well developed after 7 days.  The faint darker region 
between the cell layer and the ePTFE may indicate the beginning of an elastic lamina or 
basement membrane.  Further analysis with a trichome stain may better indicate the 
presence of collagen and/or basement membrane formation.   
 
Cost Analysis 
In addition to supporting the concept of growing HUVSMC on ePTFE and 
establishing the protocols for creating and sustaining smooth muscle blood vessel 
mimics, an underlying objective of this work was to also evaluate the associated costs of 
developing a BVM system that could serve as an analysis tool.  The following charts 
describe the cost of setting up one HUVSMC BVM, including the steps and associated 
costs of thawing a 1 mL vial of cells, passing once, and running one bioreactor.  
Although HUVSMC cells up to P14 were used during the course of studies contained 
within this thesis, for cost analysis purposes the assumption was made that cells were 
passed at a ratio of 1:2 up to P8.  Overall, results demonstrate that the cost per HUVSMC 
graft is approximately $100.  Smooth muscle cell cost alone account for only about one 
dollar per graft, provided that the single vial of purchased cells were passed to P8 at 1:2.  
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  Setup of one HUVSMC Graft   Culturing of cells prior to setup 
  
QTY 
used unit cost/graft   (includes thawing into T75 and one passage into T225)   
ePTFE 4 cm  40.00           
100% EtOH 40 ml  0.48      QTY used unit cost  
70% EtOH 40 ml  0.33    T75 1 ea  2.64  
Fill chamber w/ Bioreactor Media (BrM) 300 ml  27.05    T225 1 ea  3.87  
Fill reservoir w/ Conditioning Media 50 ml  5.44    5ml Pipet 2 ea  0.26  
Replace reservior w/ BrM 50 ml  4.51    10ml Pipet 2 ea  0.28  
Flush w/ BrM after sodding 5 ml  0.45    25ml Pipet 2 ea  0.72  
Syringe 1 ea  0.10    2ml Asp Pipet 3 ea  0.73  
10ml Pipet 2 ea  0.28    Typrsin 3 ml  0.24  
25ml Pipet 2 ea  0.72    SMC Media used:       
2ml Asp Pipet 2 ea  0.49    T75 Thaw 20 ml  3.52  
50 conical 3 ea  1.25    T75 Feed 12 ml  2.11  
Trypsin 9 ml  0.72    T225 Passage 36 ml  2.11  
Trypan-blue 100 µl  0.01    Total   B  16.48  
Hemocytometer 1 ea  2.10            
Average cell cost      1.04    Total Cost per HUVSMC graft A+B=  100.19  
Total   A  83.71    (For thawing to harvesting graft; one passage in between) 
 
Table 2.1 – Cost analysis sheet for the construction of one HUSMC BVM.  See 
Appendix L for costs of standard items and cell yield calculation.  
 
Discussion 
Human umbilical vein smooth muscle cell studies from Study 1 to Study 4 
focused on evaluating the feasibility and sodding densities necessary to achieve a 
confluent smooth muscle cell layer.  The overlying objective of creating a confluent SMC 
layer at the time of sodding was such that endothelial cells could be ultimately sodded 
onto the SMC layer to create a dual layered vessel.   
Analysis following each study resulted in the conclusion that human umbilical 
vein smooth muscle cells could be sodded onto an ePTFE scaffold and sustained at least 
up to 7 days in an in vitro environment.  The results of the study showed that confluent 
layers of cells could be achieved with sodding densities beginning around 5.0x105 
cells/cm2.  Histological analysis further demonstrated that the smooth muscle cells might 
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also require a growth period by which the SMC layer grows and thickens.  The 
thickening of the layer observed of the grafts is presumed to be a result of the cells 
proliferating rather than variation in sodding technique since the histology images from 
both Study 2 and 4 showed a thickening of the SMC layer over the 7-day time period.  
Furthermore, although the increase in cell layer thickness may be a result of both 
proliferation and hypertrophy, proliferation is suspected to be the more significant factor 
given that the 100 plus micron increases in cell layer thickness is not likely accounted for 
by cell hypertrophy.  Additionally, while sodding density experiments were focused on 
determining the minimum sodding necessary to achieve a confluent layer, the results do 
not necessarily represent the starting density required to achieve a physiologically 
representative thickness.   Depending on whether a future dual layer protocol will allow 
for the SMC layer to develop over time or will require the immediate sodding of 
endothelial cells, future refinement of the SMC sodding should include analysis to 
determine the starting cell solution density required to achieve a SMC layer that is 
physiologically thick to the native coronary media layer (approximately 200 microns) 
immediately after sodding, as opposed to only sodding to achieve a confluent cell layer.     
Observation of the grafts revealed that cells did not generally show a particular 
alignment.  Literature demonstrates that with dynamic flow conditions as well as vessel 
distensibility, smooth muscle cells will tend to align circumferentially about the graft 
lumen [28].  Future work aimed at incorporating pulsatile flow to better mimic the 
dynamic flow within native arteries, and using a more compliant scaffold material could 
potentially lead to improved physiologic smooth muscle cell alignment.   
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While air bubbles were not always recorded or observed at the time of graft 
harvest, bubbles would periodically form inside the grafts during the run, possibly 
contributing to cellular voids and pockets observed during SEM and histological analysis.  
Efforts to avoid bubbles captured within the lumen included elevating the distal end of 
the bioreactor 5 to 10 mm, however it was inconclusive whether the cellular voids 
observed in some of the grafts were a result of low sodding densities or air bubbles.   
Additionally, while cellular material was observed through day 7, phenotypic 
characterization was not completed to confirm that the smooth muscle cells maintained 
their phenotype both at passages up to P14 or during the course of a bioreactor run. 
Future work performing focused immunohistochemical characterization should be 
completed to confirm the phenotype of sodded HUVSMC, and to determine whether 
SMC cells maintain their phenotype or undergo any phenotypic changes when exposed to 
flowing media.   
Finally, cost analysis confirms the cost effectiveness of the HUVSMC graft.  The 
total cost of one HUVSMC BVM was approximately 100 dollars, which is directly 
comparable to the previous HMVEC BVM since the only additional costs are for the 
smooth muscle cells.  According to the cost analysis, the cost for the smooth muscle cells 
alone was approximately 1 dollar per graft, and therefore, the increase in BVM cost 
would be at most a dollar, assuming HMVEC could be acquired for free from liposuction 
fat.   
In conclusion, studies presented in this chapter demonstrate that first, large vessel 
smooth muscle cells can be commercially acquired, cultured, and expanded at the Cal 
Poly tissue engineering lab.  Second, the Chapter 2 studies show that HUVSMC can be 
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sodded onto ePFTE and sustained in-vitro for up to 7 days.  Additionally, histological 
analysis shows that the grafts appear to develop a thicker cell lining over a seven day 
period.  Finally, cost analysis demonstrates that creating a SMC BVM adds minimal 
additional cost when compared to the previous HMVEC BVM.          
Study Summaries 
Study 1 
Evaluated the feasibility of sodding HUVSMC on ePFTE with variable cell 
sodding densities to achieve a confluent smooth muscle cell layer immediately after 
sodding.  Determined that SMC could be sodded on ePTFE and demonstrated that a 
minimum sodding density of 5.0x105 cells/cm2 could be used to achieve a confluent cell 
layer. 
 
Study 2 
Evaluated the development of a SMC BVM sodded at 5.0x105 cells/cm2 over the 
course of 7 days.  Cells could be maintained in-vitro over the 7-day time period and a 
confluent cell layer of up to 210 µm was achieved.  
 
Study 3 
Served to reevaluate the sodding density experiments of Study 1.  Concluded that 
a sodding density of 7.5x105 cells/cm2 was required to more confidently achieve a 
confluent SMC layer immediately after sodding.  
 
Study 4 
Evaluated the development of a SMC BVM sodded at 7.5x105 cells/cm2 over the 
course of 7 days.  Cells could be maintained in-vitro over the 7-day time period 
producing a confluent cell layer.   Cell layer thicknesses of up to 260 µm were achieved.  
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Introduction 
With the aim of creating a more physiologically representative blood vessel 
mimic, the focus of this thesis was on cellular changes to the previous BVM system, 
specifically the incorporation of large vessel human cell sources.  In addition to work 
with large vessel smooth muscle cells, the next step in the development of the in-vitro 
blood vessel mimic included creating a BVM system using large vessel endothelial cells.  
A considerable volume of literature exists illustrating various endothelial cell 
experiments using human umbilical vein endothelial cells (HUVECs), predominately due 
to the availability and cost effectiveness of extracting cells from the umbilical vein.  
Therefore, for these same reasons as well as to remain consistent with the practices 
described within the literature, HUVECs were selected as the large vessel human 
endothelial cell source.  
Building upon the previous work by Cardinal et al. who developed a BVM system 
using human micro-vascular endothelial cells (HMVEC) on ePTFE scaffolds [1], the 
large vessel EC studies described within this chapter focused on experiments to 
determine whether the selected large vessel cells adhere to the polymer scaffold and can 
be sustained in-vitro.  Although examples of work using HUVEC and ePTFE exist 
throughout the literature [38, 46, 66, 67], albeit none using HUVECs on tubular ePTFE 
scaffolds, it was important that an experiment be conducted specifically at the Cal Poly 
laboratory to ensure that our lab group and lab facilities could successfully culture, sod, 
and sustain HUVECs within our in-vitro BVM model.  Thus, the goal of Study 5 was to 
establish whether HUVECs could be pressure-sodded onto ePTFE and to determine an 
initial sodding density that would create a confluent layer of endothelial cells that could 
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potentially be sodded onto a SMC layer.  Drawing from the previous work with 
HMVECs and ePTFE, the study was completed at a density of 5.0x105 cells/cm2 and 
conducted over a period of 7 days.  While the growth dynamics of HMVECs and 
HUVECs are presumably not identical, since Study 5 was used to ensure that HUVECs 
could at a minimum be pressure sodded as opposed to creating a complete and confluent 
HUVEC only BVM, it was decided that 5.0x105 cells/cm2 be used as a sodding density 
roughly similar to sodding densities used for other endothelial types. 
Materials and Methods 
Cell Selection and Culture 
Human umbilical vein endothelial cells (HUVECs) were selected as the cell type 
for the BVM intimal component.  This cell type was selected based on use of umbilical 
vein cells throughout tissue engineered blood vessel literature, primarily due to the cost 
effectiveness and availability of HUVECs.  The HUVECs used were purchased from 
Sciencell Research Laboratories, Carlsbad, California.  Sciencell shipped the cells at a 
concentration of at least 5.0x105 cell/ml in 1 ml cryopreserved vials on dry ice.  The vials 
were quickly placed into a liquid nitrogen dewar upon arrival at Cal Poly, San Luis 
Obispo.  When ready for culture, the vials of cells were thawed and cultured according 
standard practices.  During culturing, the cells were maintained in a humidified incubator 
at 37°C and 5% CO2.  T75 and T225 BD cell culture flasks were coated with 1% gelatin, 
and Sciencell endothelial cell media was used for endothelial cell culture and population 
expansion.  Cell cultures were monitored using an inverted light microscope.  
Components of the endothelial cell culture media can be found in Appendix G.  
Passaging of the cells was conducted at approximately 80% to 95% confluency using 
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0.25% trypsin.  HUVECs were received at P0 and passed and frozen at each passage 
level up to P6.  Endothelial cells for Study 5 were used at P6.    
Preparation of Bioreactor and ePTFE Grafts Prior to Set-up 
Set-up and preparation for Study 5 began approximately one week prior to cell 
sodding, as described in Chapter 2.  Four grafts of four millimeter (4mm) diameter 
ePTFE tubing were cut to four-centimeter (4 cm) lengths, followed by fitting insertion, 
sterilization, and bioreactor prep as described previously in the Preparation of Bioreactor 
and ePTFE Grafts Prior to Set-Up section of Chapter 2.  Bioreactor and conditioning 
medias were also made as described previously, followed by media de-gassing, graft 
denucleation, and graft conditioning.  The Study 5 HUVEC experiment described within 
this chapter was conducted following the described preparatory steps without deviations.  
Set-up day 
Preparation on the set-up day of a bioreactor run began by warming the 
previously mixed bioreactor and conditioning media in a water bath at 37°C.  Next, four 
bioreactor chambers, lids, two-port lids, and forceps, were gathered and organized for 
easy access throughout the set-up.  The set-up proceeded with the insertion of the sterile 
grafts into the sterile bioreactor chambers.  These steps required the use of sterile gloves 
and the assistance of a non-sterile partner to ensure the sterility of the grafts during the 
set-up.  Insertion of the grafts followed the same procedure as outlined in Chapter 2, 
including filling of the bioreactor chamber with media and manually conditioning the 
grafts with conditioning media.  No deviations from the described procedure were 
recorded during Study 5.  
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After priming each graft, reservoirs were assembled containing approximately 40-
45mL of conditioning media.  The two-port tubing was primed with media and attached 
to the bioreactor chamber in a similar manner as the previous smooth muscle studies 
described in Chapter 2.  The assembled bioreactor systems, illustrated in figure 1.3, were 
attached to a peristaltic pump set-up inside a large incubator and run at 100 rpm (9 
mL/min).  After the conditioning period, the media flow was stopped the reservoirs 
containing conditioning media were exchanged with reservoirs containing bioreactor 
media.  All clamps on the bioreactor system were closed.      
Cell Harvesting and Counting 
Cell culture of HUVEC for Study 5 began 2 days prior to the set-up day.  The 
sodding density for Study 5 was targeted at 5.0x105 cells/cm2, and a sufficient number of 
HUVECs required for Study 5 was achieved by thawing two vials of P5 HUVEC into 1 
T225.  Cell culture was closely monitored in the days immediately preceding set-up of 
the study, and scheduling of the set-up was adjusted accordingly to ensure that the 
required number of cells were available. 
Following set-up and conditioning of the BVM grafts, cells were removed from 
the small incubator to inspect morphology.  Cells were next harvested with trypsin, and 
release of the cells was confirmed by observation under the light microscope.  After cell 
release, trypsin was deactivated with an equivalent volume of Sciencell EC media.  A 
small volume (<1mL) of the suspension was transferred to a 15mL tube.  The remaining 
suspension of cells was transferred to a 50 mL conical tube and centrifuged for 5 minutes.  
During centrifugation of the cell culture, cells were counted as described previously.  
Once the total number of cells was determined for the cell suspension, a re-suspension 
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volume was determined as before. After establishing the re-suspension volume, and 
allowing the centrifugation to complete the 5-minute cycle, the 50 mL conical tube 
containing the centrifuged cells was taken back into the hood and the supernatant 
aspirated off.  The cell pellet was next re-suspended using the established volume of 
Sciencell EC media.      
Sodding of Cells 
In preparation for cell sodding, the conditioned bioreactors and attached media 
reservoirs were removed from the large incubator and moved into the hood, as described 
for SMC studies.  The sodding volume was determined as before, as was the 4.4cm2 
surface area of the graft.  
Based on a sodding density of 5.0x105 cells/cm2 and a resuspension concentration 
of 1.0x106 cells/mL, a 2.2 mL volume of cell suspension was collected into a syringe and 
injected through the three-way valve of the bioreactor inlet to transmurally deposits cells.  
A steady pressure of approximately 2 mL/min was maintained during the pressure 
sodding.  Immediately following the deposit of cells, each graft was chased with 
bioreactor media as described in Chapter 2.  The valves on the system were closed and 
the outlet of the bioreactor was reconnected to the reservoir.  The system was 
reconnected to the peristaltic pump and transmural flow immediately resumed at 10 rpm 
(0.8 mL/min) in the same manner as before.    
Pump Settings and Ramp-up Schedule 
Transmural flow established after cell sodding continued at 10 rpm for one hour, 
after which time the outlet valve of the bioreactor was opened, and luminal flow was 
maintained at 10 rpm for an additional hour.  After an hour of luminal flow at 10 rpm, the 
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pump speed was increased to 20 rpm and maintained overnight.  The following day, 
luminal flow was increased in 15-rpm increments every hour until approximately 12 
mL/min (150 rpm) was achieved.  Flow was maintained at this rate until each graft was 
harvested.  Harvest points of 1, 3, 5, and 7 days were collected, where the day 1 graft was 
harvested before pump ramp up.  Additionally, for the day 5 and 7 grafts, bioreactor 
media was changed after 3 days.   
Harvesting and Prepping of grafts for analysis 
Graft harvesting was completed at the conclusion of each time point (see 
Appendix C).  As indicated in Chapter 2, the bioreactor system was removed from the 
peristaltic pump and large incubator to a non-sterile work environment.  The grafts were 
then removed using a surgical scalpel and fixed with Hisotchoice.   
SEM Imaging and Histological Analysis 
Depending on the analysis modality chosen, grafts were prepared according to the 
varying methods.  Analysis modalities for HUVEC studies included scanning electron 
microscopy and histological preparation.  Preparation for SEM analysis was completed as 
previously described in Chapter 2.  Samples for histological analysis were also prepared 
and stained as before, with the exception that embedding was completed at Cal Poly for 
all Study 5 samples.  
Cost Analysis 
Cost analysis was conducted to compare the cost of setting up one HUVEC BVM 
to both the previous HMVEC and HUVSMC models.  The analysis assumed a standard 
passage number P6 and was used to determine associated costs of setting up and running 
one bioreactor.              
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Results 
Endothelial Cells Under Light Microscopy  
Upon receipt of the cryopreserved HUVEC vials from Sciencell, cells were 
passed, expanded, and frozen for later use.  Throughout this process, morphological and 
growth characterization was examined using an inverted light microscope.  When grown 
on culture flasks coated with 1% gelatin, human umbilical vein endothelial cells showed 
relatively homogeneous size and form, generally appearing round in shape.  Some cells 
developed elongated shapes as confluency in the flask increased.  Approximate 
population doublings occurred over 8-12 hours.  As an example of the growth 
characteristics of the HUVECs, a culture was passed at P2 at approximately 40% 
confluency at 9:00 am.  The cells were checked on the same day at 1:45 pm and 5:00 pm 
and showed 50% and 80-85% confluency respectively.  The following morning the cells 
exhibited 100% confluency.  Unlike the HUSMC described in Chapter 2, HUVECs 
showed a confluency-induced plateau phase, and appeared to suspend growth after 100% 
confluency was achieved.         
 
Figure 3.1 - HUVEC in culture 
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Study Results 
General Study Observations and Deviations: Study 5 
Study 5 aimed at demonstrating the ability to create and sustain a large vessel 
endothelial cell blood vessel mimic using HUVEC and ePTFE over a time period of 7 
days.  Previous experience with micro-vascular endothelial cells and ePTFE led to the 
decision to choose 5.0x105 cells/cm2 as the sodding density for Study 5.   
One T225 of HUVEC was cultured to P5 from the original Sciencell vial to 
achieve a confluent cell population for sodding.  The 100% confluent T225 yielded an 
averaged cell count of 17.44x106 cells; the “A” and “B” cell count results from the 
hemocytometer were 15.12x106 cells and 19.76x106 cells respectively.  The centrifuged 
pellet was resuspended in 17.4 mL of media to yield a solution with a cell density of 
1.0x106 cells/mL.   
Renucleation during insertion of the grafts was not observed and sodding 
protocols were followed as described.  Furthermore, during extraction of the graft at time 
point one (day 1), a small luminal air bubble was observed at the distal end of the graft.  
Air bubbles were not observed in the grafts at any other time point.     
 SEM Images: Study 5 
Scanning electron microscopy evaluation following each BVM study showed the 
presence of cellular material after sodding.  The SEM images below illustrate atypical 
cell morphology but do show the development of a layer within the graft lumen over a 7-
day period.  This statement regarding the layer developing is based on the observation 
that the exposed ePTFE visible in the day 1 and 3 images is no longer present in the day 5 
and 7 grafts.  HUVEC do not show cobblestone morphology or longitudinal alignment as 
is observed of native blood vessel structure. 
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Fig. 3.2a 
     
 
Fig. 3.2b 
Cell material 
      
Figure 3.2 – Study 5, 5.0x105 cells/cm2 sodding density: Day 1 at 32x (a) and 492x (b) 
magnification. Presence of cell material confirmed. This cell material is assumed to be 
HUVECs since the only thing added were HUVECs. 
 
 
 
 
 
Fig. 3.3a 
     
 
Fig. 3.3b 
 
Figure 3.3 – Study 5, 5.0x105 cells/cm2 sodding density: Day 3 at 33x (a) and 160x (b) 
magnification. Under confluent luminal lining as exposed ePTFE is present.  Cell 
material is visible (indicated by the arrow and assumed to be HUVECs).    
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Fig. 3.4a 
     
 
Fig. 3.4b 
 
Figure 3.4 – Study 5, 5.0x105 cells/cm2 sodding density: Day 5 at 34x (a) and 157x (b) 
magnification.  Increased luminal coverage.  Development of the HUVEC lining shows 
no exposed ePTFE, potentially a result of sodding techniques or changes in the 
development of the cells over time.    
 
 
Fig. 3.5a 
     
 
Fig. 3.5b 
   
 
 
Fig. 3.5c 
Direction of 
Flow 
 
Figure 3.5 – Study 5, 5.0x105 cells/cm2 sodding density: Day 7 at 56x (a), 91x (b) and 
154x (c) magnification.  Confluent luminal lining of HUVEC after 7 days.  Cells appear 
to be generally aligned with respect to each other but not in alignment with the direction 
of flow.  As with day 5, no exposed ePTFE.   
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Histology Images: Study 5 
Histological evaluation following each BVM study served to evaluate the 
formation and of a luminal HUVEC lining.  The histology images below illustrate weak 
evidence of an endothelial lining, but do show some cellular material.  These results 
further confirm the SEM results that showed morphologically atypical HUVECs but also 
demonstrate that HUVEC can be sodded onto ePTFE using the in-vitro BVM system.  
The cells that are visible in the day 1 and day 3 grafts appear balled up and sparse over 
the lumen of the graft.  Later day 5 and 7 grafts show a very thin more spread out cell 
layer.     
 
Balled up 
Cell 
Fig. 3.6  
Figure 3.6 – Study 5, HUVEC 5.0x105 cells/cm2 sodding density: Day 1.  Cells are 
present, but appear balled up, sparse, and not forming a luminal lining. 
 
 
Cellular Material 
Fig. 3.7  
Figure 3.7 – Study 5, HUVEC 5.0x105 cells/cm2 sodding density: Day 3.  Cell layer is 
very thin (if present). Some cells still appear balled. 
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Fig. 3.8  
Figure 3.8 – Study 5, HUVEC 5.0x105 cells/cm2 sodding density: Day 5.  Cells are no 
longer balled, but cell layer is very thin.  
 
 
Figure 3.9 – Study 5, HUVEC 5.0x105 cells/cm2 sodding density: Day 7.  Very thin 
cell layer visible.  Cells appear flat and not balled up. 
 
Cost Analysis 
In addition to exploring the ability to grow HUVEC on ePTFE within the Cal 
Poly BVM, an underlying objective was to evaluate the associated costs in developing a 
BVM system that could serve as a cost effective analysis tool.  The following charts 
describe the cost of setting up one HUVEC BVM, including the steps and associated 
costs with thawing a 1 mL vial of cells, passing once, setting up, and running one 
bioreactor.  For cost analysis the assumption was made that cells were passed at a ratio of 
1:2 to P6.  The cost analysis of setting up a HUVEC BVM is approximately $100, 
including all supplies and necessary disposables.   
Fig. 3.9 
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    Setup of one HUVEC Graft         Culturing of cells prior to setup     
  QTY used unit cost/graft   
(includes thawing into T75 and one passage into 
T225)   
ePTFE 4 cm  40.00            
100% EtOH 40 ml  0.48      QTY used unit cost  
70% EtOH 40 ml  0.33    T75 1 ea 2.64 
Fill chamber w/ BrM 300 ml  27.05    T225 1 ea 3.87 
Fill reservoir w/ CM 50 ml  5.44    5ml Pipet 2 ea 0.26 
Replace reservior w/ BrM 50 ml  4.51    10ml Pipet 2 ea 0.28 
Flush w/ BrM after sodding 5 ml  0.45    25ml Pipet 2 ea 0.72 
Syringe 1 ea  0.10    2ml Asp Pipet 3 ea 0.73 
10ml Pipet 2 ea  0.28    Typrsin 3 ml 0.24 
25ml Pipet 2 ea  0.72    EC Media:       
2ml Asp Pipet 2 ea  0.49    T75 Thaw 20 ml 3.76 
50 conical 3 ea  1.25    T75 Feed 12 ml 2.26 
Trypsin 9 ml  0.72    T225 Passage 36 ml 2.26 
Trypan-blue 100 µl  0.01    Total   B 17.01 
Hemocytometer 1 ea  2.10            
Average cell cost      1.94    Total Cost per HUVEC graft A+B= 101.63 
Total   A  84.62    (For thawing to harvesting graft; one passage in between) 
 
Table 3.1 – Cost analysis sheet for the construction of one HUVEC BVM.  See 
Appendix L for costs of standard items and cell yield calculation.  
Discussion 
The human umbilical vein endothelial cell Study 5 served to demonstrate the 
potential to create a blood vessel mimic system using large vessel endothelial cells on an 
ePTFE scaffold, both as an improved blood vessel mimic as well as an intermediary 
element toward the development of a dual layered in-vitro blood vessel.  While it was 
significant to experiment with HUVEC and ePTFE alone as an improved model over 
HMVEC and ePTFE, the objective of Study 5 was to demonstrate that endothelial cells 
could be sodded onto ePTFE and that a layer could be established at a sodding density of 
5.0x105 cells/cm2.   
Analysis following each study resulted in the conclusion that, first, human 
umbilical vein endothelial cells could be sodded onto an ePTFE scaffold and sustained at 
least up to 7 days in an in-vitro environment.  Second, the results of the study showed 
that at 7 days a thin layer of cells could be achieved with a sodding density of 5.0x105 
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cells/cm2.  However, evaluation of cell morphology via SEM indicated that cells 
displayed unexpected and atypical cellular morphology.  These results indicate the 
potential need to change or add media constituents, adjust sodding techniques and 
cultivation duration, or possibly adjust SEM preparation and imaging methods in order to 
achieve a cell layer better resembling the cobble stone surface shown below in figure 
3.10 as presented by McFetride et al.  Histological analysis further confirms a very thin 
presence of cellular material, and future investigation should be undertaken to improve 
results of the HUVEC-only graft, potentially including the addition of growth factors or 
surface treatments to the ePTFE to improve cell adherence.  Yet, despite the undesirable 
results in creating a HUVEC-only BVM graft, Study 5 served more as a necessary 
intermediate to test and ensure that HUVEC could be cultured and sodded onto ePTFE 
for the future use of dual sodding.  Given that the SEM and histology results showed the 
presence of some cell material, the thesis work could move onto developing the dual 
sodding protocols.  
 
Figure 3.10 - SEM image of luminal surface of HUVEC displaying cobblestone 
morphology [30]. (Image used with permission, see Appendix M) 
 
Furthermore, observations made during analysis of the grafts showed that the cells 
did not generally show cellular alignment to the direction of flow as is observed of native 
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vessels.  Literature shows that with varying shear stress characteristics, endothelial cells 
tend to align longitudinally about the graft lumen and in the direction of flow.  Future 
work aimed at incorporating media with physiologic viscosity and shear stress 
characteristics to better mimic native vessels could potentially lead to improved 
physiologic endothelial cell alignment.   
Finally, cost analysis confirms the cost effectiveness of the HUVEC graft relative 
to either a HUVSMC or HMVEC BVM.  Analysis of the HUVEC BVM cost shows the 
grafts to be approximately 100 dollars, with the individual cost of the cells per graft to be 
about 2 dollars.  Although the cost per vial of HUVEC is less than HUVSMC, Sceincell 
suggests using the ECs at a lower passage than the SMCs and therefore the cost of the 
HUVECs per graft is slightly more than HUVSMCs.  Since the disposable costs is 
approximately the same for HUVEC, HUVSMC, and HMVEC, and the cell cost for the 
ECs is essentially the same as SMC and HMVEC, there is no added cost for sodding an 
in-vitro BVM with HUVEC.  This conclusion is made with one caveat.  Considering the 
results of Study 5 did not demonstrate expected HUVEC results, there may be additional 
elements that need to be added to the HUVEC BVM to achieve a “successful” graft that 
increase the overall cost of the graft.   
Study Summaries 
Study 5 
Study 5 demonstrated that HUVEC could be sodded onto ePTFE at a density of 
5.0x105 cells/cm2 and maintained in-vitro over a 7-day time period to create a thin cell 
layer.   Further studies are necessary to develop the HUVEC-only protocols and 
procedures. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
HUVSMC and HUVEC Dual Layer Blood Vessel Mimic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 – HUVSMC and HUVEC Dual Layer Blood Vessel Mimic  
 
 88 
Introduction 
Recognizing the communication between endothelial and smooth muscle cells 
and the critical role smooth muscle cells play in both the effects of restenosis and as 
targets of anti-proliferative agents, the ensuing steps for the development of a more 
physiologic BVM system included the co-culture of smooth muscle and endothelial cells.  
The independent development and experimentation of the smooth muscle and endothelial 
cell studies throughout this thesis led to co-culture experimentation with an effort toward 
the creation of a dual layer blood vessel mimic.  While much literature exists describing 
co-culture smooth muscle and endothelial cell systems, little work has been described 
using human cell sources in a three-dimensional construct, especially for the explicit use 
of in-vitro device evaluation.   
The work presented by Lavender, L’Heureux, and Sun summarized in the 
Introduction to this thesis describes co-culture dual layer systems, however each method 
possessed unique limitations for an in-vitro BVM application with regard to creating an 
optimal model for high-throughput device evaluation.  The Lavender model, while an 
optimized co-culture system, did not utilize human cell sources and did not possess the 
three dimensional shape necessary to evaluate devices.  Similarly, the L’Heureux blood 
vessels, although utilizing human cell sources and possessing three-dimensional shape, 
may not be commercially feasible as a scaleable and high throughput model due to the 
extensive labor and time required for the development of each graft.  The Sun work 
represents the closest SMC and EC co-culture system, given that the cells are pressure 
sodded onto an ePTFE substrate, however the model differs from the proposed in-vitro 
BVM seeing as bovine rather than human cell sources were used.  Thus, to create a more 
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physiologic in-vitro blood vessel mimic, Studies 6 and 7 of this thesis aimed to synergize 
both the work described throughout the literature with the work of the five preceding 
studies, in an attempt to determine the feasibility of an in-vitro dual-sodding protocol.   
Materials and Methods 
The experimental approach for the dual sodding co-culture of SMC and EC 
studies was to first establish a protocol by which the two separate cell types could be 
delivered.  The goal was to understand how both cell types could be efficiently and 
effectively delivered to the lumen of the graft.  Once a sodding protocol was determined, 
two studies were completed using smooth muscle cell densities of 7.5x105 cells/cm2 and 
endothelial cell densities of 5.0x105 cells/cm2, based on the results of Study 1 – Study 5 
presented in the previous chapters.  Although a perfectly confluent layer was not created 
with HUVECs in Study 5, the aim of the dual layer experiments was more focused on 
establishing a protocol for the sequential sodding of two cell types than it was to create an 
optimized dual layer graft; therefore 5.0x105 cells/cm2 was used to be consistent with 
previous experiments.  The first attempt, Study 6, was conducted over the period of one 
day to confirm the presence of cells immediately after sodding, since it was unknown 
whether cells would withstand two sequential transmural soddings or if the SMC layer 
first established would prevent the subsequent sodding of ECs.  To adhere to the cost 
goals for the BVM system, the overall target set-up and cultivation was established at one 
week (7 days), such the graft could be set-up and ready for device deployment.  
Therefore, Study 7 was completed over a 7 day time period.  Scanning electron 
microscopy, histology, and fluorescence microscopy was utilized to evaluate the grafts 
after harvesting. 
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Cell selection and Culture 
After previously completing individual studies using human umbilical vein 
smooth muscle cells (HUVSMC) and human umbilical vein endothelial cells (HUVEC), 
studies aimed at combining the two cell types were undertaken.  The human umbilical 
vein cell source was used in the dual layer Studies 6 and 7 to remain consistent with the 
earlier studies of this thesis.  Human umbilical vein smooth muscle and endothelial cells 
were the same purchased from Sciencell Research Laboratories, Carlsbad, California for 
Studies 1-5, and the culture of cells was conducted according to the methods previously 
described.  HUVSMCs used in Studies 6 and 7 between P6 to P7.  HUVECs were used at 
P5.  
Prep of Bioreactor and ePTFE Graft Prior to Set-up 
Set-up and preparation for each study was conducted in the same manner as the 
studies described in Chapters 2 and 3, beginning approximately one week prior to cell 
sodding.  For each study, of four-millimeter (4mm) diameter ePTFE tubing was cut to 
four-centimeter (4 cm) lengths.  Sterilization, media preparation, denucleation, and 
passive conditioning were conducted as before.  Both dual sodding studies described 
within this chapter were conducted following the outlined preparatory steps prior to each 
run.  No deviations from the described steps were recorded.  
Set-up day 
Bioreactor set-up and graft insertion was conducted the same as previous studies.  
The required medias were warmed and sterile and non-sterile partners were required for 
the insertion of the grafts.  Conditioning of the grafts followed the assembly of the 
bioreactor systems as previous described. 
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Cell Culture  
Cell culture for both HUVSMC and HUVEC began 2 to 4 days prior to set-up 
day.   A confluent T225 of each cell types provided a sufficient number of cells for the 
dual layer studies.  Cell culture was closely monitored in the days immediately preceding 
set-up of a bioreactor run, and scheduling of the set-up was adjusted accordingly to 
ensure that the required number of cells for a given run were available.  Additionally, in 
order to distinguish the cell types after sodding, fluorescence microscopy techniques were 
used, including the use of Cell Tracker™ dye (Invitrogen Molecular Probes, Catalog 
#C7025).  The Cell Tracker™ probe is generally administered during cell culture and is 
maintained within the cytoplasm for later analysis.  Further description of the use of Cell 
Tracker™ for Study 6 and 7 is contained in subsequent sections. 
Cell Harvesting and Counting - HUVSMC 
Following set-up and conditioning of the ePTFE grafts, HUVSMCs were 
removed from the small Shellab incubator and inspected.  Harvesting and counting was 
completed as described in Chapter 2.  After counting and centrifugation, the cell pellet 
was re-suspended using the established volume of bioreactor media and prepared for 
sodding pending the arrangement of bioreactor chambers within the hood.    
Sodding of Cells - HUVSMC 
In preparation for cell sodding, the conditioned bioreactors and attached media 
reservoirs were removed from the large incubator, moved into the hood, and arranged as 
previous studies.  Given that the sodding density of SMC remained consistent for both 
Study 6 and 7 at 7.5x105 cells/cm2, a 3.3mL volume of cell suspension was collected into 
a syringe per graft of both studies and injected through the three-way valve of the 
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bioreactor inlet to transmurally deposit cells onto the ePTFE graft.  A steady yet gentle 
pressure (approximately 2 mL/min) was maintained during the pressure sodding.   
Intermediate Transmural Flow 
Immediately following the deposit of SMC cells by pressure sodding, each graft 
was chased with 7 – 10 mL of bioreactor media, maintaining a gentle steady pressure.  
All valves on the system were closed and the outlet of the bioreactor was reconnected to 
the reservoir.  The system was reconnected to the peristaltic pump in the large incubator 
and transmural flow (outlet valve from graft closed, all other valves open) immediately 
resumed at 10 rpm (0.8 mL/min).  Transmural flow on the SMC grafts were maintained 
for 30 minutes, during which time HUVEC cells were harvested and counted in 
preparation for sodding. 
Cell Harvesting and Counting – HUVEC 
Immediately following the start of transmural flow through the grafts, HUVECs 
were removed from the small Shellab incubator and inspected to ensure cells appeared 
healthy.  Cells were next harvested with trypsin in an analogous manner to SMC and 
previous studies.  Release of the cells from the culture flask was confirmed by 
observation under the light microscope.  As before, the cell solution was counted and 
centrifuged to form a cell pellet.  The cell pellet was re-suspended using a volume of 
bioreactor media based on the cell count.  The HUVEC cell suspension, now ready for 
sodding, was set-aside while the SMC grafts completed the 30-minute transmural cycle. 
The time required to harvest, count, centrifuge, and resuspend the cells took 
approximately 30 minutes, resulting in minimal down time between resuspension and 
sodding of HUVECs.  However, to minimize the chance of cells settling during the time 
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between resuspension and sodding, the HUVEC solution was agitated by pipette or gentle 
hand swirling.   
Sodding of Cells – HUVEC 
Following the 30-minute SMC transmural sodding, the SMC grafts and 
bioreactors were removed from the large incubator and moved into the hood.  The 
bioreactors and reservoirs were arranged again such that the bioreactor outlet could be 
disconnected into a petri dish to relieve the buildup of pressure during sodding.  Once the 
bioreactors were arranged appropriately, the outlet valve of the bioreactor chamber 
connected to the graft was closed for pressure sodding and the suspended mixture of cells 
was gently agitated to ensure a uniform cell suspension. The sodding volume was 
determined according the surface area of each graft used.  The sodding density of 
endothelial cells for Study 6 and 7 remained at 5.0x105 cells/cm2, and a 2.2 mL volume 
of cell suspension per graft was collected into a syringe and injected through the three-
way valve of the bioreactor inlet for both studies.  As with the SMC sodding, injection of 
the HUVEC was completed transmurally such that the endothelial cells were 
hypothetically deposited directly onto smooth muscle cell layer previously established.  A 
steady yet gentle pressure (approximately 2 mL/min) was again maintained. 
Pump Settings and Ramp-up Schedule 
After both HUVSMC and HUVEC sodding were complete, bioreactors were 
connected to the pump and transmural flow continued at 10 rpm for an additional 30 
minuets.  Following this second 30-minute transmural flow, the luminal outlet valve of 
the bioreactor was opened and luminal flow was maintained at 10 rpm for an additional 
hour.  After an hour of luminal flow at 10 rpm, the pump speed was increased to 20 rpm 
Chapter 4 – HUVSMC and HUVEC Dual Layer Blood Vessel Mimic  
 
 94 
and maintained overnight.  Depending on the duration of the study, two actions 
proceeded the following morning.  For Study 6, luminal flow was maintained at 20 rpm 
until the grafts were harvested for analysis the following morning.  Luminal flow of 
Study 7 was increased in 15-rpm increments every hour until approximately 12 mL/min 
(150 rpm) was achieved.  Flow was maintained at this rate until each graft was harvested.  
For the seven-day study, time points of 1, 3, 5, and 7 days were collected; the day 1 graft 
was harvested before pump ramp up.  Additionally, for the day 5 and 7 grafts, the 
bioreactor media was changed every 3 days.   
Harvesting and Prepping of grafts for analysis 
Graft harvesting was completed at the conclusion of each run (see Appendix C).   
All clamps on the bioreactor system were closed and the system was disconnected from 
the pump.  Grafts were removed and fixed in Histochoice as described in Chapter 2.  
SEM Imaging and Histological Analysis 
Analysis modalities for dual layer co-culture studies included scanning electron 
microscopy (SEM) and histological analysis.  Preparation for SEM imaging was 
conducted the same as previously described, including cutting samples, drying, and gold 
sputtering.  
Samples for histological analysis were circumferentially cut and sent for 
embedding in paraffin wax.  After embedding, the samples were sectioned and stained 
with Hemotoxylin and Eosin (H&E) according to the protocol outlined in Appendix H.  
As before, images were analyzed using ImageJ software.  
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Florescence Microscopy Analysis 
In addition to SEM and Histological analysis, fluorescence imaging techniques 
were attempted in order to distinguish between cell types after sodding.  Specifically, a 
combination of Cell Tracker™ Green CMFDA (5-chloromethylfluorescein diacetate, Em 
λ 517 nm) and Bis-benzimide (BBI, Em λ 460 nm) were used for distinction of 
HUVSMC and HUVEC.  Cell Tracker™ is a fluorescent chloromethyl derivative that 
freely diffuses through the membranes of live cells and is maintained within the cell 
membrane for up to several days; BBI conversely targets DNA within all cell types.   
The proposed theory for imaging the co-culture graft by fluorescence microscopy 
hinged on the fact that endothelial cells could be stained independently while in culture 
prior to sodding, maintain their fluorescent identity, and BBI could be later used to stain 
both SMC and EC following graft harvesting.  Images would then be taken at 
approximately λ 517 nm to identify the location of endothelial cells, and then images at 
approximately λ 460 nm would be taken to identify the location of all cells on the graft.  
The two images would be superimposed to identify the location and distribution of EC 
and SMC, with the goal of seeing two distinct regions of each cell type.   
Stock solutions of Cell Tracker™ were made according to protocols provided by 
Invitrogen by diluting 50 µg powder packages to a concentration of 10 mM using DMSO.  
Depending on the desired staining concentration, volumes of the stock solution were 
mixed with plain Dulbecco's Modified Eagle Media (DMEM) to dilutions between 10 
µM to 20 µM.  Immediately prior to harvesting, culture media of cells to be stained with 
Cell Tracker™ was aspirated off and a volume between 2-4 mL of diluted dye for T75 
and 8-10 mL for T225 was injected into the culture flask.  The cells and dye were 
incubated for 30 minutes, at which time the dye solution was aspirated off and replaced 
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with fresh culture media.  The stained cells and fresh culture media were incubated for an 
additional 30 minutes.   
Unlike Cell Tracker™ Green, BBI did not need an incubation period prior to use 
and could be used on cells that were already fixed.  Stock solutions of BBI were made 
and directly administered for 15 to 30 minutes to the cells of sodded grafts previously 
fixed with Histochoice; fixed grafts were rinsed with phosphate buffered saline (PBS) 
before staining.  After staining with BBI, constructs were washed with PBS.  In the case 
of dual sodding experiments, endothelial cells were the cell type stained with Cell 
Tracker™.   
Analysis of the stained cells, for both Cell Tracker™ and BBI was conducted on 
Olympus epifluorescent and Olympus confocal microscopes.  Furthermore, to prevent 
photo bleaching of the stains before analysis, stock solutions and stained samples were 
prepared in the dark and wrapped with aluminum foil until ready for use.               
Cost Analysis 
Cost analysis was conducted to compare the cost of setting up one dual sodded 
BVM to other BVM models.  The analysis assumed a standard passage number of P6 for 
ECs and P8 for SMCs, and was used to determine associated costs of thawing a 1 mL vial 
of cells for each cell type, passing once, and running one bioreactor, including media and 
disposable costs.              
Results 
Study Results 
General Study Observations and Deviations: Study 6 
Study 6 aimed to evaluate the concept of the dual sodding protocol by focusing on 
the timing and feasibility of consecutively pressure sodding two cell types.  Two 
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bioreactors were set-up to practice and trouble-shoot the sodding protocol, as well as to 
determine if consistency could be achieved between multiple set-ups.  Evaluation of the 
grafts after one day was intended to confirm the presence of cells and the preliminary 
arrangements of the cell types after sodding.  SEM and Histological analysis confirmed 
the presence of cells, however challenges surrounding the dyes used for fluorescence 
microscopy limited the analysis of cell arrangement.  Further discussions of these results 
are covered in subsequent sections.   
One T225 of HUVSMC was cultured to P6 from the original Sciencell vial to 
achieve a confluent cell population for sodding.  The 70% confluent T225 yielded an 
averaged cell count of 13.3x106 cells; the “A” and “B” cell count results from the 
hemocytometer were 13.4x106 cells and 13.2x106 cells respectively.  The centrifuged 
pellet was resuspended in 13.3 mL of media to yield a solution with a cell density of 
1.0x106 cells/mL.  Similarily, two T75s of HUVEC were cultured to P5 to achieve two 
50% confluent T75s yielding a combined averaged cell count of 5.3x106 cells.  The 
centrifuged pellet was resuspended in 5.3 mL of media to yield a solution with a cell 
density of 1.0x106 cells/mL.   
Renucleation during insertion of the grafts was not observed and sodding was 
completed in accordance with the protocol.  Furthermore, no observations of luminal 
bubbles were noted during extraction of the grafts. 
SEM Images: Study 6 
Scanning electron microscopy evaluation following Study 6 showed the presence 
of a lining of cells within the lumen of the graft.  Distinction between cell types could not 
be definitively made by SEM imaging, however, the cell layer appears confluent and no 
ePTFE is visible. 
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Fig. 4.1a 
     
 
Fig. 4.1b 
 
Figure 4.1 – Study 6, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 1 at 34x (a) and 150x (b) magnification.  SEM images confirm the 
presence of cells, but cell type identification cannot be made.  Cell layer appears 
confluent and no ePTFE is visible.  
 
Histology Images: Study 6 
Histology images taken after Study 6 show the presence of a thin layer of cells.  
The cell layer appears to be as thick or thicker than previous day one histology images 
suggesting that more cells may be present after sodding.  Although ECs and SMCs 
cannot be distinguished, the fact that a cell layer is present after one day that is at least as 
thick as the HUVEC or HUVSMC-only grafts suggest that the protocol for dual sodding 
could result in both cell types sodded in the lumen of the graft.  
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Fig. 4.2  
Figure 4.2 – Study 6, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density.  Thin cell layer visible.  Cell layer appears to be as at least as thick (10-20 µm) 
as the previous SMC day one histology images.  
 
General Study Observations and Deviations: Study 7 
After demonstrating the feasibility of the dual sodding protocol during Study 6, 
Study 7 aimed at examining the cellular dynamics and BVM changes over a time period 
of 7 days.  An additional P6 vial of HUVSMC were thawed, cultured, and used at P7. 
Similarly, a P4 vial of HUVEC was cultured to P5.  One 65% confluent T225 of P7 
HUVSMC and one 50% confluent T225 of P5 HUVEC were obtained and yielded an 
averaged cell count of 14.3x106 cells and 11.0x106 cells respectively.  The centrifuged 
SMC pellet was resuspended in 14.3 mL of media and the EC pellet in 11 mL of media to 
yield solutions with a cell density of 1.0x106 cells/mL each.   
One deviation was recorded throughout Study 7 when a small volume of 
resuspended HUVSMC was spilled during the transfer between the centrifuge conical 
tube and the sodding trough.  Since 13.2 mL of the SMC solution was needed to sod four 
grafts at a density of 7.5x105 cells/cm2 and only 14.3 mL was available before spilling, 
the decision was made to sod bioreactor 1 with only 2.2 mL of solution, equivalent to a 
sodding density of 5.0x105 cell/cm2.  This decision was based upon the fact that 
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bioreactor 1 was to be taken down after one day and that two grafts were created during 
Study 6 at a one-day time period that could be used for comparison.  
Furthermore, luminal bubbles were noted at the proximal end of Day 1 graft and 
throughout the Day 7 graft at the time of harvesting.  Renucleation during insertion of the 
grafts was not observed and sodding protocols were followed completely.   
SEM Images: Study 7 
SEM images taken after Study 7 showed the establishment of a cellular lining 
generally throughout the lumen of the graft.  Distinction between cell type could not be 
identified by SEM imaging.  The absence of exposed ePTFE suggests that at least more 
cells were sodded than just HUVEC alone, given that the HUVEC Study 5 grafts showed 
under confluent linings at day 1 and 5.   
 
Fig. 4.3a 
     
 
Fig. 4.3b 
 
Figure 4.3 – Study 7, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 1 at 32x (a) and 151x (b) magnification.  No exposed ePTFE suggest that 
potentially as many cells as the SMC studies were sodded. 
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Fig. 4.4a 
      
Figure 4.4– Study 7, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 3 at 32x (a) and 153x (b) magnification.  Dense cell layer with no 
exposed ePTFE.  Cells cannot be distinguished or identified.  
 
 
 
 
 
Fig. 4.5a 
     
 
Fig. 4.5b 
 
Figure 4.5– Study 7, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 5 at 46x (a) and 144x (b) magnification.  Dense confluent cell coverage 
with no ePTFE exposed.  
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Fig. 4.6a 
     
 
Fig. 4.6b 
 
Figure 4.6– Study 7, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 7 at 36x (a) and 158x (b) magnification.  Uniform cell coverage 
confirmed.  The irregular appearance can be attributed to damage to the sample during 
SEM preparation.  Aside from the dark artifact in 4.6a, the graft shows dense cell 
coverage with no ePTFE exposed.  Cell type cannot be identified.   
 
Histology Images: Study 7 
Histological evaluation following each BVM study served to evaluate the 
formation and thickness of a luminal lining.  The histology images below illustrate the 
establishment of a luminal lining approximately 140 µm thick after 7 days.  Hemotoxylin 
and Eosin staining did not provide definitive distinction between endothelial and smooth 
muscle cells.  Histological analysis using cell type specific stains could aid in the 
characterization of cell layers within the lumen of the blood vessel mimic.  
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Fig. 4.7  
Figure 4.7 – Study 7, HUVSMC 7.5x105 cells/cm2 HUVEC 5.0x105 cells/cm2 sodding 
density: Day 7. Cell layer of approximately 140 µm developed after 7 days.  Cell types 
could not be distinguished.  
 
Fluorescence Microscopy Analysis 
Few definitive results about the dual layer BVM could be made using 
fluorescence microscopy primarily due to the discovered incompatibility of Cell 
Tracker™ Green and BBI.  Experiments using either Cell Tracker™ or BBI alone 
successfully yielded images of fluorescently stained cells, presented in figures 4.13 - 
4.20.  However, in the case of co-culture where endothelial cells were preliminarily 
incubated with Cell Tracker™ before being combined with smooth muscle cells and 
together stained BBI, no fluorescent images could be achieved.  This result prompted a 
supplementary experiment in which a culture of HUVEC was first stained with Cell 
Tracker™ and successfully imaged.   
Following imaging with Cell Tracker™, BBI was next added to the same culture 
and imaged again.  Results of this experiment showed no detectible fluorescence 
confirming that although both dyes are designed to fluoresce at different wavelengths, the 
Cell Tracker™ Green and BBI were incompatible as complementary fluorescent stains.  
No conclusion could be made whether a chemical interaction occurred between the two 
fluorescent probes or whether adjustments to the microscopes and filter cubes could be 
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made to successfully image dual stained cells.   Future analysis of the dual layer grafts by 
fluorescence microscopy would first require the identification of two complementary 
probes.   
 
Fig. 4.8a      
 
Fig. 4.8b  
 
Fig. 4.8c  
Figures 4.8 – HUVECs stained with Cell Tracker alone, en face.  HUVEC grafts (a-c) 
sodded at 5.0x105 cells/cm2 en face stained with cell tracker. 
 
 
Fig. 4.9  
Figure 4.9 – HUVECs stained with Cell Tracker alone, cross-section.  HUVEC graft 
sodded at 5.0x105 cells/cm2 cross-section stained with cell tracker. 
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Fig. 4.10a      
 
Fig. 4.10b  
Figure 4.10 – HUVEC Stained with BBI alone. HUVEC in culture stained with BBI (a) 
and a HUVEC graft sodded at 5.0x105 cells/cm2 en face stained with BBI (b). 
 
 
Fig. 4.11a      
 
Fig. 4.11b  
Figure 4.11 – Combination Cell Tracker and BBI: HUVEC in culture stained with 
Cell Tracker and BBI.  Cells were stained with Cell Tracker during culture and imaged 
to confirm fluorescence.  Next the cell culture was stained with BBI producing the above 
images at emission wavelengths of 517 and 460 nm.  No cells were visible at either 
wavelength. 
Cost analysis 
Fundamental to the development of a commercially feasible co-culture BVM of 
human smooth muscle and human endothelial cells on ePTFE was to also evaluate the 
associated costs.  The following charts describe the cost of setting up one dual layer 
BVM, encompassing the steps and associated costs with thawing a 1 mL vial of cells of 
each type, passing once before sodding, and running one bioreactor.  Although 
HUVSMC cells up to P14 were used during the course of studies contained within this 
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thesis, for cost analysis purposes the assumption was made that cells were passed at a 
ratio of 1:2 up to P8.  HUVEC were assumed passed at a ratio of 1:2 up to P6. 
 
Setup of one dual layer graft QTY used unit cost/graft   
ePTFE 4 cm 40   
100% EtOH 40 ml 0.48   
70% EtOH 40 ml 0.33   
Fill chamber w/ BrM 300 ml 27.05   
Fill reservoir w/ CM 50 ml 5.44   
Replace reservior w/ BrM 50 ml 4.51   
Flush w/ BrM after sodding 10 ml 0.90   
Syringe 2 ea 0.20   
10ml Pipet 4 ea 0.56   
25ml Pipet 4 ea 1.44   
2ml Asp Pipet 4 ea 0.98   
50 conical 4 ea 1.66   
Trypsin 18 ml 1.44   
Trypan-blue 200 µl 0.02   
Hemocytometer 2 ea 4.20   
Average cell cost   2.99   
    Total 92.19 A 
 
 
 
 
Culturing of HUVSMC prior to 
setup 
QTY 
used 
unit cost 
  
(includes thawing into T75 and one passage into T225)   
T75 1 ea 2.64   
T225 1 ea 3.87   
5ml Pipet 2 ea 0.26   
10ml Pipet 2 ea 0.28   
25ml Pipet 2 ea 0.72   
2ml Asp Pipet 3 ea 0.73   
Typrsin 3 ml 0.24   
T75 Thaw 20 ml 3.52   
T75 Feed 12 ml 2.11   
T225 Passage 36 ml 2.11   
   Total 16.48 B 
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Culturing of HUVEC prior to 
setup 
QTY 
used 
unit cost 
  
(includes thawing into T75 and one passage into T225)   
T75 1 ea 2.64   
T225 1 ea 3.87   
5ml Pipet 2 ea 0.26   
10ml Pipet 2 ea 0.28   
25ml Pipet 2 ea 0.72   
2ml Asp Pipet 3 ea 0.73   
Typrsin 3 ml 0.24   
T75 Thaw 20 ml 3.76   
T75 Feed 12 ml 2.26   
T225 Passage 36 ml 2.26   
   Total 17.01 C 
       
Total cost per dual layer graft A+B+C= 125.67   
(from thawing to harvested graft, one passage in 
between) 
          
 
Table 4.1 – Cost analysis sheet for the construction of one dual layer BVM.   See 
Appendix L for costs of standard items and cell yield calculation.  
 
Discussion 
Based on the first five studies, which served to evaluate the feasibility and 
minimum cell sodding densities necessary to achieve a confluent large vessel smooth 
muscle and endothelial cell layer on ePFTE, Studies 6 and 7 served to develop and 
examine the feasibility of creating a co-culture in-vitro blood vessel mimic.  The 
attempted protocol allows for both smooth muscle and endothelial cells to be sodded onto 
an ePTFE scaffold sequentially in a single set-up day, with minimal additional labor as 
compared to the current single cell type in-vitro BVM.  Most significantly, Studies 6 and 
7 demonstrated that two cell types could be pressure sodded sequentially, as it was 
unknown whether the SMCs would clog the ePTFE pores or physically prevent the 
subsequent transmural sodding of the ECs, or whether cells would even be present after 
two sequential soddings. 
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 Histological and SEM analysis showed the presence of cells, however the 
phenotypic identity of these cells could not be determined using the available methods.  
Furthermore, while the histology images collected showed the development of a cell 
layer after 7 days, the cell layer was thinner than observed of the SMC-only grafts after 
the same cultivation period.  Although development of the cell layer may have occurred 
in the dual layer grafts, the cells may not have responded in the same manner as with 
SMC alone, potentially due to the presence of endothelial cells or a result of the sodding 
protocol.  Additionally, it is unknown whether the dual sodding protocol actually resulted 
in more cells within the lumen.  While the day one grafts of Studies 6 and 7 appear to 
show a slight increase in cell material suggesting that additional cells were deposited 
after sodding, it was not definitively shown whether the dual sodding protocol resulted in 
an increased number of cells in the lumen.  Therefore, the thinner development of the 
dual layer graft could also be due to fewer cells in the lumen after sodding.  Future work 
will be required to understand the repeatability of the experiments and determine whether 
the development of the dual cell layer is less pronounced when both cell types are sodded 
or if variations in sodding technique cause the discrepancy of the cell layer thickness.   
Moreover, fluorescence microscopy, attempting to track and identify the location 
and movement of the two cell types on the BVM, was inconclusive due to a lack of 
compatibility between the fluorescent probes chosen.  Initial future work should focus on 
alternative analytical methods to definitively characterize the cellular composition of the 
dual sodded in-vitro blood vessel mimic, potentially including phenotypic specific 
antibody stains and compatible fluorescent probes.   
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While shortcomings in analysis techniques described in this thesis limited the 
ability to definitively characterize the cellular aspect of the dual layer graft, Studies 6 and 
7 successfully demonstrated the potential feasibility of a protocol for development of a 
physiologically representative dual layer blood vessel mimic.  Further characterization of 
the BVM will serve to establish and compare the analytical value of the dual layer BVM 
by implanting intravascular devices and comparing results to the single source HMVEC 
BVM.   
If characterization shows that tissue-engineered blood vessels created using the 
described dual layer protocol do not show representative cellular arrangement or 
morphology, refinement of the sodding protocol may include adjusting the sodding 
timing or addition of dynamic flow characteristics.  For example, the Sun paper allowed 
the smooth muscle layer to develop over 5 days before introducing endothelial cells.  
Future work for the in-vitro BVM may show that this time is required to better facilitate 
the creation of distinct media and intima layers.  Although Sun et al reported waiting for 
the SMCs to develop before sodding ECs, the sequential sodding technique developed for 
this thesis was pursued for rapid setup and minimal labor.  The intent was to develop a 
commercially feasible protocol that could create a dual layer graft requiring only one day 
of cell sodding, thereby minimizing the time and labor associated with culturing, 
harvesting, and sodding cells.  However, especially given the results of Studies 2 and 4 
which showed a better developed SMC layer, future refinement of the dual sodding 
protocol may require waiting for the SMC layer to develop before adding endothelial 
cells, despite the additional time and labor added for set up and graft development.     
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Furthermore, given the literature describing the motility and arrangement 
characteristics displayed by endothelial and smooth muscle in response to mechanical 
factors such as shear stress and stretching [28, 68], adjusting the flow or scaffold 
characteristics may also be required to establish the desired dual layer system.  Any 
additional steps or added culture time should be carefully considered to remain consistent 
with the goal of producing a cost and time effective protocol.   
Finally, comparison of dual layer BVM to the current single source HMVEC 
BVM model show that the dual layer grafts cost approximately the same to the previous 
HUVSMC, HUVEC, and HMVEC blood vessel mimics.  Including the cost of both 
SMCs and ECs, as well as the costs of the additional media and culture disposables, the 
dual layer BVM cost approximately 125 dollars per graft.  While the dual layer system is 
only about 25 dollars more than previous systems, the majority of the added cost comes 
from the additional culture media required to culture and support two different cell 
populations.   
 Therefore, if characterization of the dual layer graft proves the BVM to be a more 
physiologically relevant model, supplementing bench-top and early animal studies with 
the dual layer BVM could be a valuable tool for rapid device development and cost 
savings during the in-vitro stages of product development. 
Study Summaries 
Study 6 
Evaluated the feasibility of a protocol to dual sod HUVSMC and HUVEC.  
Demonstrated that cells could be sustained after dual sodding, however characterization 
of cell types within the graft was inconclusive.  
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Study 7 
Evaluated the feasibility of a protocol to dual sod HUVSMC and HUVEC.  
Demonstrated that cells could be sustained after dual sodding over a 7-day time period, 
however characterization of the cell types within the graft was inconclusive. 
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Evolving in parallel with developments in cellular and molecular biology, tissue 
engineering has become a field of study that offers the potential for novel and unmatched 
medical therapies and treatments.  While the majority of tissue engineering approaches 
focus on clinically applicable therapies, secondary niches and applications have emerged 
to provide additional value to the technology.  One such application aims to utilize tissue-
engineered constructs for in-vitro evaluation of associated devices and therapies; in 
particular, in-vitro blood vessel mimics as described throughout this thesis.  The purpose 
of a blood vessel mimic is to create a bench top model that can be used to test and 
evaluate vascular disease treatments and intravascular devices, thereby minimizing the 
development time and costs of the device.   
Previous in-vitro blood vessel work developed by Cardinal et al. used fat derived 
human microvascular endothelial cells sodded on an ePTFE scaffold.  Noteworthy is the 
similarity in concept between previous in-vitro models presented in the literature, like the 
model described by Johnson [62], and the in-vitro blood vessel mimic created by 
Cardinal.  The key distinction between these two systems being that the Cardinal model 
maintains anatomical shape so that intravascular devices can be inserted and studied in an 
anatomically representative environment.  Other models may not have tubular or similar 
three-dimensional shape or may be used to study cell biology as opposed to the cellular 
response to implanted devices.   
Therefore, building upon the Cardinal HMVEC blood vessel mimic, the work 
described in this thesis represents an effort to continue the development of the BVM by 
creating a more physiologically accurate model.  This objective was pursued through the 
investigation and use of large vessel human cell sources and the incorporation of a 
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smooth muscle media layer.  Human umbilical vein endothelial cells (HUVEC) and 
human umbilical vein smooth muscle cells (HUVSMC) were chosen as the large vessel 
cell type and cultivated according to standard procedures.  In addition to investigating the 
feasibility of constructing a more physiologic blood vessel mimic using large vessel cells 
and dual layer co-culture, a cornerstone theme in the continued development of the in-
vitro BVM was minimizing monetary and labor costs, and therefore cost analyses were 
performed for incorporation of each new cell type.   
Based upon the studies in this thesis, several conclusions were reached.  First, an 
investigation of the literature revealed the prevailing use of human umbilical vein cells, in 
particular human umbilical vein endothelial cells (HUVEC), for both vascular biology 
study as well as tissue engineering approaches.  After identifying the umbilical vein for 
the large vessel cell source, commercially available human umbilical endothelial and 
smooth muscle cells sources were sought.  It was determined that both HUVEC and 
HUVSMC could be acquired from numerous commercial sources at competitive prices.  
Therefore, based on proximity to Cal Poly and overall costs, Sceincell was chosen as the 
HUVEC and HUVSMC supplier for this thesis, establishing a commercially and 
economically viable large vessel cell supply.   
Aside from simply using large vessel sources to improve the physiological 
characteristics of the new model, future work could be completed to ensure the phenotype 
of the umbilical vein cells remained large vessel within the BVM.  Identifying factors 
typical of larger vessel arteries may better characterize the physiologic advantage of 
using large vessel cells over microvascular cells.  As an example, testing for 
thrombomodulin production or similar anticoagulation factors may be used to distinguish 
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between large vessel and microvascular phenotype, analogous to the work completed by 
Hedeman et al. [46].      
After exploring and identifying a large vessel cell source for the in-vitro BVM, 
sodding density experiments with HUVSMC were first performed to determine the 
number of cells required to create a confluent medial cell layer prior to HUVEC sodding.  
These studies served to show that a large vessel smooth muscle cell layer could be 
established and maintain in-vitro on an ePFTE scaffold, and laid the groundwork for 
future co-culture experiments.  Scanning electron microscopy and histological analysis 
were used to confirm the presence and development of the SMC layer; however future 
work should focus on the phenotypic characterization to ensure that the smooth muscle 
cells retain their identity in the BVM.  Furthermore, the SMC sodding density studies 
completed during this thesis aimed at finding a minimum density to achieve a confluent 
layer, however future SMC sodding density work should aim to develop a graft with 
physiologically analogous media thickness that is comparable to coronary arteries. 
After study with smooth muscle cells, an experiment with HUVEC and ePTFE 
was conducted to determine whether a BVM could be created and sustained in-vitro 
using a large vessel endothelial cells source on a polymer scaffold.  Given the differences 
described between micorvascular and large vessel endothelial cells [46], the HUVEC 
blood vessel mimics created in this study could alone be considered a next step model 
from the previous HMVEC vessel, albeit with further work to identify and correct the 
unexpected HUVEC morphology observed during Study 3.  Although the HUVEC study 
did not result in a desired luminal lining of cells, Study 3 results did demonstrate that 
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cells could be sodded onto the ePTFE, and thus subsequent dual-sodding investigation 
ensued. 
In the pursuit of a more physiologic blood vessel model, the final two studies 
contained within this thesis served to develop a dual sodding protocol to create a BVM 
using large vessel endothelial and smooth muscle cells.  The protocol that was developed 
demonstrates a method by which two cell types can be sequentially sodded onto an 
ePTFE scaffold.  Results show that cellular material can be sustained within the vessel 
for seven days; however, analysis could not conclusively confirm the phenotype or 
spatial orientation of the cells.  Future work for the development of the dual layer blood 
vessel system should focus on the refinement of sodding densities, better characterization 
of vessels, and subjection of the vessel to intravascular devices.  In particular, 
investigation of compatible fluorescent dyes and phenotypic specific antibody or protein 
stains should be used to better analyze the dual layer sodding protocol and the potential 
value of the dual layer graft for device evaluation.   
Additionally, the repeatability and consistency of the experiments described 
within this thesis should be investigated in future work.  Given the scope of this thesis 
was to investigate a more physiological BVM, only one experimental run for each study 
was performed in an attempt to lay a foundation for future studies and future work.  Thus, 
the consistency of the protocols and the effect of any variations to the protocols remain 
largely unknown and future work testing repeatability should be conducted.   
Additional future work could include the incorporation of other BVM elements 
such as pulsatile flow, media viscosity, or scaffold variations, potentially improving the 
cellular response and physiologic aspects of blood vessel model.  Furthermore, inspired 
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by tissue engineering methods using biologic and decellularized scaffolds[69-71], 
attempts to develop biologic scaffold materials were also undertaken by the Cal Poly 
tissue engineering team.  Although pursued in limited scope, the preliminary work using 
molded collagen tubes and decellularized porcine arteries as biologic scaffolds is 
addressed in Appendix K. 
Overall, the work completed within this thesis provides preliminary support that a 
large vessel BVM could be created inexpensively using commercially available cell 
sources.  Cost analysis shows that a BVM may cost between 100 and 125 dollars per 
vessel for all materials and disposables.  As a complement or even a replacement for 
some animal study and other in-vitro bench top analysis tools, the proposed dual layer 
blood vessel mimic offers potential to serve as a valuable tool in the development, 
testing, and continual advancement of intravascular devices.    
Overall Thesis Summary 
The work described within this thesis serves to lay the groundwork for future 
development of a dual layer blood vessel mimic.  The following list highlights the and 
summarizes the overall findings of this thesis: 
- Blood vessel mimics containing human smooth muscle cells (HUVSMC), human 
endothelial cells (HUVEC), and a co-culture of HUVSMC and HUVEC can be 
established and maintained in-vitro.  
- Human SMCs from large vessel sources (HUVSMC) can be sodded on 
ePTFE at a density of 7.5x105 cell/cm2 and developed in-vitro. 
- Human ECs from large vessel sources (HUVEC) can be sodded on ePTFE 
at a density of 5.0x105 cell/cm2 and sustained in vitro. 
- Large vessel human SMCs and ECs can be dual-sodded using an efficient, 
scalable protocol that lends itself to the high throughput development of 
dual-layered blood vessel mimics  
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- Economically feasible to obtain, cultivate, and utilize large vessel SMCs and ECs 
from a commercial source for use in an in-vitro blood vessel mimic system.  
 
While much work will be required to achieve a commercially ready BVM system, 
continued effort and constant development within the field of tissue engineering may one 
day allow the proposed BVM to become a valuable tool in the development of vascular 
devices and treatments.
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APPENDIX A 
Single Cell Sodding Blood Vessel Mimic Protocol 
 
Purpose: 
The following protocol describes the methods for the setup and cultivation of an 
in-vitro blood vessel mimic and bioreactor system using a single cell type.   
 
Components: 
• ePTFE tubing  
• HUVSMC or HUVEC 
• Conditioning Media (see Conditioning Media Preparation protocol Appendix E) 
• Bioreactor Media (see Bioreactor Media Preparation protocol Appendix D) 
• Sterile/Filtered EtOH; 70% and 100% concentrations 
• Silk Suture 
• Bioreactor system: bioreactor chamber, lid, two port reservoir 
• Female luer to barb connector fittings 
• Cole-Palmer peristaltic pump 
• Sterile gloves 
• Hemocytometer (Neubauer Improved grid type) 
• Trypan-Blue 
 
Procedure: 
1 Prep: Approximately 1-week prior  
1.1 Gas sterilize the bioreactor chambers, lids, and 2-port reservoirs in individual 
sterilization bags.  Ensure that the inlet and outlet tube of the reservoir are 
connected in series.  
1.2 Determine the target number of cells and passage schedule.  Thaw and culture 
cells accordingly. 
1.3 Cut ePTFE tubing to the appropriate length.  For example, when using two 
connectors on inside of the bioreactor chamber a 4 cm long segment will be 
required.  Wear gloves to avoid transferring oils to the ePFTE. 
1.4 Connect a female luer to barb connector to each end of the ePTFE graft and 
suture using silk suture. 
1.4.1 Position the suture just inside the barb of the slip fit connector so that the 
graft and suture cannot be pulled off the connector. 
1.4.2 Triple tie the suture with a simple knot as tight as possible, reversing the 
direction of the knot each time.     
1.5 Autoclave grafts, vacuum flask, media troughs, and forceps.  
 
2 Prep: Day Before  
2.1 Make media 
2.1.1 Bioreactor Media (see Appendix D) 
2.1.2 Conditioning Media (see Appendix E) 
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2.2 Begin degassing approximately 12-15 mL of conditioning media per graft in a 
vacuum flask under standard vacuum.  Set-aside during graft denucleation. 
2.3 Denucleate ePFTE grafts using sterile/filtered Ethanol (EtOH) 
2.3.1 In the sterile hood, fill a 50 mL conical tube with enough 70% EtOH to 
completely submerge each graft, approximately 40- 45 mL. Label 
appropriately and set aside.  Repeat to fill a 50 mL conical tube with 
enough 100% EtOH. Label appropriately and set aside. 
2.3.2 Using sterilized forceps and proper sterile technique, remove each graft 
from the sterilization bags and submerge in 70% EtOH for 15 minutes.  
Agitate periodically by hitting the bottom of the conical tube to aid the 
duculeation.   
2.3.3 After 15 minutes in 70% EtOH, transfer the grafts to the 100% EtoH for 
an additional 15 minutes.  Continue to periodically agitate.  Throughout 
the denucleation period the grafts should become increasingly transparent.  
2.4  Transfer 10-12 mL of degassed conditioning media into 15mL conical tubes and 
immediately transfer one denucleated graft into each conical tube of degassed 
media.  Leave grafts in degassed media overnight in an incubator at 37°C.  
 
3 Set-up day: Blood Vessel Mimic Conditioning 
3.1 Warm up Bioreactor media and Conditioning media in water bath.  
3.2 Set-up Cole-Palmer pump in large incubator 
3.3 Transfer the tubes containing the denucleated grafts into the flow hood. 
3.4 Insert conditioned sterile grafts into bioreactor chambers. NOTE: Non-sterile 
partner required. 
3.4.1 Put on sterile gloves according to sterile handling practices.  Maintain 
sterility when handling the grafts or any interior bioreactor surface.   
3.4.2 Have an aseptic partner open a sterilization bag containing a bioreactor 
chamber, taking care not to touch any sterile surface.  Remove the 
bioreactor from the packaging.  
3.4.3 Fill the bioreactor chamber (aseptic partner) to completely submerge the 
graft, approximately 250-350 mL.  Make sure that all valves on the 
bioreactor system are closed before filling the chamber.   
3.4.4 Have the aseptic partner open one of the graft tubes, and using sterile 
forceps transfer one graft into the bioreactor chamber.  Replace the forceps 
onto a sterile surface and attach the graft onto the fittings of the bioreactor 
chamber. 
3.4.5 Attach the lid to the bioreactor and set the partial assembly aside.  This 
can be preformed by either partner as long as the aseptic partner takes care 
not to touch the inside surface of the lid. 
3.4.6 Repeat steps 3.2.3 – 3.2.6 for all grafts of a given setup.  Once all 
bioreactors are sealed, the sterile partner can begin working aseptically. 
3.5 Fill 50 mL conical tubes with approximately 40-50 mL of conditioning media 
and attach two port lids.  Keep the inlet and outlet tubes connected in series and 
prime the tubing of the two port lids by inverting the reservoir.  Set aside.  
3.6 Prime grafts with conditioning media 
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3.6.1 Using a syringe connected to the inlet stopcock of the bioreactor system, 
open all of the valves and flush the lumen of the graft with conditioning 
media to remove any air bubbles. After flushing the lumen, close the outlet 
of the bioreactor chamber inject approximately 20-30 mL of conditioning 
media transmurally through the ePTFE. 
3.6.2 Close all valves on the bioreactor chamber. 
3.7  Attach the primed two port reservoirs to the bioreactor taking care to make sure 
that the outlet of the reservoir (long tube inside reservoir conical) attaches to the 
inlet of the bioreactor and the outlet of the bioreactor attaches to the inlet of the 
reservoir (no tube inside reservoir conical). 
3.8  Transfer the primed and assembled bioreactor and reservoir system into the large 
incubator and attach the pump tubing to the Cole-Palmer pump. 
3.9 Open all valves of the bioreactor and begin flow through the lumen at a low 
pump rpm to remove air.  Make sure that no leaks are present and fluid is flowing 
through the graft and bioreactor tubing.  Close the luminal outlet valve of the 
bioreactor to begin transmural flow. Increase the pump RPM to 75-100 and 
condition the graft for 10-15 minutes.     
3.10 During conditioning, fill 50 mL conical tubes with 40-50 mL of bioreactor 
media and set aside in the hood. 
3.11 After conditioning, close all bioreactor valves and stop the pump.  Leave the 
conditioned bioreactor chambers in incubator until ready for sodding.  
 
4 Set-up day: Blood Vessel Mimic Sodding 
4.1 Harvest cells with trypsin according to standard culture practices.  Take note of 
the total volume of liquid cells are suspended in (trypsin plus volume of media 
used to deactivate). 
4.2 Gently agitate the solution and transfer a small sample (<0.5 ml) of suspended 
cells into a separate conical tube for counting.  Set aside   
4.3 Transfer majority volume of harvested cells into a 50 mL conical tube for 
centrifuging.  Centrifuge at setting 4 for 5 minutes (brand, model centrifuge). 
4.4 During the 5-minute centrifugation cycle, gently agitate (finger vortex) the cell 
suspension and trasnfer 100 µL of cell suspension into a conical microfuge tube.  
Add 100 µL of trypan blue solution (Brand) to the cell suspension and pipette up 
and down several times to ensure a uniform cell suspension.  Determine the cell 
concentration using a hemocytometer or similar cell counting method.  
4.5 After determining the total cell count, resuspend the centrifuged pellet with 
bioreactor media to a known cell solution concentration.  A general rule of thumb 
for easy sodding calculations is to resuspend using 1 mL of media per 1.0x106 
cells. 
4.6 Determine volume of cell re-suspension required to achieve the desired sodding 
density. The volume is determined according the surface area of each graft used, 
following the formula:  
Functional Surface Area = 2πr(L) 
Where r is the radius and L is the functional length of the graft.  Determine the 
sodding volume according to the following equation: 
  
 
 128 
Volume cell re-suspension (mL) = [(1/Re-suspended cell density (cell/mL)) * Desired 
sodding density (cells/cm2) * Functional Surface Area (cm2)] 
4.7 Disconnect the primed bioreactor chambers from the pump and move the systems 
into the hood for sodding as appropriate. 
4.8 Disconnect the connection between the bioreactor chamber and reservoir at the 
bioreactor outlet stopcock.  Arrange the system such that the outlet stopcock is 
feeding into a catch container (ie. trough or petri dish) and the inlet stopcock is 
easily accessible.  Take care to maintain proper sterile technique, especially 
around the open tube fittings.  
4.9 Agitate the cell solution to maintain a uniform suspension and fill a syringe with 
the appropriate volume of cell re-suspension; connect the syringe to the inlet 
stopcock of the bioreactor.   
4.10 Keeping the luminal outlet valve closed, open the inlet stopcock and begin 
injecting the cell solution.  Maintain a gentle steady flow, approximately 2 
mL/min, so not to force cells through the pores of the graft.  Take care not to 
inject air bubbles into the system.   
4.11 After sodding, chase the graft transmurally with 1-3 mL of bioreactor media, 
close all valves, and reattach the bioreactor outlet to the reservoir inlet. Take the 
BVM systems back to the large incubator and reconnect to the pump. 
4.12 Immediately begin transmural flow at 10 RPM and maintain for 1 hour. 
4.13 Repeat steps 4.7 - 4.12 for each BVM step up.  
4.14 Following 1 hour of transmural flow at 10 RPM, open the luminal outlet valve 
and continue flow at 10 RPM for an additional 1 hour. 
4.15 Following 1 hour of luminal flow at 10 RPM, increase flow to 15 RPM for an 
additional 1 hour. 
4.16 Following 1 hour of luminal flow at 15 RPM, increase flow to 20 RPM and 
maintain overnight. 
 
5 The Next Day and Beyond 
5.1 Increase flow by 10-15 RPM each hour until 150 RPM is reached.  
5.2 Replace the media reservoirs with bioreactor media every 3rd day. 
5.3 Check CO2 and incubator temperature. 
5.4 See Appendix C for graft harvesting protocol.   
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APPENDIX B 
Dual Cell Sodding Blood Vessel Mimic Protocol 
 
Purpose: 
The following protocol describes the methods for setup and cultivation of the in-
vitro blood vessel mimic and bioreactor system for a single cell type.   
 
Components: 
• ePTFE tubing 
• HUVSMC 
• HUVEC  
• Conditioning Media (see Conditioning Media Preparation protocol Appendix E) 
• Bioreactor Media (see Bioreactor Media Preparation protocol Appendix D) 
• Sterile/Filtered EtOH; 70% and 100% concentrations 
• Silk Suture 
• Bioreactor system: bioreactor chamber, lid, two port reservoir 
• Female luer to barb connector fittings 
• Cole-Palmer peristaltic pump  
• Sterile gloves 
• Hemocytometer (Neubauer Improved grid type) 
• Trypan-Blue  
 
Procedure: 
6 Prep: Approximately 1-week prior  
6.1 Gas sterilize the bioreactor chambers, lids, and 2-port reservoirs in separate 
sterilization bags.  Ensure that the inlet and outlet tube of the reservoir are 
connected in series.  
6.2 Determine the target number of cells and passage schedule.  Thaw and culture 
cells accordingly. 
6.3 Cut ePTFE tubing to the appropriate length.  For example, when using two 
connectors on inside of the bioreactor chamber a 4 cm long segment will be 
required.  Wear gloves to avoid transferring oils to the ePFTE. 
6.4 Connect a female luer to barb connector to each end of the ePTFE graft and 
suture using silk suture. 
6.4.1 Position the suture just inside the barb of the slip fit connector so that the 
graft and suture cannot be pulled off the connector. 
6.4.2 Triple tie the suture with a simple knot as tight as possible, reversing the 
direction of the knot each time.     
6.5 Autoclave grafts, vacuum flask, media troughs, and forceps.  
 
7 Prep: Day Before  
7.1 Make media 
7.1.1 Bioreactor Media (see Appendix D) 
7.1.2 Conditioning Media (see Appendix E) 
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7.2 Begin degassing approximately 12-15 mL of conditioning media per graft in a 
vacuum flask under standard vacuum.  Set-aside during graft denucleation. 
7.3 Denucleate ePFTE grafts using sterile/filtered Ethanol (EtOH) 
7.3.1 In the sterile hood, fill a 50 mL conical tube with enough 70% EtOH to 
completely submerge each graft, approximately 40- 45 mL. Label 
appropriately and set aside.  Repeat to fill a 50 mL conical tube with 
enough 100% EtOH. Label appropriately and set aside. 
7.3.2 Using sterilized forceps and proper sterile technique, remove each graft 
from the sterilization bags and submerge in 70% EtOH for 15 minutes.  
Agitate periodically by hitting the bottom of the conical tube to aid the 
duculeation.   
7.3.3 After 15 minutes in 70% EtOH, transfer the grafts to the 100% EtoH for 
an additional 15 minutes.  Continue to periodically agitate.  Throughout 
the denucleation period the grafts should become increasingly transparent.  
7.4  Transfer 10-12 mL of degassed conditioning media into 15mL conical tubes and 
immediately transfer one denucleated graft into each conical tube of degassed 
media.  Leave grafts in degassed media overnight in an incubator at 37°C.  
 
8 Set-up day: Blood Vessel Mimic Conditioning 
8.1 Warm up Bioreactor media and Conditioning media in water bath.  
8.2 Set-up Cole-Palmer pump in large incubator 
8.3 Transfer the tubes containing the denucleated grafts into the flow hood. 
8.4 Insert conditioned sterile grafts into bioreactor chambers. NOTE: Non-sterile 
partner required. 
8.4.1 Put on sterile gloves according to sterile handling practices.  Maintain 
sterility when handling the grafts or any interior bioreactor surface.   
8.4.2 Have an aseptic partner open a sterilization bag containing a bioreactor 
chamber, taking care not to touch any sterile surface.  Remove the 
bioreactor from the packaging. 
8.4.3 Fill the bioreactor chamber (aseptic partner) to completely submerge the 
graft, approximately 250-350 mL.  Make sure that all valves on the 
bioreactor system are closed before filling the chamber.   
8.4.4 Have the aseptic partner open one of the graft tubes, and using sterile 
forceps transfer one graft into the bioreactor chamber.  Replace the forceps 
onto a sterile surface and attach the graft onto the fittings of the bioreactor 
chamber. 
8.4.5 Attach the lid to the bioreactor and set the partial assembly aside.  This 
can be preformed by either partner as long as the aseptic partner takes care 
not to touch the inside surface of the lid. 
8.4.6 Repeat steps 3.2.3 – 3.2.6 for all grafts of a given setup.  Once all 
bioreactors are sealed, the sterile partner can begin working aseptically. 
8.5 Fill 50 mL conical tubes with approximately 40-50 mL of conditioning media 
and attach two port lids.  Keep the inlet and outlet tubes connected in series and 
prime the tubing of the two port lids by inverting the reservoir.  Set aside.  
8.6 Prime grafts with conditioning media 
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8.6.1 Using a syringe connected to the inlet stopcock of the bioreactor system, 
open all of the valves and flush the lumen of the graft with conditioning 
media to remove any air bubbles.  After flushing the lumen, close the 
outlet of the bioreactor chamber inject approximately 20-30 mL of 
conditioning media transmurally through the ePTFE. 
8.6.2  
8.6.3 Close all valves on the bioreactor chamber. 
8.7  Attach the primed two port reservoirs to the bioreactor taking care to make sure 
that the outlet of the reservoir (long tube inside reservoir conical) attaches to the 
inlet of the bioreactor and the outlet of the bioreactor attaches to the inlet of the 
reservoir (no tube inside reservoir conical). 
8.8  Transfer the primed and assembled bioreactor and reservoir system into the large 
incubator and attach the pump tubing to the Cole-Palmer pump. 
8.9 Open all valves of the bioreactor and begin flow through the lumen at a low 
pump rpm to remove air.  Make sure that no leaks are present and fluid is flowing 
through the graft and bioreactor tubing.  Close the luminal outlet valve of the 
bioreactor to begin transmural flow. Increase the pump RPM to 75-100 and 
condition the graft for 10-15 minutes.     
8.10 During conditioning, fill 50 mL conical tubes with 40-50 mL of bioreactor 
media and set aside in the hood. 
8.11 After conditioning, close all bioreactor valves and stop the pump.  Leave the 
conditioned bioreactor chambers in incubator until ready for sodding.  
 
9 Set-up day: Blood Vessel Mimic Sodding 
9.1 Harvest HUVSMC with trypsin according to standard culture practices.  Take 
note of the total volume of liquid cells are suspended in (trypsin plus volume of 
media used to deactivate). 
9.2 Gently agitate the solution and transfer a small sample (<0.5 ml) of suspended 
cells into a separate conical tube for counting.  Set aside   
9.3 Transfer majority volume of harvested cells into a 50 mL conical tube for 
centrifuging.  Centrifuge at setting 4 for 5 minutes (brand, model centrifuge). 
9.4 During the 5-minute centrifugation cycle, gently agitate (finger vortex) the cell 
suspension and trasnfer 100 µL of cell suspension into a conical microfuge tube.  
Add 100 µL of trypan blue solution (Brand) to the cell suspension and pipette up 
and down several times to ensure a uniform cell suspension.  Determine the cell 
concentration using a hemocytometer or similar cell counting method.  
9.5 After determining the total cell count, resuspend the centrifuged pellet with 
bioreactor media to a known cell solution concentration.  A general rule of thumb 
for easy sodding calculations is to resuspend using 1 mL of media per 1.0x106 
cells. 
9.6 Determine volume of cell re-suspension required to achieve the desired sodding 
density. The volume is determined according the surface area of each graft used, 
following the formula:  
Functional Surface Area = 2πr(L) 
Where r is the radius and L is the functional length of the graft.  Determine the 
sodding volume according to the following equation: 
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Volume cell re-suspension (mL) = [(1/Re-suspended cell density (cell/mL)) * Desired 
sodding density (cells/cm2) * Functional Surface Area (cm2)] 
9.7 Disconnect the primed bioreactor chambers from the pump and move the systems 
into the hood for sodding as appropriate. 
9.8 Disconnect the connection between the bioreactor chamber and reservoir at the 
bioreactor outlet stopcock.  Arrange the system such that the outlet stopcock is 
feeding into a catch container (ie. trough or petri dish) and the inlet stopcock is 
easily accessible.  Take care to maintain proper sterile technique, especially 
around the open tube fittings.  
9.9 Agitate the HUVSMC solution to maintain a uniform suspension and fill a 
syringe with the appropriate volume of cell re-suspension; connect the syringe to 
the inlet stopcock of the bioreactor.   
9.10 Keeping the luminal outlet valve closed, open the inlet stopcock and begin 
injecting the cell solution.  Maintain a gentle steady flow, approximately 2 
mL/min, so not to force cells through the pores of the graft.  Take care not to 
inject air bubbles into the system.   
9.11 After sodding, chase the graft transmurally with 1-3 mL of bioreactor media, 
close all valves, and reattach the bioreactor outlet to the reservoir inlet. Take the 
BVM systems back to the large incubator and reconnect to the pump. 
9.12 Immediately begin transmural flow at 10 RPM and maintain for 30 minutes. 
9.13 Repeat steps 4.7 - 4.12 for each BVM step up.  
(Begin Endothelial cell Sodding) 
9.14 During the 30-minute transmural conditioning of the BVM with HUVSMC, 
harvest HUVEC with trypsin according to standard culture practices.  Take note 
of the total volume of liquid cells are suspended in (trypsin plus volume of media 
used to deactivate). 
9.15 Gently agitate the solution and transfer a small sample (<0.5 ml) of suspended 
cells into a separate conical tube for counting.  Set aside   
9.16 Transfer majority volume of harvested cells into a 50 mL conical tube for 
centrifuging.  Centrifuge at setting 4 for 5 minutes (brand, model centrifuge). 
9.17 During the 5-minute centrifugation cycle, gently agitate (finger vortex) the cell 
suspension and trasnfer 100 µL of cell suspension into a conical microfuge tube.  
Add 100 µL of trypan blue solution (Brand) to the cell suspension and pipette up 
and down several times to ensure a uniform cell suspension.  Determine the cell 
concentration using a hemocytometer or similar cell counting method.  
9.18 After determining the total cell count, resuspend the centrifuged pellet with 
bioreactor media to a known cell solution concentration.  A general rule of thumb 
for easy sodding calculations is to resuspend using 1 mL of media per 1.0x106 
cells. 
9.19 Determine volume of cell re-suspension required to achieve the desired sodding 
density. The volume is determined according the surface area of each graft used, 
and the previously given formulas in 4.6.  
9.20 Disconnect the bioreactors containing HUVSMC from the pump following the 
30-minute cycle and move the systems into the hood for sodding as appropriate. 
9.21 Disconnect the connection between the bioreactor chamber and reservoir at the 
bioreactor outlet stopcock.  Arrange the system such that the outlet stopcock is 
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feeding into a catch container (ie. trough or petri dish) and the inlet stopcock is 
easily accessible.  Take care to maintain proper sterile technique, especially 
around the open tube fittings.  
9.22 Agitate the HUVEC solution to maintain a uniform suspension and fill a syringe 
with the appropriate volume of cell re-suspension; connect the syringe to the inlet 
stopcock of the bioreactor.   
9.23 Keeping the luminal outlet valve closed, open the inlet stopcock and begin 
injecting the cell solution.  Maintain a gentle steady flow, approximately 2 
mL/min, so not to force cells through the pores of the graft.  Take care not to 
inject air bubbles into the system.   
9.24 After sodding, chase the graft transmurally with 1-3 mL of bioreactor media, 
close all valves, and reattach the bioreactor outlet to the reservoir inlet. Take the 
BVM systems back to the large incubator and reconnect to the pump. 
9.25 Immediately begin transmural flow at 10 RPM and maintain for an additional 
30-minutes. 
9.26 Repeat steps 4.14 - 4.26 for each BVM step up until all grafts are sodded with 
both HUVSMC and HUVEC.  
9.27 Following the second 30-minutes of transmural flow at 10 RPM, open the 
luminal outlet valve and continue flow at 10 RPM for an additional 1-hour. 
9.28 Following 1-hour of luminal flow at 10 RPM, increase flow to 15 RPM for an 
additional 1-hour. 
9.29 Following 1-hour of luminal flow at 15 RPM, increase flow to 20 RPM and 
maintain overnight. 
 
10 The Next Day and Beyond 
10.1 Increase flow by 10-15 RPM each hour until 150 RPM is reached.  
10.2 Replace the media reservoirs with bioreactor media every 3rd day. 
10.3 Check CO2 and incubator temperature. 
10.4 See Appendix C for graft harvesting protocol.   
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APPENDIX C 
Graft Harvesting Protocol 
 
Purpose: 
The following protocol describes the methods for breakdown of the bioreactor 
systems and harvesting of blood vessel grafts.   
 
Components: 
• Surgical Scapel 
• Histochoice Fixing Reagent 
• Complete BVM graft and bioreactor set-up 
 
Procedure: 
1. Close all valves and remove the BVM set-up from the pump, including reservoir 
and bioreactor chamber.  Take the BVM unit to an open workspace; sterility not 
required. 
2. Label a 15 mL conical tube with the appropriate BVM information and fill the 
tube with approximately 10- 12 mL of Histochoice.  CAUTION: Wear gloves and 
take care when handling Histochoice. 
3. Open the lid to the bioreactor chamber and set aside.  
4. Mark the distal end of the graft using a permanent laboratory pen. 
5. Put the ePFTE graft at the edge of the barb fitting using a surgical scalpel, taking 
care not to bend, twist, or distort the graft.  
 
 
 
6. Transfer the graft into the prepared histochoice tube and set aside for future use. 
7. Remove residual ePTFE from the barb fittings and dispose of properly.  Empty 
the media from the bioreactor unit and clean thoroughly with hot water 
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APPENDIX D 
Bioreactor Media Preparation 
 
Purpose: 
The following protocol describes the methods for preparing Bioreactor media for 
use in the bioreactor systems during BVM culture. 
 
Components: 
 
• M199, basal media, 500 mL  
• Fetal Bovine Serum (FBS), 56 mL  
• L-Glutamine, 5 mL  
• 1M HEPES buffer, 2.8 mL  
• Penicillin/Streptomycin solution (P/S), 5 mL  
• Fungizone, 0.6 mL  
 
Procedure:  
Makes 570 mL ECM 
1. In the hood, vacuum filter approximately 400 mL of the M199, leaving the 
remaining 100 ml to wash the other media components.   
2. Add the 56 mL FBS, 5 mL P/S, 0.6 mL Fungizone, 5 ml L-Glutamine, and 2.8 
mL HEPES through the vacuum filter   
3. Wash the filter with the remaining 100 mL of basal medium.  
4. Place filtered media in the refrigerator (4°C) until ready for use. 
5. Warm to 37°C in a water bath before using for cell culture. 
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APPENDIX E 
Conditioning Media Preparation 
 
Purpose: 
The following protocol describes the methods for preparing Conditioning media 
for conditioning of the ePTFE grafts prior to cell sodding. 
 
Components: 
 
• M199, basal media, 500 mL  
• Fetal Bovine Serum (FBS), 83 mL  
• Penicillin/Streptomycin solution (P/S), 5 mL 
• Fungizone, 0.6 mL  
 
Procedure:  
Makes 570 mL ECM 
1. In the hood, vacuum filter approximately 400 mL of the M199, leaving the 
remaining 100 ml to wash the other media components.   
2. Add the 56 mL FBS (6:1 ratio of M199:FBS), 5 mL P/S, and 0.6 mL Fungizone, 
through the vacuum filter   
3. Wash the filter with the remaining 100 mL of basal medium.  
4. Place filtered media in the refrigerator (4°C) until ready for use. 
5. Warm to 37°C in a water bath before using for cell culture. 
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APPENDIX F 
Smooth Muscle Cell Media (Sciencell) Preparation 
 
Purpose: 
The following protocol describes the methods for preparing Smooth Muscle Cell 
Media (SMCM) provided by Sciencell Laboratories for the culture of smooth 
muscle cells. 
 
Components: 
 
• Smooth Muscle Cell Media, basal medium (SMCM), 500 mL [Sciencell – P/N 
1101] 
• Smooth Muscle Cell Growth Supplement (SMCGS), 5 mL [Sciencell – P/N 1152] 
• Penicillin/Streptomycin solution (P/S), 5 mL [Sciencell – P/N 0503] 
• Fetal Bovine Serum (FBS), 10 mL [Sciencell – P/N 0010] 
 
Procedure:  
Makes 535 mL SMCM 
1. In the hood, vacuum filter approximately 400 mL of the basal medium, leaving 
the remaining 100 ml to wash the other media components.   
2. Add the 10 mL FBS, 5 mL P/S, and 5 mL SMCGS through the vacuum filter   
3. Wash the filter with the remaining 100 mL of basal medium.  
4. Place filtered media in the refrigerator (4°C) until ready for use. 
5. Warm to 37°C in a water bath before using for cell culture. 
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APPENDIX G 
Endothelial Cell Media (Sciencell) Preparation 
 
Purpose: 
The following protocol describes the methods for preparing Endothelial Cell 
Media (ECM) provided by Sciencell Laboratories for the culture of endothelial 
cells. 
 
Components: 
 
• Endothelial Cell Media basal medium (ECM), 500 mL [Sciencell – P/N 1001] 
• Endothelial Cell Growth Supplement (ECGS), 5 mL [Sciencell – P/N 1052] 
• Penicillin/Streptomycin solution (P/S), 5 mL [Sciencell – P/N 0503] 
• Fetal Bovine Serum (FBS), 25 mL [Sciencell – P/N 0025] 
 
Procedure:  
Makes 535 mL ECM 
1. In the hood, vacuum filter approximately 400 mL of the basal medium, leaving 
the remaining 100 ml to wash the other media components.   
2. Add the 25 mL FBS, 5 mL P/S, and 5 mL ECGS through the vacuum filter   
3. Wash the filter with the remaining 100 mL of basal medium.  
4. Place filtered media in the refrigerator (4°C) until ready for use. 
5. Warm to 37°C in a water bath before using for cell culture. 
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APPENDIX H 
Hematoxylin and Eosin ePTFE Staining Protocol 
 
The following protocol describes the methods for preparing staining embedded samples 
of ePTFE blood vessel mimics with hematoxylin and eosin.  
 
Components: 
 
• Hematoxylin (Fisher Scientific) 
• Eosin (Fisher Scientific) 
• Distilled Water 
• Xylene (Fisher Scientific) 
• 75% and 100% EtOH 
• Clarifier (Fisher Scientific) 
• Bluing Reagent (Fisher Scientific) 
 
Procedure: 
 
1. After sectioning, mounting, and drying the samples overnight, warm the slides 
until the wax becomes clear.  
2. Remove the warmed slides and allow the wax to begin cooling until some of the 
wax becomes cloudy again. 
3. Place the slides into a slide carrier and stain according to the following workup: 
 
• 3 minutes - Xylene 
• 1 minute – Air dry 
• 2 minutes – 100% EtOH 
• 2 minutes – 95% EtOH 
• 20 minutes – Air Dry 
• 4 minutes – Hematoxylin 
• 1 minute – Distilled water 
• 30 seconds – Clarifier 
• 1 minute – Bluing reagent 
• 1 minute – 95% EtOH 
• 1:20 minutes – Eosin 
• 1 minute – 100% EtOH 
• 1 minute – Air Dry 
• 1 minute – 95% Xylene 
 
4. Let samples air dry until xylene has evaporated.  Affix with a cover slip and allow 
to dry overnight.  
 
 
  
 
 140 
APPENDIX I 
Collagen Gel Preparation 
 
The following protocol describes the methods for preparing Rat Tail Type I Collagen gel 
for tissue engineering cell cultures 
 
Components: 
 
• Rat Tail Collagen, Type I (BD Biosciences - P/N 354236) 
• 4x DMEM (Invitrogen – P/N 31600-034) [see 4x DMEM Preparation protocol] 
• Sterile Deionized Water 
• Sterile/Filtered 1N NaOH 
• Sterile/Filtered 1N HCl 
 
Procedure: 
 
1. Determine the final volume of collagen solution to be used 
2. Calculate the volume of collagen to be used by the following equation, using 3 
mg/ml for the final collagen concentration: 
! 
Final Collagen Volume x Final Collagen Concentration in mg/ml 
Concentration in Bottle
=  Volume Collagen to be Added
 
3. Place necessary pipettes in freezer prior to use 
4. Place a tube on ice of sufficient volume to hold final volume of collagen solution 
5. Add 250 µL of ice-cold 4x DMEM per final ml of collagen solution 
6. Add ice-cold sterile water to make up remaining volume: 
Final Collagen Vol. – [Vol. of 4x DMEM + Vol. of Collagen Added] = Vol. Water  
7. Observe the color of the solution and take either of the following actions: 
• If color of collagen solution is yellow, add ice-cold 1N NaOH dropwise until 
color matches DMEM  
• If color of collagen solution is purple, add ice-cold 1N HCl dropwise until 
color matches DMEM  
8. Vortex solution and keep on ice until ready for use 
9. The collagen solution can be used immediately or held on ice for 2-3 hours 
10. When ready for use, aseptically deliver the solution into the cell culture device 
and allow to gel at 37°C for 30 minutes.  
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APPENDIX J 
4x DMEM Preparation 
 
Purpose: 
The following protocol describes the methods for preparing 4x Dulbecco's 
Modification of Eagle's Medium (DMEM) for use in collagen gel preparation. 
 
Components: 
 
• 1L package DMEM (Invitrogen – P/N 31600-034) 
• Powdered NaHCO3 
• Deionized Water 
• 1N NaOH 
• 1N HCl 
 
Procedure:  
Makes 250 ml 4x DMEM 
 
1. Add 235 ml sterile water into 500 ml beaker  
2. Add stir bar and maintain moderate mixing 
3. Add one (1) package of DMEM powder  
4. Add 3.7g NaHCO3 
5. Wash DMEM packet and NaHCO3 weigh boat with remaining 15 ml sterile water 
6. pH the solution to 7.1 - 7.2.  Adjust pH using NaOH or HCl as needed 
7. Immediately filter sterilize  
8. Place final solution in refrigerator (4°C) until ready for use 
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APPENDIX K 
Alternative Biological Scaffolds 
 
Introduction 
To address the biocompatibility and bioactive limitations of synthetic scaffolds, 
many groups have attempted to use biological scaffolds, including extracted collagen and 
decellularized porcine carotids [12, 30].  Typically, biological scaffolds are chosen as 
tissue engineering scaffolds for improved compatibility and biological compliance, 
however, these scaffolds tend to be weak or difficult to handle, and therefore, many 
groups rely on the customizability and repeatability of synthetic materials.  While the 
focus of this thesis was directed at developing the cellular components of the BVM, 
prelusive work aimed at investigating potential biological scaffolds, including collagen 
tubes and decellularized vessels, was also pursued.  The following serves to document the 
work completed to create both a collagen tube and decellularized porcine carotid 
scaffolds.   
 
Materials and Methods 
Collagen tube protocol 
1 Assemble the tube mold by taping the two outside shell pieces together with 
the center pin.  Place the assembled mold into a plastic weigh boat. 
2 Prepare collagen according to the collagen gel protocol (Appendix I) 
3 Pour the collagen mixture into the top of the tube mold.  Set aside and allow 
solidification overnight.   
4 Once the collagen has solidified into a gel, remove the center pin by carefully 
pushing the pin from the top and then pulling from the bottom.  
5 Cut the tape holding the outside of the mold and carefully pull the two halves 
of the mold apart.  Remove the collagen tube from the mold. 
 
    
Figure K.1 – Rapid prototyped ABS mold used to cast gel tubes. 
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Figure K.2 – Agar gel tube 
 
Decellualrized Porcine Arteries protocol 
1 Unless used fresh, samples were kept in a freezer at -80°C.   
2 To defrost, set samples on the bench top at room temperature.  The defrosting 
is complete when the entire sample is malleable.  If the sample is fresh, ignore 
this step.  Document the type of storage and the duration the vessel has been 
stored. 
3 Once defrosted, cut the samples into as many 5cm sized pieces as required.   
Each sample should be put into individual 50mL tubes labeled with the 
sample number.   
4 Prepare the decellularization solution. A total volume of 20 mL of solution is 
required per 50mL tube.   
4.1. The SDS solution is a concentrated amount of 10% SDS in Mill-q water.  
The samples are to be decellularized in a 0.075% SDS solution.  Mix 
solutions in the hood to maintain sterility and be sure to clean the hood 
thoroughly with bleach before and after mixing to avoid contamination 
from the porcine tissue.    
5 Put all the tubes in a tube rack.  Anchor the tube rack to a shake table using 
adhesive tape.  Run the shake table at level 7, or enough movement to agitate 
the solution.  Leave the solutions on the shake table for 15 hours.  The ideal 
set-up would also have the solutions agitated a constant elevated temperature 
of 32 °C.  
6 After 15 hours take the samples off the shake table and pour out the SDS 
solution.   
7 Begin the rise process.   
7.1. Rinse by filling 20 mL of PBS in the tubes with the samples (even the 
control).  Place samples back on the shake table for 10 min.   
7.2. Pour out the solution, refill with 20mL of PBS and place it back on the 
shake table for 10 min.   
7.3. This process should be repeated 5 times, for a total of 50 min. 
8 Prepare new 15mL tube for each sample with 10-12mL of Histochoice.  Label 
the tubes accordingly.  Store for future analysis. 
 
Note: For H&E histological analysis, follow the following work up after 
mounting samples: 
• 3 min – Xylene 
• 3 min – Xylene 
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• 3 min – Xylene 
• 2 min – 100% EtOH 
• 2 min – 100% EtOH 
• 2 min – 95% EtOH 
• 1 min – Air dry 
• 4 min – Hematoxlin 
• 1 min – Water Distilled 
• 30 – 45 sec – Clarifier 
• 1 min – Water Distilled 
• 1 min – Bluing 
• 1 min- Water Distilled 
• 1 min – 95% ETOH 
• 1:30 min – Eosin 
• 1 min - 100% EtOH 
• 1 min - 100% EtOH 
• 1 min - 100% EtOH 
• 3 min – Xylene 
• 3 min – Xylene 
• 3 min – Xylene 
 
Results 
Collagen tubes  
Due to the cost associated with concentrated collagen, standard agarose gel was 
first used to test the concept of creating a gel tube for use as a tissue engineering scaffold.  
A CAD model of the tube mold was made and rapid prototyped using ABS plastic.  
Experiments using the agar gel proved that a gel tube could be created (see figure K.2), 
however, the tubes made of agarose gel possessed poor mechanical properties and were 
susceptible to tearing and crumbling.  The agar tubes were therefore deemed too weak to 
be fit on the barbs of the bioreactor system, and would not have sufficient burst pressure 
strength to withstand the pressure of sodding or flow during setup and cultivation of the 
BVM.   
After proving the concept of making gel tubes using agarose gel, collagen gel was 
next used in conjunction with the tube molds.  After pouring the collagen into the molds 
and allowing the gel to set, the mold was disassembled according to the protocol, and in a 
similar fashion to the agar tubes.  However, unlike the agar tubes, which held their shape 
upon removal of the mold, the collagen wilted into a globular mass that could not be 
handled or connected to the bioreactor setup.  
 
Decellualrized Porcine Arteries 
After decellularization, the fixed samples were embedded in paraffin wax.  Each 
samples was then sectioned across entire the length of the sample to evaluate the 
decellularization process throughout the vessel.  The samples were sectioned at 6µm and 
subsequently stained with hematoxylin and eosin.  The samples were then viewed under 
standard light microscopy and compared to control vessels.  Evaluation and comparison 
of the histology images shows that the decellularization protocol produced vessel 
constructs void of cells (see figure K.3).  While the decellularization experiments 
  
 
 145 
demonstrated that vessel constructs could be created from porcine sources, the 
decellularized grafts were not attached to the bioreactor system, and the feasibility of 
using the graft with the in-vitro BVM system was not determined.      
 
Conclusions 
While the main focus of this thesis was to develop the cellular components of the 
in-vitro BVM system, preliminary work was additional undertaken to evaluate the 
feasibility of incorporating biological scaffolds, including collagen tubes and 
decellularized porcine arteries.  Results of these experiments provided insight into the 
potential of these scaffold materials as BVM scaffolds, especially in comparison to 
ePTFE.  Collagen gel and agarose gel tubes proved to be mechanically too weak to be 
functional substrates for the in-vitro BVM.  If gel tubes are to be pursued in the future as 
a BVM scaffold substrate, additional work is needed to refine and determine optimum 
collagen concentrations to improve mechanical properties.      
Decellularization experiments served to show that native vessels could be striped 
of cells for the potential use as tissue-engineered scaffolds.  Groups like Ott et al have 
showed that decellularized scaffolds can be used to create function tissue-engineered 
cardiac heart tissue, and a similar approach could be applied to the porcine vessels to 
create the in-vitro BVM[69].  Future work evaluating the porcine vessels can focus on 
incorporating the grafts in the bioreactor and attempting to sod endothelial and potentially 
smooth muscle cells.  Although, the porcine vessels provide a completely biologic 
scaffold substrate, availability and consistency of the vessels proves to be some of the 
greatest challenges with using decellularized scaffolds.   
In total, the experiments testing both collagen gel tubes and decellularized porcine 
arteries, suggest that synthetic scaffolds provide the most cost effective and repeatable 
tissue engineering scaffold.  Continued work may prove the value of either biological 
scaffold approach. 
 
 
Figure K.3 – Comparison of porcine artery before and after 
decellularization.  The left image (a) represents a control sample that was not 
decellularized.  The image on the right (b) is a sample that was decellularized 
using 0.75% SDS.  Notice the absence of blue nuclei in the decellularized 
sample. 
Fig. K.3a Fig. K.3b 
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APPENDIX L 
Standard Cost Sheet for Lab Consumables 
 
CONSUMABLE LIST         
Item QTY unit purchase price price per unit 
       
DMEM 500 ml 11 0.02 
M199 500 ml 18 0.04 
FBS 500 ml 270 0.54 
ePTFE 80 cm 800 10.00 
L-glut 100 ml 10 0.10 
HEPES 20 ml 10 0.50 
Fungizone 20 ml 15 0.75 
P/S 100 ml 15 0.15 
T75 60 ea 158.33 2.64 
T225 30 ea 116.04 3.87 
HUVSMC 1 vial 340 340.00 
SMCM 500 ml 88 0.18 
HUVEC 1 vial 198.00 198.00 
ECM 500 ml 94.00 0.19 
5ml Pipet 200 ea 25.65 0.13 
10ml Pipet 200 ea 27.9 0.14 
25ml Pipet 200 ea 71.89 0.36 
2ml Asp Pipet 200 ea 48.83 0.24 
100% EtOH 3785 ml 45 0.01 
Trypsin 500 ml 40 0.08 
Syringe 100 ea 10 0.10 
Trypan-blue 100 ml 10 0.10 
Hemocytometer 20 ea 42 2.10 
50 ml conical tubes 500 ea 208 0.42 
 
 
Bioreactor Media (BrM)     
Item QTY used unit cost/bottle  
M199 500 ml 18.00  
FBS 56 ml 30.24  
L-glut 5 ml 0.50  
HEPES 2.8 ml 1.40  
Fungizone 0.6 ml 0.45  
P/S 5 ml 0.75  
     
TOTAL:   51.34 per bottle 
   0.09 per ml 
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Conditioning Media (CM)          
M199 500 ml 18.00   
FBS 83 ml 44.82   
Fungizone 0.6 ml 0.45   
P/S 5 ml 0.75   
       
TOTAL:   64.02 per bottle 
      0.11 per ml 
 
 
Cell yield HUVSMC per Sciencell vial         
Passages 8     
Passage ratio 2 :1    
Approximate # T75s 256     
100% T75 4.00E+06 cells    
5.0x105 cells/cm2; 4cm long graft 2.51E+06 cells (4 cm long 4mm dia ePTFE) 
7.5x105 cells/cm2; 4cm long graft 3.77E+06 cells (4 cm long 4mm dia ePTFE) 
grafts/T75 @ 5.0x105 cells/cm2 1.59     
grafts/T75 @ 7.5x105 cells/cm2 1.06     
total # grafts @ 5.0x105 cells/cm2 407 ea    
total # grafts @ 7.5x105 cells/cm2 272 ea    
cell cost per graft @ 5.0x105 cells/cm2 0.83     
cell cost per graft @ 7.5x105 cells/cm2 1.25     
       
AVE cost per HUVSMC graft 1.04     
       
Cell yield HUVEC per Sciencell vial      
Passages 6     
Passage ratio 2 :1    
Approximate # T75s 64     
100% T75 4.00E+06 cells    
5.0x105 cells/cm2; 4cm long graft 2.51E+06 cells (4 cm long 4mm dia ePTFE) 
7.5x105 cells/cm2; 4cm long graft 3.77E+06 cells (4 cm long 4mm dia ePTFE) 
grafts/T75 @ 5.0x105 cells/cm2 1.59     
total # grafts @ 5.0x105 cells/cm2 102 ea    
 
cell cost per graft @ 5.0x105 cells/cm2 1.94       
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APPENDIX M 
Permissions 
 
Figures 1.1, 1.2, 1.4: 
Usage Agreement – Encyclopedia Britannica 
 
Terms of Use 
These Terms of Use govern your use of Encyclopædia Britannica® Online and, unless 
other terms and conditions expressly govern, any other electronic services provided by 
Encyclopædia Britannica, Inc. ("Britannica") that may be available from time to time 
(collectively, the "Services"). 
General: Your use of the Services constitutes your agreement to these Terms of Use. If 
you do not agree with these Terms of Use, please do not use the Services. Britannica 
reserves the right to change, modify, add, or remove portions of these Terms of Use at 
any time. Please check this page periodically for any modifications. Your use of any of 
the Services following the posting of changes constitutes your acceptance of the changes. 
Ownership: The content on the Services is the property of Britannica, its affiliated 
companies or licensors and is protected by international copyright, patent, and trademark 
laws. 
Advertising: Advertisements, promotions, and marketing messages may appear on the 
Services from time to time. 
Use of Content: You may display, reproduce, print or download content on the Services 
only for your personal, non-commercial use. If you are a teacher, scholar or student, you 
may copy reasonable portions of the content for lesson plans, interactive whiteboards, 
reports, dissertations, presentations, school newspapers and for similar nonprofit 
educational purposes to the extent permitted by applicable law. In each case, however, 
you may not remove or alter any copyright, trademark, service mark or other proprietary 
notices or legends. You may not publish, distribute, retransmit, sell or provide access to 
the content on the Services, except as permitted under applicable law or as described in 
these Terms of Use. Britannica works to ensure that all the content on its Services is in 
compliance with applicable U.S. copyright laws. However, in the case of works on the 
Services authored by parties other than Britannica, you may wish to check on their 
copyright status before downloading them if you are in another country.  
If you want to reproduce or use content for any purpose or in any manner other than as 
described above, you will need Britannica's permission. Requests should be directed to 
this syndication form. 
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Figure 3.10:  
WOLTERS KLUWER HEALTH LICENSE 
TERMS AND CONDITIONS 
May 21, 2009  
This is a License Agreement between Dimitri E Delagrammaticas ("You") and Wolters 
Kluwer Health ("Wolters Kluwer Health") provided by Copyright Clearance Center 
("CCC"). The license consists of your order details, the terms and conditions provided by 
Wolters Kluwer Health, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number:    2193440242748  
License date:     May 21, 2009  
Licensed content publisher:   Wolters Kluwer Health  
Licensed content publication:  ASAIO Journal  
Licensed content title:  
  
Endothelial and Smooth Muscle Cell Seeding onto Processed Ex Vivo Arterial Scaffolds 
Using 3D Vascular Bioreactors.  
 
Licensed content author:  McFetridge, Peter  
Licensed content date:   Jan 1, 2004  
Volume Number:   50  
Issue Number:    6  
Type of Use:     Dissertation/Thesis  
Requestor type:     Individual  
Title of your thesis/dissertation: 
 
Development of an In-Vitro Tissue Engineered Blood Vessel Mimic Using Human Large 
Vessel Cell Sources 
 
Expected completion date:  May 2009  
Estimated size(pages)    163  
 
Terms and Conditions 
 
1. A credit line will be prominently placed and include: for books - the author(s), title of 
book, editor, copyright holder, year of publication; For journals - the author(s), title of 
article, title of journal, volume number, issue number and inclusive pages.  
2. The requestor warrants that the material shall not be used in any manner which may be 
considered derogatory to the title, content, or authors of the material, or to  
Wolters Kluwer/Lippincott, Williams & Wilkins.  
3. Permission is granted for one time use only as specified in your correspondence. 
Rights herein do not apply to future reproductions, editions, revisions, or other derivative 
works. Once term has expired, permission to renew must be made in writing.  
4. Permission granted is non-exclusive, and is valid throughout the world in the English 
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language and the languages specified in your original request.  
5. Wolters Kluwer Health/ Lippincott, Williams & Wilkins, cannot supply the 
requestorwith the original artwork or a "clean copy."  
6. The requestor agrees to secure written permission from the author (for book material 
only).  
7. Permission is valid if the borrowed material is original to a LWW imprint  
(Lippincott-Raven Publishers, Williams & Wilkins, Lea & Febiger, Harwal, Igaku-  
Shoin, Rapid Science, Little Brown & Company, Harper & Row Medical, American 
Journal of Nursing Co, and Urban & Schwarzenberg - English Language).  
8. If you opt not to use the material requested above, please notify Rightslink within 90 
days of the original invoice date.  
 
v1.0  
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required.  
 
 
